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Summary 
In vivo bioluminescence imaging (BLI) technology allows to monitor tumor growth, to track 
cells or to follow pathogens. As BLI is still in its relative infancy, my work was focused on 
the choice of an optimal luciferase. Subsequently this optimal luciferase was used for 
establishment of vivo BLI models for tumor immunological studies. Additionally, 
visualization of tumors with luminescent bacteria was investigated. 
First, I have compared the most commonly used luciferase, namely firefly luciferase (Fluc), 
with the green and red luciferases (CBGr99 and CBRed) from the click beetle which recently 
became available. For this purpose, cell transfectants were generated expressing equimolar 
amounts of CBGr99, CBRed or Fluc. Equimolarity was achieved by coexpression of the 
luciferase with eGFP using a novel bicistronic 2A system, which results in stoichiometric 
coexpression of the respective proteins. In vitro the CBGr99 transfectant exhibited the highest 
total photon yield. By injecting the transfectants into mice at different locations, the click 
beetle luciferases (CBLucs) have been shown to be superior over Fluc for BLI. Moreover the 
comparison of the CBLucs showed that CBGr99 has either a superior or a similar sensitivity 
in vivo as compared to CBRed, depending on the time point of the analysis. In addition, the 
analysis of CBGr99 transfectants showed that CBGr99 expression correlates with cell number 
and can be used for monitoring of tumor growth in vivo.  
Therefore, using a Cre/loxP system an inducible transgenic mouse line that expresses 
specifically CBGr99 in the liver (ASC line) was generated. These mice were crossed with the 
AST line generated in the laboratory that has been shown to develop autochthonous 
hepatocarcinoma growth after injection of adenovirus encoding Cre recombinase. The 
resulting mice, named ASCT, permit non-invasive monitoring of hepatocarcinoma 
development in live animals via in vivo BLI of CBGr99 expression. The ASCT model permits 
longitudinal monitoring of tumor onsets, progression and may be used effectively for testing 
response to therapy.   
Another approach for visualization of tumors is to employ bacteria expressing luciferase. 
Several bacterial strains are known to specially target and survive in tumors after intravenous 
injection while they are cleared in other tissues. Tumor homing by Vibrio cholerae expressing 
a bacterial luciferase gene (luxCDABE) was visualized by BLI in immunodeficient deficient 
mice bearing tumors. I have shown that V.choleare as well as the Top10 E.coli strain could 
efficiently target subcutaneous tumors in immunocompetent mice which are able to mount an 
immune response against the bacteria. Moreover, the tumor colonization observed in various 
  Summary 
xi 
tumors such as AG104A, B16, and RMA was a transient phenomenon. In addition, the ability 
of bacteria to target tumors in different spontaneous tumor model such as a hepatoma model 
(Albumin-Tag mice), an insulinoma model (RIP.Tag-5 mice) and a mammary carcinoma 
model (Her-2/neu mice) was investigated. Vizualisation of bacterial homing by BLI showed 
that in these models the tumor targeting efficiency is lower than in subcutaneous tumors.  
In addition, I envisaged the usage of bacteria as delivery vector for GM-CSF and IL-2 in 
order to enhance elimination of tumors by the immune system. Secretion of GM-CSF and IL-
2 by Top10.lux bacteria was achieved by inserting their DNA sequences into a plasmid 
encoding the Hemolysin A secretory system allowing their secretion in the tumor site. In a 
therapeutic vaccination study, intravenous injection of Top10.lux.GM-CSF in mice bearing 
subcutaneous tumor did not enhance the delay on tumor growth which was observed with 
Top10.lux  
Finally, to monitor the infiltration of T cells in tumors, a transgenic mouse line (CAG-L2ACh 
line) that can serves as a source of CBGr99 positive cells was generated. In the CAG-L2ACh 
mouse line CBGr99 and a red fluorescent protein (mCherry) are co-expressed under the 
control of a ubiquitous promoter. By BLI, CBGr99 expression was visualized in all tissues. At 
the single cell level, 100% of the T cells expressed mCherry and thereby CBGr99. Therefore, 
CAG-L2ACh constitutes a universal donor for cell trafficking studies by BLI.  
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Zusammenfassung 
Die Überwachung des Tumorwachstums bzw. das Verfolgen von Zellen oder Pathogenen 
kann anhand des bildgebenden Verfahrens der in vivo Biolumineszenz (engl. in vivo 
bioluminscence imaging, Abk. BLI) erfolgen. Da die Methode des BLI noch in ihren 
Anfängen steht, konzentrierte sich diese Arbeit auf die Auswahl der optimalen Luciferase, um 
diese anschließend zur Etablierung eines in vivo BLI-Modells, das Studien der 
Tumorimmunologie dient, zu nützen. Außerdem sollte anhand von lumineszierenden 
Bakterien die Visualisierung von Tumoren untersucht werden. 
Zuerst wurde daher die meist verwendete Luciferase, die firefly luciferase (Fluc), mit der neu 
zur Verfügung stehenden grünen sowie roten Luciferase (CBGr99 und CBRed) des 
Schnellkäfers (engl. click beetle) verglichen. Zu diesem Zweck wurden equimolare Mengen 
der verschiedenen Proteine, CBGr99, CBRed bzw. Fluc, mit Hilfe von Zelltransfektion 
exprimiert. Um eine Equimolarität zu erzielen, wurde die jeweilige Luciferase mit eGFP 
(engl. enhanced green fluorescent protein) koexprimiert. Dies erfolgte durch Anwendung 
eines neuartigen bicistronischen 2A Systems, das in einer stöchiometrischen Koexpression 
der entsprechenden Proteine resultiert. Durch in vitro Experimente konnte die höchste 
absolute Photonen Ausbeute bei CBGr99 festgestellt werden. Injektion der Transfektanten an 
verschiedenen Stellen einer Maus zeigtendass die click beetle Luciferasen (CBLucs) besser 
gelisnet als Fluc fur die BLI sind. Der Vergleich zwischen den verwendeten CBLucs ergab, 
dass CBGr99 eine bessere oder ähnliche in vivo Sensitivität als CBRed aufwies, die jedoch 
vom Zeitpunkt der Analyse abhing. Die Analyse der mit CBGr99 transfizierten Zellen zeigte, 
dass die CBGr99 Expression mit der Zellanzahl korrelierte und somit für das Überwachen des 
Tumorwachstums in vivo verwendet werden konnte.  
Dafür wurde eine induzierbare transgene Mauslinie genereriert, die mit Hilfe des Cre/loxP 
Systems CBGr99 spezifisch in Leberzellen (ASC Linie) exprimiert. Diese transgene 
Mauslinie wurde mit der Linie AST gekreuzt, die nach Injektion eines Cre-recombinase 
kodierenden Adenoviruses autochthones Hepatokarzinom Wachstum entwickelt. Der 
Nachwuchs dieser Kreuzung, als ASCT benannt, ermöglichte das nicht-invasive Beobachten 
der Entwicklung des Hepatokarzinoms in lebenden Tieren durch in vivo BLI mittels der 
Expression von CBGr99. Das in dieser Arbeit entwickelte ASCT-Modell kann daher zur 
zeitlichen Überwachung des Tumorbeginns und -fortschreitens genützt und effektiv für 
Analysen zur Wirkug von Therapien verwendet werden.  
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Ein weiterer Ansatz zur Visualisierung von Tumoren ist die Verwendung von Luciferase-
exprimierenden Bakterien. Viele Bakterienstämme visieren nach intravenöser Injektion 
speziell Tumore an (engl. tumor targeting) und können dort überleben, während sie in 
Geweben vernichtet werden. BLI-Messungen zeigten, dass transgene Vibrio cholerae, die ein 
bakterielles Luciferase Gen (luxCDABE) exprimieren, Tumore in tumortragenden, 
immundefizienten Mäusen besiedeln („Tumor homing“). In dieser Arbeit konnte sowohl mit 
V. cholerae als auch mit Top10 E.coli ein effizientes „targeting“ von subkutanen Tumoren in 
immunkompetenten Mäusen, die eine Immunantwort gegen Bakterien erzeugen können, 
erzielt werden. Es konnte vorübergehend beobachtet werden, dass in verschiedenen Tumoren, 
wie z.B. AG104A, B16 sowie RMA, Tumorkolonisierung stattfand. Zusätzlich wurde die 
Fähigkeit der Bakterien, Tumore in verschiedenen spontanen Tumormodellen anzuvisieren, 
untersucht, z.B. in dem Hepatom-Modell (Albumin-Tag Mäuse), dem Insulinom-Modell 
(RIP.Tag-5 Mäuse) oder den Mammakarzinom-Modell (Her-2/neu Mäuse). Mit Hilfe des BLI 
konnte das bakterielle „homing“ in diese Tiermodellen untersucht werden und zeigte, dass die 
Effizienz des „tumor targeting“ geringer war als in subkutanen Tumoren. 
Außerdem konnte nachgewiesen werden, dass Bakterien als Vektoren für GM-CSF und IL-2 
genützt werden können, um die Abwehr von Tumoren durch das Immunsystem zu verstärken. 
Damit eine Sekretion von GM-CSF und IL-2 mit Hilfe des Bakterienstammes Top10.lux im 
Tumorgewebe ermöglicht werden konnte, wurden die entsprechenden DNA-Sequenzen in ein 
Hemolysin A sekretorisches System kodierendes Plasmid inseriert. Die therapeutische 
Vakzinierung zeigte, dass Mäuse mit subkutanen Tumoren nach intravenöser Injektion mit 
Top10.lux.GM-CSF keine verstärkte Verzögerung des Tumorwachstums aufweisen, was im 
Gegensatz dazu bei Injektion mit Top10.lux beobachtet wird. 
Um die Infiltration von T-Zellen in das Tumorgewebe zu analysieren, wurde zusätzlich eine 
transgene Mauslinie (CAG-L2ACh) generiert, die CBGr99-positive Zellen liefert. Die CAG-
L2ACh Linie koexprimiert CBGr99 und ein rot fluoreszierendes Protein (mCherry) unter der 
Kontrolle eines ubiquitären Promoters. Anhand des BLI konnte in allen Geweben eine 
CBGr99 Expression festgestellt werden. Jede einzelne T-Zelle exprimierte mCherry und 
somit CBGr99. Daher zeichnet sich die CAG-L2ACh Linie als universeller Donor für „cell-
trafficking“ Studien mit Hilfe der BLI-Methode aus.  
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1. Imaging 
 Tumor imaging in mouse model of cancer 
The ability to manipulate the mouse genome has resulted in improved mouse models of 
human diseases. Transgenic mouse lines were generated in which inactivation of genes or 
expression of oncogenes leads to the development of autochthonous tumors. These models 
better recapitulate many futures of human tumorigenesis and facilitate the understanding of 
cancer development as well as the development of novel tumor therapies. However, the 
stochastic and often non-visible nature of tumorigenesis has limited their applications. 
Imaging techniques could be used to obviate these limitations allowing identification of tumor 
bearing mice and monitoring the tumor responses to therapy. The imaging modalities 
commonly used in cancer patients have been adapted for use in small animals, including 
magnetic resonance imaging (MRI), computed tomography (CT), positron emission 
tomography (PET), single photon emission computed tomography (SPECT) and ultrasound 
(US). Several features should be taken into account when selecting an imaging modality for 
use in the laboratory as each of these approaches has its advantages and limitations (Table1). 
 
 MRI 
MRI uses strong magnetic fields to align the spin of hydrogen nuclei in tissues. A pulse of 
radiowaves is applied, which “flips” the spin of the hydrogen nuclei into an exitated state. The 
relaxation of the spin of the hydrogen atom to realign with the principal magnetic field emits 
pulse of radiowaves that are detected and quantified. Contrast agents modulate the properties 
of the tissues and can enhance the signal. There is no loss of resolution due to the changes in 
tissue depth (Massoud and Gambhir, 2003).  MRI allows a much higher spatial resolution 
than optical techniques. It is also safer than techniques that use ionizing radiation. In small 
animals, MRI has shown promise in stem cell and lymphocyte trafficking studies (Rudin et 
al., 1999). The major drawbacks are the relative long time required for imaging (sometimes 
several hours). Moreover the use of contrast agents may be toxic and the sensitivity is 
relatively poor, thus requiring accumulation of large amounts of a molecular probe at a target 
site. 
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 CT 
CT imaging is most commonly method used for identification of anatomical structures. 
Images are obtained from the differential absorption of the X-rays through the various tissues. 
The resolution achievable is 50 µm, and there is no limit on the depth of penetration. CT 
refers to the method of obtaining serial images and volumetric data from the source and 
detector around the specimen. Unlike MRI, there are little natural contrasts between different 
soft tissues. CT has limited potential as a molecular imaging tool owing to the difficulty in 
designing contrast agents and probes for this modality. 
 
 US 
Ultrasound pictures are obtained by using high-frequency sound waves that are transmitted 
through tissues and are then reflected back and detected. Diagnostic ultrasound using 7.5-15 
MHz frequencies has a spatial resolution of 300-500 µm, while ultrahigh frequency (40 MHz) 
systems have been developed for mouse imaging than can obtain resolution of 40-60 µm 
(Foster et al., 2002). Typically, US is used to observe perfusion and anatomical 
characteristics. 
 
 PET and SPECT 
PET is used to detect decaying nuclides such as 
11
C, 
18
F, 
15
O, 
124
I. PET images the distribution 
in vivo of trace quantities of positron-emitting molecular probe. Positrons emitted from the 
probe travel few millimeters in the tissue before being annihilated by collision with an 
electron resulting in a pair of high-energy photons. These photon pairs are detected by the 
PET scanner and are then used to reconstruct volumetric images of the positron emitting 
probe (Reader and Zweit, 2001). This technique can be applied in studies of gene therapy and 
gene expression in transgenic mice. 
SPECT acquires information on the concentration of gamma emitting radionuclides, such as 
111
IN, 
123
I, 
201
TI introduced into the organism. These radionuclides emit a single photon. 
SPECT imaging involves the rotation of a photon detector array around the body to track the 
position and concentration of radionuclide distribution from multiple angles. SPECT has been 
used to image cell-surface-expressed receptors and transporters (Zinn et al., 2001). 
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 Optical imaging 
Additional modalities based on genetically engineered proteins are also available including 
optical imaging technologies that detect fluorescence or luminescence. Optical imaging holds 
several advantages over the other imaging modalities. Imaging times are shorter and multiple 
animals can be imaged simultaneously. Operation of a CCD camera is typically easier than 
that of other modalities, permitting the use by a non-specialist. Optical imaging also permits 
quantification of metabolically active cells and permits the visualization of gene expression 
(Rice et al., 2001). For the purpose of our studies, bioluminescence imaging is superior to 
other optical methods, such as fluorescence. A key advantage of BLI is that no light is 
produced or detectable until the substrate/enzyme interaction of luciferase and luciferin 
occurs. Consequently, there are very low background luminescence levels in mice. In 
contrast, the light used for excitation in fluorescence imaging can also excite other fluorescent 
molecules within tissues, and often results in high levels of background autofluorescence that 
sometimes hinders detection of the reporter proteins.  Moreover, in fluorescence imaging the 
tagged cells within an animal need to be illuminated with an external light source in order to 
fluoresce, essentially doubling the path length for the light during which it can be scattered or 
absorbed in the tissue before it is detected.  
Table 1 summarizes the main features of the various imaging systems. 
 
 MRI CT PET SPECT BLI US 
Equipment size Large Small Small Small Small Small 
Resolution High High Low Low Low High 
Session time Hours Minutes Hours Hours Minutes Minutes 
Provides functional 
information 
Not 
usually* 
No Yes Yes Yes Not usually 
Staffing/training 
requirements 
High Intermediate Intermediate Intermediate Low Intermediate 
Table 1 : Comparison of tumor imaging modalities for use with small animals. (Adapted from Olive and 
Tuveson; 2006) 
*advance applications incorporate magnetic particles or other contrast agent to provide functional information. 
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 Bioluminescence imaging 
 Bioluminescence 
Bioluminescence exists in nature in a variety of forms. A number of organisms emits visible 
light, ranging from the firefly to marine bacteria. Organisms exhibit bioluminescence for a 
variety of reasons: courtship and mating signaling, luring prey, defense, camouflage, and in 
response to stress (Greer and Szalay, 2002). This natural phenomenon has been harnessed for 
use in research as an optical reporter tool. Bioluminescence results from interaction of the 
luciferase enzyme with the substrate luciferin in presence of oxygen. A wide range of 
luciferase enzymes exists, each of which catalyze the oxidation of luciferin with 
corresponding release of photons of light. Luciferases have been cloned and their chemical 
properties characterized to a point where they can be used routinely in the laboratory. 
 
 Principle of Bioluminescence imaging 
Bioluminescence imaging (BLI) of tissues requires that the gene encoding the bioluminescent 
reporter protein has been transferred to tissues of interest. This can be accomplished using any 
number of standard gene transfer method such as virus infection, bacteria or cell injection and 
also constitutive or inducible expression of luciferase genes in transgenic mice [Fig. 1A and 
B]. For BLI, the animals are anesthetized and placed in a light-tight box equipped with a CCD 
camera [Fig. 1C]. A grayscale reference image is acquired under weak illumination thereafter 
in complete darkness the photons emitted from luciferases in the body of the animals are 
detected externally using a range of integration times from 1 s to 5 min. The data are 
transferred to a computer equipped with an image acquisition and analysis software for 
quantification [Fig. 1D]. To display the anatomical origin of photon emission, a pseudocolor 
image representing light intensity is generated and superimposed over the grayscale reference 
image. The observation and the quantification of the photons emitted by the reporter 
expressed in these cells that pass through the host tissue reveals the spatial and temporal 
distribution of the labeled cells in the living animal. 
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Figure 1 : Schematic of bioluminescence imaging. 
(A) Cells, infectious agents or genes can be bioluminescently labeled. (B) Live mice harboring labeled cells or 
genes are imaged with (C) a CDD camera mounted on a black box. (D) Acquired data can be quantified with 
imaging software.   Adapted from Doyle et al 2004 (Doyle et al., 2004). 
 
 Luciferases 
 Firefly luciferase 
The firefly (Photinus pyralis) is one of the most familiar bioluminescent organisms. The 
luciferase from this organism is a single polypeptide related to the CoA ligase family proteins 
(Conti et al., 1996). It uses luciferin substrate together with ATP and oxygen for generation of 
light through the following reaction (Gould and Subramani, 1988).  
 
 
 
In the presence of oxygen, magnesium, and ATP, the reaction of the luciferase enzyme with 
the substrate luciferin yields an electronically excited oxyluciferin. The return of oxyluciferin 
to its ground state is accompanied by the release of a single photon (Nguyen et al., 1988). 
Thus, in the presence of excess luciferin, oxygen, and ATP, the number of photons emitted is 
proportional to the number of molecules of luciferase present (Brasier et al., 1989). The gene 
encoding firefly luciferase (Fluc) has been cloned, and the coding sequence has been 
optimized for mammalian expression (de Wet et al., 1987). Cells expressing this enzyme, 
when provided with luciferin, will emit a yellow-green light with an emission peak at ~ 560 
nm using cellular ATP as the energy source. Recently, green (CBGr68; CBGr99) and red 
(CBRed) luciferases from yellow click beetle (Pyrophorus plagiophthalamus) have been 
cloned and optimized for mammalian expression. They also use luciferin as a substrate and 
have been reported to exhibit a spectral peak at 543 and 618 nm, respectively.  
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 Renilla luciferase 
Bioluminescence is common in the marine Cnidaria. The luciferase from the sea pansy 
Renilla has been cloned and sequenced (Lorenz et al., 1991). This enzyme uses coelenterazine 
as a substrate. Unlike the firefly luciferase, it does not require a cellular energy source; the 
coelenterazine substrate itself provides the necessary energy (Cormier et al., 1989).  Light 
emission from the enzymatic reaction peaks at ~ 475 nm. 
 
Renilla luciferase catalyzes the oxidative decarboxilation of coelenterazine in the presence of 
dissolved oxygen to yield coelenteramide, CO2, and blue light. 
 
 Bacterial luciferase (lux operon) 
Several bacteria use a dimeric luciferase to generate light using as substrate long-chain fatty 
aldehydes (e.g. decanal), reduced flavin mononucleotide (FMNH2) and oxygen to produce a 
blue-green light (emission peak at 490 nm).  
 
 
 
For all the bacterial luciferases characterized to date, the gene lux that encodes the luciferase 
enzyme (Lux) and biosynthetic enzyme for synthesis of the substrate are present in a single 
operon (the lux operon). There are 5 genes called luxA-luxE, with luxA and B encoding the 
alpha and beta subunits of the heterodimeric luciferase and lux CDE encoding proteins for 
aldehyde production (Meighen, 1993). The lux operon from P.luminescens is ideally suited 
for the study of pathogens in mammalian animal models as the enzyme retains significant 
activity at 37°C (Meighen and Dunlap, 1993; Szittner and Meighen, 1990). 
 
 Light transmission through mammalian tissue 
The signal intensity at the animal surface is dependent on the optical properties (absorption 
and scattering) of the tissues through which the photons pass. Blue and green light 
(wavelengths shorter than 600 nm) are largely absorbed by tissues, and red light (wavelengths 
longer than 600 nm) is less affected. The pigment hemoglobin is the primary absorber in the 
body with strong absorption peaks in blue-green wavelengths. Melanin in the skin is also a 
significant contributor to absorption if the animal is pigmented.  Therefore it is preferable to 
use a red light emitting luciferase as a source of light for a higher sensitivity (Zhao et al., 
2005) . Rluc, for example, hardly emits light above 590 nm. Thus light produced by Rluc 
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would not be expected to transmit through deep tissues. In contrast about 30% of the emission 
spectrum of Fluc is above 600 nm, which is probably the region of the emission spectrum 
which is detected when used an in vivo reporter [Fig. 2] (Rice et al., 2001).  
 
 
Figure 2 : Comparison of luciferases emission spectrum 
 
 Use of BLI in monitoring biological processes 
Many small animal models of human biology and disease have been investigated successfully 
using BLI. This modality was first demonstrated using bacteria, Salmonella typhimurium, that 
were engineered to express the lux operon (Contag et al., 1995). In infected mice the labeled 
bacteria were detectable in various organs. Since this initial demonstration many bacterial 
strains have been engineered similarly  and used in different models of infectious disease 
(Burns et al., 2001). BLI can be used to either track the course of an infection or monitor the 
efficacy of antimicrobial therapies. Similarly, other classes of pathogens such as fungi and 
viruses have been engineered to express luciferase or deliver luciferase genes to host cells 
(Cook and Griffin, 2003; Luker et al., 2002).  
An essential step towards being able to monitor host response to infection was to label 
mammalian cells and assess cell numbers and gene expression patterns in vivo (Contag et al., 
1997). This was most easily demonstrated in tumor models where cells can be engineered in 
culture and transferred to animal models (Mandl et al., 2002; Sweeney et al., 1999). This has 
proven to be a powerful approach to study tumor biology as signals originating in body 
tissues can be detected thereby allowing measurements of tumor growth. Patterns of gene 
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expression have also been imaged in animal models using transgenes composed of the 
luciferase linked to specific promoters (Contag et al., 1997).  
BLI has also lent itself to extending some of the innovative tools developed for the study of 
molecular events in cells and cell lysates into similar studies in live animals. Tools such as the 
yeast two-hybrid screen to identify protein–protein interactions have been modified for use in 
living rodents (Ray et al., 2002), as has the suppression of gene expression by RNA 
interference using small RNA molecules (McCaffrey et al., 2002; McCaffrey et al., 2003) 
with bioluminescence as the reporter. As such, these approaches can be validated in the more 
complex milieu that exists in the animal that is absent in cultured cells. 
 
2. Animal models for tumor immunology 
Animal models have played and still play a critical role in establishing basic paradigms of 
tumor immunology because they provide an in vivo milieu that cannot be reproduced in vitro. 
Animal models are also often important for the development of novel immunotherapies and 
for preclinical testing. Therefore, much effort has been invested into the establishment of 
murine models that closely mimic pathological and biochemical features of cancer in humans. 
Historically, investigators have used transplantable tumor models, in which inbred animals 
are inoculated with tumor cells. The transplantation tumors were initially derived from 
spontaneous occurring malignancies or induced by chemicals or irradiation, and maintained 
either by in vivo or in vitro passage. Unfortunately, many of these tumor models are not good 
predictors for human clinical trials, as numerous therapies that look promising in 
experimental animals have turned out to be ineffective in patients. Therefore, efforts have 
been directed towards the development of transgenic mouse models in which tumors develop 
spontaneously and thereby mimic the complex set of interactions occuring in human tumor 
development. 
 
 Transplantable tumor models 
Experiments with transplantable mouse tumors are usually performed with well characterized 
tumor lines that are maintained in vitro. This allows the execution of experiments under well 
standardized conditions concerning the minimal lethal dose, the latency and the growth 
characteristics in syngeneic recipients, or immunodeficient nu/nu mice, as in the case of 
xenotransplanted human tumors. Although transplantable tumors have long been integral to 
tumor immunology research, their applicability to human disease is limited which, therefore, 
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renders them less optimal for predicting immunotherapy efficacy in patients. First, 
transplanted tumors are typically inoculated subcutaneously (s.c.) or intravenously (i.v.) and 
therefore do not grow in the anatomical appropriate site. As a result the animal model does 
not mimic the organ-specific physiological characteristics of the tumor. Hence, the positive 
responses of such tumors to certain therapies have been questioned. In some cases it has been 
shown that orthopically transplanted tumors do not necessarily recapitulate the “encouraging” 
responses of their ectopically grown counterparts (Wilmanns et al., 1992). Second, 
transplantable tumors generally grow very rapidly following inoculation, whereas 
spontaneous human tumors tend to develop more slowly through a gradual series of cellular 
changes from pre-malignant to malignant stages. Therefore, the immune system of patients 
may gradually accept the tumor, whereas in transplanted mice the immune system is abruptly 
exposed to the foreign tumor antigens. Third, vaccination against “artificial” tumor antigens 
only expressed by transplanted tumor may be totally foreign for the mouse. In this case, the 
induction of a protective immunity against the transplanted tumor does not have to overcome 
tolerance. Most human cancer antigens are normal, non-mutated differentiation molecules or 
non-mutated proteins found only in tumor germ cells. Therefore, the human immune system 
is often tolerant of these tumor antigens, either completely or partially. Despite these short 
comings, transplantable tumor models are still useful for many aspects of tumor 
immunological studies, but it is clear that models are required that mimic the clinical 
situation. 
 
 Autochthonous tumor models 
Autochthonous tumors, e.g. spontaneously occurring tumors and chemically, virally, or 
carcinogen-induced tumors are believed to model human tumors more closely than 
transplanted tumors. Advantages of autochthonous tumors include orthotopic growth, tumor 
histology devoid of transplantation introduced changes, and metastasis via lymphatic and 
vascular vessels surrounding and within primary tumor. Despite the significance of 
spontaneous and environmentally induced tumor model to biomedical research, the long 
latency of most of these models make them impractical for most preclinical studies of tumor 
modulation.  
In the last decades of the 20
th
 century, mammalian genetics has been revolutionized by the 
development of methods for modifying the mouse germ line. Efforts have been directed 
towards developing transgenic mouse models in which tumors develop spontaneously and 
progress through the pre-malignant and malignant stages; defined antigens are expressed so 
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that the host is tolerized to tumor-encoded molecules. In the initial models viral and cellular 
oncogenes were overexpressed (Brinster et al., 1984). Subsequent studies used genes targeted 
to mouse embryonic stem cells, providing oncogene-bearing transgenic mice (knockin) or loss 
of function (knockout mice). In addition, to the use of transgene overexpression models, 
conditional strategies have been developed that allow controlled gene expression in both a 
tissue- and temporal-specific manner. Therefore, tumors arise when the host has a mature 
immune system as they do in humans. 
 
 SV40-driven transgenic models  
Numerous transgenic mice have been generated by placing the transforming genes of SV40 or 
polyoma virus early regions under the control of a tissue or cell specific promoter. These mice 
spontaneously develop tumors in the targeted tissue. These models are useful because the 
mice develop organ-localized tumors and in some cases metastatic lesions (Masumori et al., 
2001). The early region of simian virus 40 (SV40) encodes a large T antigen protein (Tag), 
which is a multifunctional regulatory protein responsible for the alterations of cellular 
processes required for viral infection (Dobbelstein et al., 1992). SV40 Tag forms complexes 
with and inactivates the key cell cycle regulatory proteins, such as p53 and retinoblastoma 
(Rb) tumor suppressor gene product (DeCaprio et al., 1988; Dobbelstein et al., 1992). Loss of 
these functional tumor suppressor gene products is often associated with human’s cancers. 
SV40 Tag has been used to generate a variety of transgenic models for cancers such as bone 
sarcoma (Marton et al., 2000), hepatoma (Paul et al., 1988), prostate cancer (Greenberg et al., 
1995), ovarian cancer (Connolly et al., 2003), pancreatic cancer (Hanahan, 1985), and 
melanoma (Bradl et al., 1991). 
However, most of these models share a major limitation. Unlike human malignancies, which 
typically develop after birth, the transgenes in these mouse models are often expressed during 
embryonic development. Therefore disease onset is much earlier than in humans and the 
kinetics of tumor progression do not parallel those of human malignancies. 
 
 Inducible gene expression systems 
A number of inducible systems that can be used effectively to switch genes on and off in vivo 
have been developed. These include interferon (Bachiller and Ruther, 1990), tetracycline 
(Furth et al., 1994), Ru-486 (Morgan et al., 1999) controlled gene expression. These systems 
permit both reversible expression and tuning level of expression. Although there is a growing 
number of reports in which regulatable systems have been shown to work reliably in vivo in 
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mice, it is still not routine methodology to produce such mice. A number of variables, such as 
the promoter used, the site of transgene insertion can profoundly influence the expression and 
regulation characteristics. Extensive characterization of resultant transgenic lines is therefore 
inevitable and often a significant number has to be screened before the suitable line is 
obtained. In this class of approaches, the most widely used and characterized is the Cre 
recombination system that allows conditional gain or loss of gene expression.  
  
 Cre/LoxP system 
Site-specific DNA recombinase technology provides a means to delete, insert, invert or 
exchange chromosomal DNA with high fidelity. The Cre recombinase (causes 
recombination), a protein from bacteriophage P1, recognizes a 34 bp long sequence called 
loxP (locus of crossing-over). This sequence consists of an 8 bp long asymmetric core 
sequence, which is flanked by two 13 bp inverted sequences [Fig. 3A] (Sadowski, 1993). 
Three different combinations can be used, inversion (head-to-head), excision (head-to-tail) or 
translocation (different strands). 
The most powerful application is conditional gene inactivation, which allows analysis of the 
later functions of an essential gene (Lobe and Nagy, 1998; Lomeli et al., 2000; Sauer, 1998). 
The region to be deleted is flanked by loxP sites in such a way that does not disrupt 
expression of the wild type gene. The recombinase can be introduced via intercrosses with 
transgenic mice that express Cre in a cell or tissue specific manner. Thus, by controlling the 
expression of Cre it is possible to control where the knockout is produced [Fig. 3B]. For 
example, mice nullizigous for either Brca1 or Brca2 die early in embryogenesis, and 
heterozygous mice are not predisposed to tumorigenesis as are humans harboring a mutation 
of either gene. However, conditional mutation of either gene in the mammary epithelium 
promotes mammary tumorigenesis (Xu et al., 1999). Because a larger number of characterized 
promoters are now available, it is possible to express Cre in a variety of tissues and cells in 
the mouse, making modeling of cancer simple and efficient (Sauer, 1998). It is also possible 
to use viral systems or inducible systems to deliver Cre to specific regions of tissues or to 
more finely control Cre expression (Shibata et al., 1997; Xu et al., 1999).  
Another way to make use of the Cre/loxP system is to induce gene activation. The promoter 
and the coding region for the gene of interest can be separated by a loxP-flanked STOP 
region, which does not allow transcription iniated from the promoter to be read through. 
When the STOP region is removed by Cre-mediated excision, the gene can be expressed [Fig. 
3C]. Because targeted gene expression as well as Cre recombinase expression can be 
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modified through a tissue specific promotor, this system provides various combination 
possibilities (Sauer, 1998). The first demonstration of this idea was a lens-specific activation 
of Tag through Cre mediated excision (Lakso et al., 1992). Additional models have been 
developed that use recombination to limit the activation of K-ras oncogene to specific cells 
(Jackson et al., 2001; Meuwissen et al., 2001). Removal of the STOP element and activation 
of K-ras was accomplished by recombinant Cre adenovirus delivered to the lung, resulting in 
tumors. 
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Figure 3 : The Cre/loxP system. 
(A) DNA sequence of loxP site. The 13 bp inverted repeats (palindromes) flank an 8 bp asymmetric core 
sequence where the recombination exchange takes place. Strand cleavage positions are after the first, and 
before the last base of the 8 bp core. (B) Recombitional gene inactivation. Cre transgenic mice are mated with 
transgenic mice harboring a lox-flanked exon of the gene to inactivate. In the resulting transgenic mouse, 
excision of the exon leads to inactivation of this gene in the targeted cell type. (C) Recombitional activation of 
gene expression. Mice carrying the dormant gene are mated with Cre transgenic to generate a doubly transgenic 
mouse in which Cre has evicted the STOP sequence to activate the dormant gene. Restriction of expression of 
the transgene to a particular tissue can be achieved by a suitable choice of promoter for both the reporter and 
the cre gene. Thin arrows indicate transcription. 
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 Conditional liver tumor model 
To develop an inducible tumor model for autochthonous liver tumors, an Albumin-floxstop-
Tag (AST) transgenic mouse was generated in our laboratory (T. Sacher; PhD thesis). The 
albumin promotor/enhancer and the Tag oncogene are separated by a STOP cassette flanked 
by loxP sites. After excision of the STOP cassette by Cre Recombinase, Tag oncogene 
expression is initiated. Mating of AST mice with Cre deleter mice, which express Cre 
recombinase ubiquitously (Schwenk et al., 1995) leads to double transgenic mice that have 
been shown to express Tag already two days after birth. Tag expression results in the 
development of liver dysplasia at the age of four weeks, proceeding over nodular carcinoma 
into multinodular hepatocellular carcinoma (HCC) accompanied by a dramatically decreased 
life span of about 12 weeks. Tumor formation is observed exclusively in the liver whereas 
AST single transgenic show no signs of tumor growth in the liver or other organs at the age of 
12 months as examined by histology. 
To obtain temporal control over Tag expression, a recombinant adenoviral vector encoding 
cre was generated. Intravenous injection of the adenovirus vector into AST mice mediates 
recombination in vivo mainly in the liver due to the tropism of the adenovirus. Within three 
months, injected mice develop liver tumors in a dose dependant manner. Low dose 
adenovirus injection leads to formation of dysplasia and small nodular adenoma or carcinoma 
while high dose inoculation results in multinodular HCC. [Summary of AST transgenic 
characterization done by S.Stahl, PhD thesis]. 
 
3. Bacteria and anticancer therapies 
 Bacteria and tumor colonization 
Live bacteria were first actively used in the treatment of cancer nearly 150 years ago. The first 
cancer patient to be purposefully infected with bacteria was probably treated by the German 
physician W. Busch in 1868. Busch induced a bacterial infection in a woman with an 
inoperable sarcoma by cauterizing the tumor and placing her in bedding previously occupy by 
a patient with “erysipelas” (Streptococcus pyogenes). Busch reported that within a week the 
primary tumor had shrunk by half that lymph nodes in the neck had also shrunk in size. 
Almost 30 years later, William B. Coley encountered a patient with cancer who seemed to be 
cured by a severe erysipelas infection (Coley, 1991). This observation led Coley to 
deliberately infect patient with S.pyrogenes. Unknown from Coley, similar studies had 
already started in 1883. The German surgeon, Friedrich Fehleisen, had successfully identified 
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S.pyrogenes as the cause of erysipelas and had treated cancer patients with live bacteria. 
However, all these studies are anecdotal. Moreover, they clearly would not conform with our 
standards for clinical trials. Since these early studies, many bacteria have been shown to 
infiltrate, replicate and preferentially accumulate in tumors (Table 2). These observations 
have renewed the interest in the use of bacteria as gene delivery vehicles for tumors. 
 
Organism Ref Model Length Strategy Results 
Clostridium 
tetani*  
(Malmgren and 
Flanigan, 1955) 
Carcinoma, 
hepatoma 
2 days 
Localization of obligatory 
anaerobic C.tetani to 
hypoxic and necrotic 
regions in tumors 
Rapid death of tumor 
bearing mice 
Clostridium 
butyricum* (M-
55) 
 
(Moese and 
Moese, 1964) 
Ehrlich 
carcinomas 
Short-until 
death 
Identification of the most 
effective of 14 different 
clostridium species 
Regression but eventual 
animal death 
Clostridium 
beijerinckii* 
 
(Lemmon et al., 
1997) 
EMT6  
Clostridium delivery of 
nitroreductase to activate 
prodrug CB 1954 
Nitroreductase activity 
detected in tumor lysate 
Bifidobacterium 
infantis * 
(Kohwi et al., 
1978) 
Meth-A sarcoma 30 days 
Targeted 
immunomodulation 
Tumor regression 
Bifidobacterium 
bifidum* 
 
(Kimura et al., 
1980) 
Fibrosarcoma 90 days 
B.bifidum to identify 
tumors 
B.bifidum localize to 
tumors and its non toxic 
Bifidobacterium 
longum* 
(Yazawa et al., 
2000) 
B16-F10 
melanoma 
7 days 
Gene delivery using 
engineered 
Bifidobacterium 
Engineered bacteria found 
only in tumors 
Salmonella 
typhymurium  
(Low et al., 
1999) 
B16-F10 
melanoma 
40 days 
Attenuated toxicity of 
Salmonella and  tumor 
targeting 
Significant delay in tumor 
growth 
Salmonella 
typhymurium 
 
(Clairmont et 
al., 2000) 
B16-F10 
melanoma 
30 days 
Attenuated Salmonella 
target tumor over other 
organs 
Accumulate in tumor 
>1,000 fold 
Vibrio cholerae 
 
(Yu et al., 2004) C6 glioma 6 days 
V.cholerae expressing 
lux.operon to visualize 
tumor by BLI 
Tumor colonization 
observed until day 6 
E.coli (DH5α) 
 
(Yu et al., 2004) C6 glioma 6 days 
DH5α expressing 
lux.operon to visualize 
tumor 
Tumor colonization 
observed until day 6 
Table 2 : Examples of bacteria therapy of tumors in mice. (Adapted from Jain and Forbes; 2001).  
All organism marked with * are obligatory anaerobic whereas the other are facultative anaerobic 
 
 Why do bacteria colonize tumors? 
Early observations that strains of Clostridia preferentially proliferate in necrotic centers of 
tumors (Moese and Moese, 1964) lead to hypothesis that, unlike normal tissues, the hypoxic 
environment in tumors provides anaerobic growth conditions (Dang et al., 2001; Lemmon et 
al., 1997), as it may do for the growth of anaerobic Bifibacterium longum (Yazawa et al., 
2000). If the anaerobic/necrotic environment is a pre-requisite for accumulation of anaerobic 
bacteria it may limit the use of bacteria in the treatment of cancer. However, it was 
demonstrated that the vast majority of human tumors contain large necrotic regions. Of 20 
randomly selected liver metastasis (>1cm³) all contained relatively large (25-75%) avascular 
regions (Dang et al., 2001). One major advantage that facultative anaerobes have over 
obligatory anaerobes is that their entry and accumulation in the tumor is not dependent upon 
tumor size, as small bladder (~10 mm³) and large glioma and breast (100-400 mm³) tumor 
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were colonized equally well, as well as micrometastases (Lee et al., 2005; Luo et al., 2001). 
Interestingly, auxotroph mutants of S.typhimurium have been shown to multiply in tumors in 
mice (Pawelek et al., 1997; Sznol et al., 2000). Therefore, anaerobicity in the necrotic center 
of tumor alone is not the factor that determines bacteria accumulation in the tumor. 
It is also believed that the tumor microenvironment is an immunological sanctuary, where 
bacterial clearance mechanisms are less active. Light-emitting bacteria have identified three 
sites of bacterial accumulation after initial infection (incision wound, primary tumor and 
metastatic tumors) (Yu et al., 2004; Yu et al., 2003). This suggests that elimination of bacteria 
from the primary tumor may not occur due its impaired lymphatic system and poor 
vasculature network. Therefore the degree of vascularization and the state of the lymphatic 
system seem to be determining factors for colonization. Thus an established tumor can protect 
bacteria from immune clearance. However, the majority of malignant tumors contain a mixed 
array of cell types, including infiltrating leukocytes whose most-prominent component is 
macrophages (Murdoch et al., 2004). These phagocytic scavenger cells are found in both the 
well vascularized stromal tissue and the avascular, hypoxic/necrotic areas, where they are 
closely associated with tumor cells. However once macrophages have migrated into the 
hypoxic/necrotic regions of the tumor, it appears that their production of reactive oxygen and 
nitrogen species is lost (Siegert et al., 1999) and their ability to make ATP is decreased 
(Leeper-Woodford and Mills, 1992) rendering them non-phagocytic. The activities of other 
immune cell types (T lymphocytes and polymorphonuclear neutrophilic granulocytes) are also 
inhibited under hypoxic conditions (Bjerknes et al., 1990; Robbins et al., 2005). Therefore in 
many respects the tumor microenvironment appears to provide an immune privileged site.  
 
 Bacteria as a vaccine vehicle 
Based on the observations that bacteria preferentially localize and proliferate in tumors, the 
use of bacteria as a tumor-targeting vector for the delivery of therapeutic agent was 
investigated. Indeed, bacteria present several advantages of being use as a vector (i) they are 
non toxic to the host; (ii) they are only able to replicate within tumor; (iii) they are slowly and 
completely eliminate from the host (iv) they can express multiple therapeutic  transgene due 
to their large genome size. Several therapeutic options have been already investigated like the 
delivery of eukaryotic antigen expression vectors into professional antigen presenting cells of 
the vaccinated host (Dietrich et al., 1998) or the delivery of therapeutic genes encoding 
angiogenic inhibitors or prodrug-converting enzymes (King et al., 2002; Lee et al., 2004; 
Yazawa et al., 2000; Zheng et al., 2000).  
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4. Aims of the study 
The main goal of my PhD thesis was the establishment of in vivo BLI tools for tumor 
immunology studies. For this purpose, this thesis is organized in four interrelated parts:  
 
• Determination of the most appropriate luciferase for in vivo BLI. 
 
• Generation of a conditional hepatocarcinoma model for BLI. 
 
• BLI of tumor targeting by bacteria and their usage in tumor therapy. 
 
• Generation of a transgenic mouse line that can be used as source of luciferase positive 
cells for transplantation and cell tracking studies in vivo by BLI. 
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1. Material 
1.1 Chemicals 
All reagents used in this study were of molecular biology grade and obtained from 
commercial sources: Sigma (Deisenhofen), Serva (Heidelberg), Merck (Darmstadt), Roche 
(Mannheim), Gibco-BRL (Eggenstein), and Roth (Karlsruhe). Restriction/modifying enzymes 
and molecular biological reagents were obtained from Fermentas Life Sciences (St. Leon-Rot) 
or New England Biolabs (Frankfurt). Plasmid isolation, gel extraction and PCR purification 
kits used in this study were obtained from Qiagen (Hilden). 
 
1.2 Basic equipment 
Plastic articles for cell culture and for molecular biological works were purchased from 
Eppendorf (Hamburg), Gilson (Villiers le Bel), Greiner (Frickenhausen), Falcon (Heidelberg), 
Nalgene (Rochester, USA), Nunc (Wiesbaden), Hybaid (Heidelberg), and Renner 
(Darmstadt). 
 
1.3 Kits 
Qiaquick Gel extraction Kit (Qiagen): Purification of DNA fragments from agarose gels via 
columns. 
Reflotron™ GPT (ALT): Measurement of Alanine aminotransferase activity. 
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1.4 Technical devices 
Name Company 
Centrifuge Minifuge Heraeus Christ (Osterode) 
Centrifuge Sorvall RC5C Plus Kendro (Hanau) 
Centrifuge TJ-6 Beckmann (Palo Alto, USA) 
Desk centrifuge Biofuge pico Heraeus (Osterode) 
Electrophoresis chamber Easy Cast MWG Biotech GmbH (Ebersberg) 
FACSAria Cell-sorting System Becton Dickinson (Heidelberg) 
FACSDiva Cell-sorting System Becton Dickinson (Heidelberg) 
FACScan/FACS-Calibur Becton Dickinson (Heidelberg) 
Fridges-freezers Bosh, Liebherr 
Ice machine Wessamat Zugck (Leimen) 
Incubator 3029 Forma Scientific (Egelsbach) 
IVIS® imaging system 100 Xenogen (Alameda, USA) 
Lumi-Imager Boehringer Mannheim (Mannheim) 
Magnetic stirrer Heidolph (Schwabach) 
Microscope Olympus (Hamburg) 
Millex-Gs, syringes and filters Millipore (Bedford, MA, USA) 
PCR block Peltier Thermal Cycler 200 MJ research Inc. (Watertown, USA) 
pH-meter 761 Calimetric Knick 
Photometer Ultraspec 2000 Pharmacia Biotech (Freiburg) 
Pipetman-pipets Gilson 
Sterile bank Biogard Hood Baker Company Inc. (Maine, USA) 
Thermomixer Compact Eppendorf (Hamburg) 
Reflovet™ plus (ALT measurement) Roche 
Waterbath (shaking) Köttermann (Hänigsen) 
 
 
 
 
 
 
 
Material and methods 
22 
1.5 Buffers and solutions 
For the preparation of buffers and solutions double distilled and autoclaved water was used. 
The concentration factor for stock solutions is listed in brackets. Autoclaved solutions (121°C, 
25 min) are marked with *. The storage of solutions at temperatures other than room 
temperature the degrees are listed in brackets. Percentages are referred to as weight per 
volume (w/v). 
Buffers : Molecular biology 
dNTP mix (10x) for Taq polymerase (-20°C) 
10 mM dATP 
10 mM dTTP 
10 mM dCTP 
10 mM dGTP 
ligation buffer (10x) (-20°C) 
500 mM Tris/HCl pH 7.5 
100 mM MgCl2 
20 mM DTT 
20 mM spermidine 
O
+
 (10x) (-20°C) 
(reaction buffer for restriction enzymes) 
500 mM Tris/HCl pH 7.5 
100 mM MgCl2 
1 M NaCl 
1 mg/ml BSA 
 
G
+
 (10x) (-20°C) 
(reaction buffer for restriction enzymes) 
100 mM Tris/HCl pH 7.5 
100 mM MgCl2 
500 mM NaCl 
1 mg/ml BSA 
Y
+
/Tango (2x) (-20°C) 
(reaction buffer for restriction enzymes) 
66 mM Tris acetate pH 7.9 
20 mM Mg acetate 
132 mM KOAc 
0.2 mg/ml BSA 
R
+
 (10x) (-20°C) 
(reaction buffer for restriction enzymes) 
100 mM Tris/HCl pH 8.5 
100 mM MgCl2 
1 M KCl 
1 mg/ml BSA 
CIAP buffer (10x) (-20°C) 
100 mM Tris/HCl pH 7.5 
100 mM MgCl2 
KOAc/HCOOH 
3 M KOAc 
5% HCOOH (v/v) 
B
+
 (10x) (-20°C) 
(reaction buffer for restriction enzymes) 
100 mM Tris/HCl pH 7.5 
100 mM MgCl2; 
1 mg/ml BSA 
PCR buffer (10x) (-20°C) 
100 mM Tris pH 8.3 
500 mM KCl 
25 mM MgCl2 ·6H2O 
Pre-lysis buffer 
50 mM glucose 
25 mM Tris/HCl pH 8.0 
10 mM EDTA 
TAE (10x) 
400 mM Tris/HAc pH 7.4 
50 mM NaOAc 
10 mM EDTA 
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Lysis buffer (NaOH/SDS) 
200 mM NaOH 
1% SDS 
Glycerol/CaCl2 
10% glycerol (v/v) 
100 mM CaCl2 
 
Loading dye 
0.1% bromphenol blue 
0.1% xylen cyanol FF 
15% glycerol 
Tail buffer 
100 mM Tris 
5 mM EDTA 
0.2% SDS 
200 mM NaCl 
TE (10x) 
100 mM Tris/HCl pH 8.0 
100 mM EDTA 
 
Injection Buffer 
10 mM Tris/HCl pH 7,5 
0.1 mM EDTA 
100 mM NaCl 
 
Buffers : Southern blot 
Prehybridization buffer (4°C) 
5x Denhardt´s 
4x SSPE 
1% SDS 
100 µg/ml salmon sperm DNA 
 
Hybridization buffer 
5x Denhardt´s 
4x SSPE 
1% SDS 
100 µg/ml salmon sperm DNA 
1% Blocking reagent 
Neutralization buffer 
500 mM Tris/HCl 
3 M NaCl 
pH 7.4 
Denaturation buffer 
500 mM NaOH 
1 M NaCl 
 
Wash buffer 
0.3x SSC 
0.1% SDS 
Dig buffer 1 
100 mM Tris-HCl pH 7,5 
150 mM NaCl 
Dig buffer 3 
100 mM Tris-HCl pH 9,5 
100 mM NaCl 
SSC(20x) 
3 M NaCl 
300 mM Natrium citrate 
pH 7.0 
Denhardt´s (-20°C)* 
1% Ficoll 
1% BSA 
1% Polyvinylpyrrolidon 
 
SSPE (20x) 
3.6 M NaCl 
200 mM NaH2PO4 
20 mM EDTA 
pH7.4 
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Buffers : Cell biology 
Trypan blue dye 
0.16% (w/v) trypan blue 
150 mM NaCl 
 
 
PBS (1x)* 
130 mM NaCl 
5 mM Na2HPO4 
2 mM KH2PO4; 
pH 7.4 
2X SDS-PAGE loading dye (-20°C) 
10mM Tris-HCl 
8% SDS 
25% glycerol 
0.02% Bromophenol blue 
4% ß-mercaptoethanol 
6X SDS-PAGE loading dye (-20°C) 
150mM Tris-HCl 
12% SDS 
30% glycerol, 
0.0015% Bromophenol blue 
5% ß-mercaptoethanol 
1x Lysis buffer (cell lysate) 
1% NP-40, 
1 protease inhibitor tablet in 50 ml 1x TBS 
Anode buffer 
25mM Tris base in H2O 
20% methanol 
pH 10.4 
Cathode buffer 
25mM Tris base in H2O (pH 9.4), 
40mM 6-aminocaproic acid 
Concentrated anode buffer 
300mM Tris base in H2O 
20% methanol 
pH 10.4 
Z-buffer 
PBS pH 7.6, 
9 mM MgCl2, 
 0.15 mM CRPG,  
100 mM ß-mercaptoethanol 
 0.125 % NP-40 
DPBS (Dulbecco`s Modified PBS)* 
8 g/l NaCl 
200 mg/l KCl 
100 mg/l MgCl2· 6H2O; 
100 mg/l CaCl2; 
1.47 g/l Na2HPO4· 2H2O; 
200 mg/l KH2PO4 pH 7.2 
1x TBS* 
50mM Tris 
150mM NaCl 
5mM MgCl2 
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1.6 Media 
Media and additives for cell and bacteria culture were purchased from Gibco BRL 
(Eggenstein), Difco (Detroit), Sigma (Munich), Merck (Darmstadt), and Boehringer 
Mannheim (Mannheim). 
 
1.6.1 Media for bacterial culture 
LB medium:  10 g/l tryptone 
  5 g/l yeast extract 
10 g/l NaCl 
 
Antibiotic stock solution: Amp
50
 (50 mg/ml Ampicillin (sodium salt) in H2O) 
    Chlr
35
 (35 mg/ml Chloramphenicol in ethanol) 
    Zeo
100
 (100mg/ml, Zeocin, Invitrogen) 
    Kan
50 
(50 mg/ml Kanamycin in H2O) 
  
LB medium for bacteria culture was prepared with distilled water, the pH was adjusted to 7.5, 
and the medium was autoclaved for 25 min at 121°C at 1 bar. For pouring plates 1.5% agar 
was added to the medium before autoclaving. After cooling down to approximately 56°C the 
mixture was filled into 10 cm Petri dishes under a hood and left there until the agar becomes 
solid. For selective agar the respective antibiotic was added after cooling down the agar to 
56°C (final concentration 50 µg/ml). Plates can be stored at 4°C for three months. 
 
1.6.2 Media for cell culture 
Standard media are completed with additives from 100x stock solutions. FCS is heated to 
56°C for 45 min before use to inactivate complement factors. L-glutamin is unstable and 
therefore has to be added to the medium after 2 weeks again. 
 
DMEM standard medium (Dulbecco`s Modified Eagle Medium): 
Additives       Final concentration 
FCS, heat inactivated      10% 
L-glutamin (200 mM)     2 mM 
penicillin/streptomycin (10000 U/ml)    100 U/ml 
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1.7 Bacterial strains 
Name Origin Source 
DH5α Invitrogen Woodcock et al., 1989 
MM294 
Provided by  Dr.Stewart 
(EMBL, Heidelberg) 
Buchholz et al, 1996 
EL250 
Provided by K.Schönig 
(ZMBH, Heidelberg) 
Lee et al., 2000 
V.cholerae.lux 
Provided by Pr.Szalay 
(Genelux Corp.; San Diego, USA) 
Yu et al., 2004 
Top10-lux 
Provided by Dr. Loessner, 
(GBF; Braunschweig, Germany) 
Loessner et al., 2007 
 
1.8 Mammalian cell lines 
 - MO4: OVA transfectant of B16 melanoma cells from C57BL/6 mice (kindly 
provided by S. Schnell; Memorial Sloan-Kettering Cancer Center, New York, USA). 
 - AG104A: Spontaneous fibrosarcoma from C3H mice (kindly provided by Dr. H. 
Schreiber; University of Chicago, USA). 
 - AG104A-Tag: Tag transfectant of AG104A cells.( generated in our lab and kindly 
provided by Dr. Ruth Ganss) 
  
1.9 Mouse lines 
Strain Origin 
C57Bl/6 Charles River, Sulzfeld, Germany 
C3H/HEN Charles River, Sulzfeld, Germany 
Cre deleter mice 
Provided by Pr. Schütz, DKFZ. (Schwenk et al., 
1995). 
Her2/neu mice (neu-N) 
Provided by Dr. Forni, University of Turin (Guy 
et al., 1992) 
Albumin-Tag (Alb-Tag) 
Established in the laboratory (Ryschich et al., 
2006).  
Albumin-Floxstop-Tag (AST) 
Established in the laboratory (T.Sacher); 
unpublished 
All mice were kept under specific pathogen-free conditions at
 
the central animal facilities of 
the German Cancer Research
 
Center (Heidelberg, Germany). 
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1.10 Antibodies 
Antibody Origin Specificity Isotype Source 
GM-CSF (MP1-22E9) Rat Monoclonal IgG BD PharMingen 
eGFP (Clone 7.1 and 13.1) Mouse 
Mixture of 2 
monoclonal 
IgG 
Roche applied 
science 
CD3-FITC (145-2C11) Hamster Monoclonal IgG BD PharMingen 
IL2 (JES6-1A12) Rat Monoclonal IgG Biozol 
 
1.11 Plasmids 
Name Gene of interest Resistance 
Size 
(bp) 
Origin 
pGMCSF2a Mouse GM-CSF Amp
r
 3841 Dr. S. Weiss 
pIHL-1 Hemolysin A secretory system Amp
r
 13157 Dr. S. Weiss 
pCMV-Cre Flp ampicillin cassette Amp
r
 4668 G. Küblbeck 
pAST Fstop cassette Amp
r
 10504 G. Küblbeck 
RP23-14C7 
Mouse BAC containing the Albumin 
gene 
Chlr
r
 237093 CHORI 
pEGFP-N3 eGFP Amp
r
 4729 Clontech 
pRSET-BmCherry mCherry Amp
r
 3600 Pr. Tsien 
pßactin-16-pl ß-actin promoter Amp
r
 6147 Dr. C. Probst 
pDrive-CAG CMV/chicken ß-actin promoter  Zeo
r
 6353 InvivoGen 
pCBRed-basic Click beetle red luciferase (CBRed) Amp
r
 4796 Promega 
pGL3 Firefly luciferase (Fluc) Amp
r
 4818 Promega 
pCBGr99-basic 
Click beetle green luciferase 
(CBGr99) 
Amp
r
 4793 Promega 
pDTR-l-eGFP-l-
CBGr99 
eGFP-linker-CBGr99 Amp
r
 6500 G. Küblbeck 
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1.12 PCR primers 
All primers used in this study were obtained from the DKFZ core facility and stock solutions 
were prepared at a concentration of 100 pmol/µl. 
 
 
Name Sequence 5´ 3´ 
Annealing 
T°C 
β2m-1 CAC CGG AGA ATG GGA AGC CGA A  60°C 
β2m-2 TCCACACAGATGGAGCGTCCAG 60°C 
Tag-1 GGACAAACCACAACTAGAATGCAGTG 60°C 
Tag-2 CAG AGC AGA ATT GTG GAG TGG 60°C 
eGFP-F GTG TGA AAG CTT GCC ACC ATG GTG AGC AAG G 50°C 
eGFP-P.2A-R 
CTG CTT GCT TTA ACA GAG AGA AGT TCG TGG CTC CGG AAC 
CGT TGT ACA GCT CGT CCA T 
50°C 
P.2A-CBG99-F 
GCC ACG AAC TTC TCT CTG TTA AAG CAA GCA GGA GAC GTG 
GAA GAA AAC CCC GGT CCC ATG GTG AAG CGT GAG AAA AAT 
GT 
59°C 
CBG 99-bam-R CGC CCA GGA TCC CTA ACC GCC GGC CTT CTC C 59°C 
F-Bsp-2A-Fluc 
GTG TGT CCG GAG CCA CGA ACT TCT CTC TGT TAA AGC AAG 
CAG GAG ACG TGG AAG AAA ACC CCG GTC CCA TGG AAG ACG 
CCA AAA ACA TAA AG 
57°C 
R-Fluc TAA AGA AGA CAG TCA TAA GTG CG 57°C 
F-2A-mCherry 
GTG TGT CCG GAG CCA CGA ACT TCT CTC TGT TAA AGC AAG 
CAG GAG ACG TGG AAG AAA ACC CCG GTC CCA TGG TGA GCA 
AGG GCG AGG A 
59°C 
R-BclI-mCherry GTG TGT GAT CAT TAC TTG TAC AGC TCG TCC ATG 59°C 
F-bfrBI-GM-CSF GTG TGA TGC ATG GCT GCA GAA TTT ACT TTT CCT 62°C 
2.R-PacI-GMCSF GCT GAT TTC ATT AAT TAA TGG ATT AAG ATC ACC CTG ACT 
TCC ATA GGC TAA TTT TTG GCT TGG TTT TTT GCA TTC 
59°C 
F-Alb2 
CAG ATC ACC TTT CCT ATC AAC CCC ACT AGC CTC TGG CAAA 
AAT AAC TTC GTA TAG CAT ACA TTA TAC 
56°C 
R-Alb2 
CGG AGA CGA AGA GGA GGA GGA GAA AGG TTA CCC ACT TCA 
TGG TCG ACT AGC CGT TAA TTA 
56°C 
F-RI-HlyA-IL2 GTC GTG AAT TCA TGC ATC ATA CAG CAT GCA GCT CGC ATC 60°C 
R-RI-PacI-IL2 
TTT CAG AAT TCT TAA TTA ATG GAT TAA GAT CAC CCT GAC 
TTC CAT AGG CTA ATT GAG GGC TTG TTG AGA TGA 
60°C 
F-XmaI-linker-Fluc 
CGT GGC CCC GGG GGC GGT GGA TCA GGT GGA GGT GGA TCC 
ATG GAA GAC GCC AAA AAC AT 
62°C 
R-Fluc GGG CAT CGG TCG ACG GAT CC 62°C 
Bac-zeo-loxP511-L 
CGG TTG AGT AAT AAA TGG ATG CCC TGC GTA AGC GGG GCA 
CAT CGA CGA GGG TGT GGA AAG T  
55°C 
Bac-zeo-loxP511-R 
GTC AGC TCC TTC CGG TGG GCG CGG GGC ATG ACT ATT GGC 
GCT CAG ACA TGA TAA GAT ACA TTG AT 
55°C 
Material and methods 
29 
2. Methods 
2.1 Molecular biology 
  Bacterial culture 
DH5α was the bacterial strain used for classical molecular cloning. It was grown in LB (Luria 
Bertani) medium and maintained on LB agar plates supplemented with suitable antibiotics 
wherever necessary. All bacteria were grown at 37°C (with shaking at 220 rpm for liquid 
cultures). For routine storage, plates were maintained at 4°C. 
EL250 Bacteria were used for Bacterial Artificial Chromosome Cloning. They were used in 
the same way than DH5α at the exception of a growth temperature at 32°C. 
 
  Preparation of CaCl2 competent (heat competent) E. coli bacteria 
A single colony of DH5α cells is grown in 20 ml LB medium over night at 37°C with 
shaking. 1 ml of this pre-culture is added to 200 ml LB medium in a 2 l flask. Bacteria are 
grown to an OD600 of 0.6. 400 ml of prewarmed LB medium are added, and cells are grown 
for another 20 min. They are then centrifuged for 5 min at 2500 rpm at 0°C. The supernatant 
is decanted, traces of liquid are removed, and the pellet is resuspended in 250 ml of ice cold 
100 mM CaCl2. The suspension is placed on ice for 1 h. After centrifugation (5 min, 6000 
rpm, 0°C) the supernatant is again decanted, traces of liquid are removed carefully, and the 
pellet is resuspended in 5 ml of ice cold glycerol/CaCl2. Aliquots of 100 µl are frozen in 
liquid nitrogen, and cells are stored at -70°C. 
A test transformation with 1 ng of double stranded circular plasmid DNA in 100 µl of 
competent cells should yield more than 3x10
3
 colonies. 
 
 Bacteria storage  
Bacteria are plated on agar plates, incubated for 24 h at 37°C and stored at 4°C (maximum 
two months). For longer storage 0.880 ml of an over night culture are mixed with 0.120 ml 
glycerol (86%) (long term storage at -70°C). With a sterile scalpel small pieces of the frozen 
bacteria suspension can be cut off for new cultures. 
 
 Transformation of heat (CaCl2) competent E. coli bacteria 
A 100 µl aliquot of deep frozen competent cells is thawn on ice for 10 min and mixed with 
5-10 µl of a ligation assay. After incubation for 30 min on ice the mix is exposed to 42°C for 
60 sec and transferred to ice for another 2 min. Bacteria are then plated out on an agar plate. 
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 DNA minipreparation (alkaline lysis) 
The lid of a 1.5 ml Eppendorf tube is pierced with a needle and filled with 1 ml of selective 
LB medium. The medium is inoculated with one bacterial colony and then incubated at 
37°C over night, with shaking. Bacteria are centrifuged (3 min, 13000 rpm), and the pellet is 
resuspended in 150 µl of pre-lysis buffer. 300 µl of NaOH/SDS are added, the suspension is 
vortexed and incubated for 5 min on ice for cell lysis. 225 µl of KOAc/HCOOH are added to 
neutralize the solution; the assay is vortexed and placed on ice for 15 min to precipitate 
genomic DNA and proteins. The solution is centrifuged (3 min, 13000 rpm), the supernatant 
is transferred to a new tube and the included DNA is precipitated with 400 µl isopropanol 
(5 min, room temperature (RT)). After centrifugation (3 min, 13000 rpm) the supernatant is 
removed while the DNA containing pellet is dried at 37°C for 10 min and finally dissolved in 
50 µl TE. 5 µl of DNA are needed for a restriction digest. 
 
 DNA midipreparation (alkaline lysis) 
For larger amount of pure DNA, large scale purification is performed: 
50-200 ml of selective LB medium are inoculated with a bacterial culture and incubated at 
37°C over night, with shaking. The suspension is centrifuged at 5000 rpm for 5 min at 4°C. 
The supernatant is discarded; rests of liquid are removed with a pipette. The pellet is 
resuspended in 4.5 ml of pre-lysis buffer. 10 ml of NaOH/SDS are added for lysis of bacteria. 
After mixing cells are placed on ice for 5 min. 7.5 ml of cooled neutralizing KAc/HCOOH are 
added for genomic DNA/protein precipitation. After mixing, and 15 min of incubation on ice, 
centrifugation (5 min, 5000 rpm, 4°C) follows. The supernatant is filtered through funnel and 
glass wool into a new Falcon. The DNA in the supernatant is precipitated with 0.6 volumes of 
2-propanol (5 min, RT) and centrifuged (5 min, 5000 rpm, 4°C). The supernatant is taken 
away while the pellet is resuspended in 2 ml of TE. For further purification 2 ml 4 M LiCl are 
added and incubated on ice for 5 min. Centrifugation (5 min, 5000 rpm, 4°C) follows. The 
supernatant is transferred to a new Falcon where the DNA is precipitated with 10 ml 100% 
ethanol at -20°C for at least 15 min. Centrifugation (5 min, 5000 rpm, 4°C) follows to pellet 
the precipitate. The pellet is washed with 5 ml 70% ethanol and is then dissolved in 400-600 
µl of TE and transferred to a 1.5 ml Eppendorf tube. 5 µl RNase (10 mg/ml) are added for 
digestion of RNA (30 min, 37°C). After addition of 8 µl 4 M NaAc pH 5.6 per 100 µl DNA 
solution the plasmid DNA is extracted with phenol/chloroform/isoamylalcohol (50:49:1) three 
times and two times with chloroform/isoamylalcohol (49:1). It is then precipitated with 0.6 
volumes of isopropanol (5 min, RT), and after centrifugation (3 min, 13000 rpm) the pellet is 
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washed with 1 ml of 70% ethanol. The pellet has to be dried at 37°C for 15 min and can then 
be dissolved in 100-1000 µl of TE. The concentration of DNA is determined by comparing 1 
µg of digested DNA to the DNA marker in an agarose gel. 
 
 Restriction digestion 
For an analytical digest 3 µg of miniprep DNA or 1 µg of midiprep DNA are incubated with 
1 µl of restriction enzyme (4 U), 2 µl of 10x buffer and H2O ad 20 µl for at least 1 h at 37°C.  
Digestions with enzymes cutting at temperatures other than 37°C are incubated at the 
respective ones. According to the enzymes demands concerning buffers the assays are 
performed with different buffers ( B
+
, R
+
, G
+
, Y
+
 etc.) 
For preparation of fragments for further ligation a 40 µl reaction is prepared with 5 µg DNA, 
4 µl 10x buffer, 2 µl enzyme and the respective amount of H2O. 
 
 Dephosphorylation of DNA ends (e.d. in vectors for ligation) 
To avoid self-ligation of cut vectors the 5´ phosphate groups at the DNA ends are removed by 
treatment with alkaline phosphatase (CIAP). 
After the preparative restriction digest in a 40 µl assay 1 µl of CIAP is added and incubated at 
37°C for 30 min. Removal of CIAP is unnecessary if gel purification of the digest is 
performed. The enzyme can also be inactivated by heating the assay to 70°C for 20 min. 
 
 Electrophoretic separation of DNA fragments in agarose gels 
DNA fragments in the range of 0.1-20 kb are separated in differently concentrated agarose 
gels (0.6-2%) depending on their lengths. Gel preparation is performed by boiling agarose 
dissolved in 100 ml of 1x TAE buffer. After cooling down it is poured into a gel chamber 
with combs for slots. When a solid gel has formed the combs can be removed for loading. The 
samples are mixed with 1/6 of 6x loading dye containing the reference dyes, which promote 
sinking of the DNA into the slots. Electrophoresis is performed in the voltage range of 
20-90 volts. For estimation of the fragments sizes a length marker (GenerRuler™ 1 kb DNA 
ladder) is separated next to the samples for comparison. After electrophoresis, DNA is stained 
by placing the gel into a dish with 500 ml of ethidium bromide solution (1x TAE, 0.5 µg/ml 
Ethidium Bromide) for 15 min. The DNA bands are made visible by a UV transilluminator at 
254 nm and are photographed with a videocamera for documentation.  
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 Isolation of DNA fragments from agarose gels with Qiaquick Gel extraction kit 
The isolation of the respective fragment is performed according to the manufacturer`s 
instruction. Briefly, the band is cut out from the gel at 366 nm under the UV transilluminator, 
weighted and dissolved in 300 µl QG buffer per 100 mg of gel (50°C, with 700 rpm shaking). 
750 µl of the assay are placed onto a Qiaquick spin column with collection tube (max. 400 mg 
per column) and centrifuged (13000 rpm, 30 sec). This step is repeated in case the Qiaquick 
Gel mix exceeds the volume of 750 µl. The column is washed with 750 µl of PE buffer 
(13000 rpm, 30 sec) and dried through a second centrifugation step (13000 rpm, 1 min). The 
column is placed onto a new collection tube. 50 µl EB buffer are placed onto the middle of 
the filter and incubated for at least 1 min at RT and DNA is eluted by centrifugation (13000 
rpm, 1 min). 
 
 Ligation of DNA fragments and vectors 
A 10 µl ligation assay is prepared using 1 µl of T4 DNA ligase, 1 µl of 10x T4 DNA ligase 
buffer, 7 µg of the gel purified DNA fragment and 1 µg of vector DNA. After over night 
incubation at room temperature, 5 µl are used to transform competent cells. 
 
 PCR (Polymerase Chain Reaction) 
This method allows specific amplification of defined regions on a DNA molecule in vitro. 
PCR is carried out in three different steps that are repeated in 20-40 cycles. In the first step 
the piece of DNA to be detected (template) is denaturated by heating it to 95°C. Subsequent 
cooling to 45-70°C allows short single stranded oligonucleotides sequence (primers) specific 
hybridisation to the template (annealing). In the third step elongation of 3´ ends of the 
annealed primer along the template DNA takes place with the help of the heat stable Taq 
polymerase. Since the primers are chosen so that the newly produced DNA strands of both 
template strands are partly complementary to each other the doubling of DNA molecules per 
cycle is achieved through the cyclic progression of the three steps.  
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 Analytical PCR 
Analytical PCR is performed to verify the presence of a transgene in the mouse genome using 
tail DNA (see 2.2.3: “Isolation of tail DNA”) as a template. For this PCR two pairs of primers 
were used, one to check the presence of the transgene, the other one to check the DNA 
preparation by amplifying a house keeping gene. It is done as follow: 
 
PCR mix (25 µl):     PCR Program :      
10x PCR reaction buffer  2.5 µl  1. Denaturation  95°C  5min  
Primer forward (10 µM)  2.5 µl  2. Denaturation  95°C  30s 
Primer reverse(10 µM)  2.5 µl  3. Annealing  60°C  30s 
Primer house keeping 1 (10 µM) 2.5 µl  4. Elongation  72°C  1min/1kbp 
Primer house keeping 2 (10 µM) 2.5 µl  5. Back to step 2  39 times 
dNTPs 10 mM   1 µl  6. Final extension 72°C  10min 
Taq polymerase (2 U/µl)  0.5 µl 
Tail DNA   5 µl  
H2O    6 µl 
 
 Preparative PCR 
It is performed to amplify specific cDNA sequences that are used for cloning. In this case, 
primers have additional restriction enzymatic sites that were used to insert the PCR product in 
a plasmid. In order to obtain an exact copy of the DNA template a specific DNA polymerase 
(AccuPrime™ pfx DNA polymerase, Invitrogen) that minimizes the chances of mistakes was 
used. The PCR was performed as follow in 200 µl tubes: 
 
PCR mix (50 µl):     PCR Program :      
10x PCR buffer (with dNTP) 5 µl  1. Denaturation  95°C  1min  
Primer forward (10 µM)  2 µl  2. Denaturation  95°C  15s 
Primer reverse(10 µM)  2µl  3. Annealing  x °C  30s 
AccuPrime Pfx (2 U/µl)  0.5 µl  4. Elongation  68°C  1min/1kbp 
cDNA (1ng/ul)   1 µl   5. Back to step 2  24 times 
H2O    39.5 µl  6. Final extension 68°C  10min 
  
 DNA sequencing 
The DNA sequencing was done by MWG Biotech, Ebersberg, Germany using the dideoxy 
method. 1µg DNA was precipitated in ethanol and air dried. The DNA was further dissolved 
in 10 µl of HPLC purified water and sent for sequencing. 
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 Preparation of DNA microinjection 
For microinjection experiments, the DNA fragment was isolated by restriction cutting from 
the vector and was isolated through an agarose gel. The DNA was taken up to microinjection 
buffer and adjusted to a concentration of 1-2 ng/µl. 
 
 Preparation of BAC DNA for transgenic mice production 
 Preparation of electrocompetent cells and generation of recombinants 
In order to generate BAC recombinants, homologue recombination is induced between a 
linear DNA and BAC DNA which is carried by EL 250 bacteria. Indeed, EL 250 bacteria are 
stably transformed with a defective prophage that carries the PL operon. PL operon encoding 
gam, exo and bet genes is under the control of the temperature sensitive λ repressor (allele 
cI857). Recombination functions can thus be transiently supplied by shifting the culture to 
42°C for 15 min. Gam inhibits the E.coli RecBCD nuclease from attacking the electroporated 
linear DNA, while Exo and Beta generate recombination activity.  
For BAC modification, overnight cultures containing the BAC were grown from single 
colonies, diluted 50-fold in LB medium, and grown to an OD600 = 0.5-0.7. 50 ml cultures were 
then induced for Beta, Exo, and Gam expression by shifting the cells to 42°C for 15 min 
followed by chilling on ice for 20 min. Cells were then centrifuged for 5 min at 5000 rpm at 
4°C and washed with 1.5 ml of ice-cold sterile water three times. Cells were resuspended in 
300 µl of ice-cold sterile water and electroporated. For BAC transformation, the induction 
step was omitted. 
Cell transformation was performed by electroporation of 100-300 ng DNA into 50 µl of ice-
cold competent  cells in cuvettes (0.1 cm) using a Bio-Rad gene pulser set at 2.3 kV, 25µF 
with a pulse controller set at 200 ohms. 1 mL of LB medium was added after electroporation. 
Cells were incubated at 32°C for 1.5 h with shaking and spread either on agar media with 
Chloramphenicol resistance for BAC transformation or on agar media with Chloramphenicol 
and Ampicillin resistance for BAC modification.  
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 Transformation and modification of RCPI23-14C7 
First, the Albumin BAC was electroporated into EL 250 cells. 10 Chloramphenicol colonies 
were obtained from 1 x 10
8
 electroporated cells. Digestion BAC DNA from the 
Chloramphenicol resistant colonies with Bam HI showed a similar digestion pattern than the 
original DNA [Fig. 4A, lane A and B]. To replace the first loxP site contained in the BAC 
vector backbone, EL250 cells were shifted to 42°C for 15 min to induce Exo, Beta, and Gam 
expression and the cells were then electroporated with 300 ng of the amplified Zeocin 
cassette. Approximately, 5000 Chlr
R
/Zeo
R
 colonies were obtained from 1 x 10
8
 electroporated 
cells (No colonies were obtained from uninduced cells). Bam HI digestion of DNA from 10 of 
these colonies showed the expected shift of a band from 8803 bp to 9777 bp in the digestion 
pattern [Fig. 4A, lane C]. This indicated that all were correctly targeted. 
Using the same procedure the amplified Fstop-CBGr99-FlpAmp cassette was inserted in 
frame with albumin start codon. 37 Chlr
R
/Zeo
R
/Amp
R
 colonies were obtained from 1 x 10
8
 
electroporated cells. Bam HI digestion of DNA from 4 out of 12 of these colonies showed the 
expected shift of a band from 17218 bp to 12815 bp in the digestion pattern and the 
appearance of a band at 6360 bp [Fig 4A, lane D]. Next, the Amp selectable marker was 
removed to prevent its possible interference with the luciferase expression. Overnight culture 
from single Chlr
R
/Zeo
R
/Amp
R
 colony was diluted 50 fold in LB medium and grown till OD600 
nm = 0.5. flpe expression from EL 250 was then induced by incubating the culture with 0.1% 
L-arabinose. The bacteria cells were spread on Chlr
R
 plates and the next day colonies were 
picked, and replated on Amp
R
 plates to test for loss of Ampicillin resistance which was 
observed in 100% of colonies. In order to check the appropriate insertion and the sequence of 
the Fstop-CBGr99 cassette, ligation of the EcoR I fragment containing the Fstop-CBGr99 
cassette was subcloned in a pBluescript vector (Fermentas). Sequencing showed expected 
insertion of the cassette as well as a correct sequence (data not shown).   
Finally, the last loxP site contained in the BAC vector backbone was removed by a final 
round of gene targeting. Ampicillin cassette flanked by homologous region was used to 
replace the loxP site. 3000 Chlr
R
/Zeo
R
/Amp
R
 colonies were obtained from 1 x 10
8
 
electroporated cells. Not I digestion of DNA from 3 of these colonies showed the expected 
shift of a band from 9833 bp to 10867 bp in the digestion pattern [Fig.  4B]. The albumin 
BAC was then purified for microinjection. 
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Figure 4 : Transformation and modification of albumin BAC. 
(A) Restriction pattern of RCPI23-14C7 BAC DNA with Bam HI before (lane A) and after transformation in 
EL250 bacteria (lane B) shows that BAC DNA is fully expressed in the host. Replacement of one loxP site 
present in the BAC vector by a Zeocin cassette leads to a shift from 8803bp to 9777bp (green arrow) of a band 
in the Bam HI restriction pattern (laneC). Apparition of one band at 6360bp (red arrow 1) and shift of a band 
from 17218bp and 12815bp (red arrow2) after insertion of the Stop-CBGr99-FlpAmp cassette (lane D). 
(B)  Replacement of the second loxP present in the BAC vector leads to a shift from 9833bp to 10867bp (lane F). 
Lane M: DNA ladder mix. 
 
 Purification of BAC DNA for microinjection 
The modified BAC DNA (30 µg-50 µg) was digested with NotI in reaction buffer including 
2.5 mM spermidine (Sigma). Digested BAC DNA mixed with gel loading buffer was run 
through the sepharose CL-4B (Pharmacia) column, which was equilibrated with 30 ml of the 
injection buffer. Fractions of 500 µl were collected and a small volume of every fractions was 
identified on a 1% agarose pulsed field gel. The appropriate fractions with intact BAC DNA 
and no vector bands were adjusted appropriate DNA concentration (1µg/ml). 
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2.2 Mouse work 
2.2.1 Production of transgenic mice 
2.2.1.1 Layout of a microinjection instrument 
An inverse stereomicroscope (5-200 x magnification) is equipped with two 
micromanipulators to operate the capillaries used for securing cells and injecting them with 
fluid. The capillaries are connected with paraffin oil filled tubes to the paraffin oil reservoir.  
Knurled screw and pistons at the end of the tubes are used to apply suction or pressure on the 
capillary. Applying slight negative pressure allows the fixation of a single oocyte to the 
capillary. The stage is designed for the use of Petri dishes with a diameter of 6 cm.   
 
2.2.1.2 Preparation of glass capillary needles 
Injection syringe:  the glass capillary is fixed in a micropipette puller and drawn after heating. 
The capillary is then broken at the end of the needle to an inner diameter of around 15 µm. 
This is followed by grinding the tip in an angle of 50°. The tip is additionally bended 30°. 
Syringe for securing cells: The glass capillary is also fixed in a micropipette puller and drawn 
after heating. The capillary is then broken at the inner diameter of around 90 -100 µm and the 
end of the needle is melted down to an inner diameter of around 15 -20 µm. 
 
2.2.1.3 Preparation of zygotes from pregnant mice 
To have sufficient high number of fertilized ovules, female mice are super ovulated. 10 
(C57BL/6) F1-females are used as donors of zygotes. Three days prior the preparation 5-10 U 
Gonadotropin in 500 µl PBS are administered i.p. to induce oogenesis. One day prior 
preparation 5-10 U Chorionic-Gonadotropin in 500 µl PBS are administered i.p. to trigger 
ovulation. Subsequently, the females will be mated with F1-males (C57BL/6). The next day, 
the females are checked for vaginal plugs, whereas positive females are killed with CO2, 
opened up, and their oviducts along with a part of the uterus are removed. Fat tissue and 
mesometrium are stripped off and the uterus is cut between the forceps and the oviduct 
directly at the ovary. The oviducts are placed in M2-medium, supplemented with 
hyaluronidase (300 µg/µl). The zygotes are found in the ampoule of the oviduct and are 
dissected under a binocular. For the dissection, the ampoule is pinched off with tweezers and 
ripped open with a second pair of tweezers. The ovules are collected with a glass capillary and 
washed twice with M2-medium. Until the injection of the DNA into the pronucleus, the ovules 
are kept in a drop culture in  M16-medium at 37°C. 
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2.2.1.4 Microinjection of the transgene cassettes 
The linearised transgene cassettes are injected in the pronucleus of the zygotes at a 
concentration of 2-6 ng/µl. The transgene cassettes are injected by piercing the pronucleus of 
the oocyte with the injection syringe and activating the special injection pump. If the injection 
into the pronucleus is correctly conducted, the swelling of the pronucleus can be observed 
under the stereomicroscope.  
 
2.2.1.5 Transfer of embryos into oviduct 
Injected embryos at the one-cell stage (the day of injection) or two-cell stage (1 day after 
injection) were transferred into the infidibulum of the oviduct of the pseudopregnant recipient 
(foster mother). To this end, 10-20 female recipient (NMRI) mice have been mated to 
vasectomized males 3 days before the preparation of the eggs. 
 
2.2.2 Typing of transgenic mice 
2.2.2.1 Isolation of tail DNA 
0.5-1 cm of the tail is cut off and placed into an Eppendorf tube with 700 µl of tail buffer and 
10 µl of proteinase K (10 mg/ml). The tail is digested over night at 56°C. The next day the 
sample is centrifuged (5 min at 13000 rpm), and the supernatant is transferred into a new 
Eppendorf tube. The DNA is precipitated with 0.6 volumes of isopropanol (420 µl) by 
shaking the tube until a DNA string becomes visible. It is fished with a closed glass capillary 
and washed first in 70% ethanol, then in 100% ethanol by dipping the capillary into the 
alcohol. The DNA on the capillary is dried at RT for 30 min. After that the capillary end with 
the DNA is broken off into an Eppendorf tube with 100-500 µl of TE (depending on the 
amount of DNA) for dissolving the DNA at 68°C with shaking. 
 
2.2.2.2 Mouse  genotyping by non-radioactive Southern blot analysis 
20 µl of tail DNA were digested with restriction enzymes and separated on a 1% agarose gel 
in 1x TAE buffer at 80 V. DNA bands were visualised under UV light after staining with 
ethidium bromide (0.5 µg/ml in 1 X TAE). After visualisation, the agarose gel was submerged 
into denaturation buffer for 30 min and to neutralisation buffer for 2 times 15 min with 
agitation. After setting up the capillary blot, the DNA was transferred onto a nitrocellulose 
membrane overnight in 20x SSC. The DNA was fixed to the membrane by baking at 80°C for 
2 hours. After fixation, the membrane was prehybridised with prehybridization buffer for 1 
hour at 65°C. For hybridisation, the Dig-labelled probe (10 ng/ml in hybridization buffer), 
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which was boiled for 10 min, was added on the membrane and hybridisation was carried out 
at 65°C overnight. To prepare Dig-labelled probe, a PCR product (100 ng to 2 µg) was 
denatured and immediately cooled down on ice and finally labelled as per directions in Dig-
labelling manual. After hybridisation, the membrane was washed 3 times for 5 min each in 
wash buffer at 65°C. After this step, all the subsequent incubations and washing were done at 
room temperature. After washing, the membrane was rinsed with Dig-buffer I and blocked in 
2% blocking buffer for 2 min. α-Dig-AP conjugate (1ul antibody/5ml of Dig-buffer I, 
Boehringer) was added to fresh Dig buffer 1 solution and incubated on the membrane for 30 
min. After washing 2 x 15 min in Dig buffer 1 solution, the membrane was first equilibrated 
in Dig-buffer III and then incubated for 10 min. Then, 20 ml of Dig-buffer III containing 
substrate (90 µl NBT and 70 µl BCIP solution) was added onto the membrane and incubated 
3-4 h before signal detection. 
 
2.2.3  Lymphocyte preparation from blood and genotyping by FACS 
Blood taken from the tail vein of mice was mixed in D-PBS/Heparin solution in order to 
prevent blood coagulation. These samples were transferred into centrifuge tubes filled with 
Ficoll solution (Lymphoprep™) to carry out a density gradient centrifugation at 1800 rpm 
(Beckman, TJ-6) for 20 minutes. Lymphocytes accumulating in the interphase were harvested 
and placed into new Eppendorf tubes.  
 
2.2.4 Splenocyte preparation 
Mice were sacrificed by CO2 inhalation. After disinfection with ethanol, the peritoneal cavity 
was opened using sterile forceps and scissors. Spleen was removed, separated from fatty and 
connective tissue and placed into a 6 well plate containing D-PBS on ice. The spleens were 
mashed through a cell strainer using the plunger of a 1 mL syringe, rinsed twice with D-PBS 
and then centrifuged at 1200 rpm, 4ºC, 5 min. Cells were counted in a Neubauer 
Heamatocytometer using trypan blue to exclude the dead cells and then washed once more 
with D-PBS before being resuspended and adjusted to the desired cell concentration in FACS 
buffer (3% FCS in D-PBS). 
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2.2.5 Tumor inoculation 
To establish subcutaneous tumors from cancer cell lines, 5 x 10
6
 cells were resuspended in 1 
ml D-PBS. 100 µl (equal to 5 x 10
5
) of suspension was inoculated subcutaneously in the flank 
using a 1 ml syringe equipped with 27G needle in the belly of each animal. After tumor 
inoculation, the growth rate of tumor was monitored by measuring the size using a caliper. To 
establish experimental metastasis 100 µl of the same cell preparation was injected 
intravenously in the tail vein and tumor development was monitored by Bioluminescence 
imaging (BLI). 
 
2.2.6 Bioluminescence imaging of mice 
Mice were imaged at indicated time points using the IVIS® imaging system 100 (Xenogen). 
D-luciferin (Synchem, Felsberg/Altenburg, Germany) dissolved in PBS was injected 
intraperitoneally at a dose of 150 mg/kg before measurement of luminescence. General 
anesthesia was induced with 5% isoflurane and continued during the procedure with 2.5% 
isoflurane introduced via a nose cone. 
After acquiring photographic images of each mouse, luminescent images were acquired with 
various (1 s - 300 s) exposure times. The resulting grayscale photographic and pseudo-color 
luminescent images were automatically superimposed by the IVIS Living Image Software 
(Xenogen) to facilitate the matching of the observed luciferase signal with its location within 
the mouse. Region of interest (ROI) were manually drawn around the signal to assess the 
signal intensity emitted. Luminescence was integrated over these ROIs and it is expressed as 
relative light units (RLU). To avoid light absorption and scattering, fur was removed from 
black mice in the region of interest by shaving prior to the start of the experiment. 
 
2.2.7 Measurement of alanine aminotransferase activity in mouse plasma 
Alanine aminotransferase (ALT) belongs to the group of transaminases which catalyse the 
conversion of amino acids to the corresponding α-keto acids. Increased serum activity of ALT 
is largely specific for liver parenchymal disease although it can indicate other organ damage. 
Measurement of high ALT level in the serum could therefore be used as an indication of 
hepatocarcinoma in AST mice previously injected with adenovirus expressing Cre. 
Blood was collected from the tail vein using capillary pipette filled with heparin. Blood is 
applied to a test strip (Reflotron™) which is immediately placed in the Reflotron instrument. 
The instrument will display 140 s later the enzyme activity in U/l. The test strip contains α-
ketoglutarate and alanine which are converted in glutamate and pyruvate in presence of ALT. 
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In a second reaction step, catalyzed by the pyruvate oxidase, the resulting pyruvate is cleaved 
into acetyl phosphate, carbon dioxide and hydrogen peroxide. In the presence of POD the 
hydrogen peroxide converts an indicator into its oxidized blue form. The formation of the dye 
is measured at 567 nm as a measure of the enzyme activity of ALT. 
 
2.3 Cell culture 
The given cell lines were maintained in monolayer cultures in defined medium (RPMI-1640 
or DMEM) supplemented with 10% inactivated foetal serum (FCS) with 2 mM L-glutamine. 
The cells were grown in a humidified atmosphere with 7% CO2. 
 
2.3.1 Long term storage 
Growing cells were trypsinized, pelleted and washed thoroughly with D-PBS to remove traces 
of trypsin and medium. Cells were then resuspended in freezing buffer (70% DMEM, 20% 
FCS, 10 % DMSO), at a density of 2-3 million cells/ml, and aliquoted into cryovial tubes. 
Vials were placed in a cell freezing box (Nalgene™) and left at -80°C overnight for gradual 
freezing. Frozen vials were then transferred to liquid nitrogen for long term storage. 
Repropagation was performed by placing the vial at 37°C and gradually thawing the cells by 
the addition of complete medium. The cell suspension was transferred to a 15 ml Falcon tube 
pelleted and washed with complete medium for removal of DMSO. After resuspension, the 
cells were added to 20 ml complete medium in a 75 cm² tissue culture flask.  
 
2.3.2 Cell transfection 
The adherent cells were transfected with DNA using Lipofectamin™ 2000 (Invitrogen, Life 
technologies, Karlsruhe, Germany) according to the manufacturer’s instruction, with minor 
modification adapted to the cell line. The day before transfection 1 to 2 x 10
6
 cells were 
seeded in a 6 cm Petri dish. Next day cells were washed with D-PBS (pH 7.4) to remove the 
serum, and 2.5 ml of DMEM serum free medium was added. DNA-Lipofectamin complexes 
were made as per instructions and 1:2 ratio of DNA:Lipofectamin™ 2000 was used. 
For a 6 cm Petri dish, respectively 10 µg DNA was diluted into 500 µl DMEM serum free 
medium and 20 µl of Lipofectamin was diluted into 500µl of DMEM serum free medium. 
After 5 min incubation time at room temperature, both were mixed and incubated at room 
temperature for 20 min. The mixture was dropwise added to the cells. Transfection efficiency 
was estimated 24 h after transfection by checking eGFP expression by FACS. 
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2.3.3 FACS measurement 
This method was used to assess eGFP expression by transfected cells, splenocytes or 
peripheral blood cells (PBL). The cells to be tested were harvested, washed 1 time with FACS 
buffer (3% FCS in PBS) and pelleted by spinning down at 1500 rpm for 5 min. Cells were 
resuspended in 500 µl FACS buffer containing 10 µg/ml propidium iodide to exclude dead 
cells.  Acquisition and analysis were done using BD Cellquest Pro™ Software. 
 
2.3.4 Luciferase assay  
The cells were trypsinized, washed 2 times in D-PBS and counted using the hemocytometer. 
Cells were plated at doses of 1 x 10
4
 in black 96-well cell culture plate in 100 µl D-PBS and 
100 µl luciferin (600 µg/ml) were added to start the enzymatic reaction. Immediately after 
luciferin addition, photon emission at different time points was obtained by taking successive 
picture with the IVIS® 100 imaging system. Quantification of the signal was done by using 
the IVIS Living Image Software (Xenogen). 
 
2.3.5 T cell proliferation assay (B3Z assay) 
Presentation of SIINFEKL peptide was assessed using the B3Z T-cell hybridoma (Karttunen 
et al., 1992). B3Z is a lacZ-inducible CD8 + T-cell hybrid specific for OVA peptide 257-264 
(SIINFEKL) presented on murine H2-K
b
 MHC class I molecules. The lacZ assay utilizes a 
reporter construct consisting on the bacterial ß-galactosidase gene (lacZ) under the 
transcriptional control of the nuclear factor of activated T cells (NF-AT) element of the 
human interleukin-2 (IL-2) enhancer. The presentation of the SIINFEKL epitope by murine 
K
b
 to B3Z cells result in the IL-2 dependent induction of galactosidase (ß-gal) synthesis and 
intracellular accumulation of ß-galactosidase by B3Z cells. The amount of ß-gal produced by 
B3Z T cells can be measured by the hydrolysis of the chromogenic substrate chlorophenolred-
ß-d-galactoside (CPRG Calbiochem, Darmstadt, Germany) and is an indication of the amount 
of SIINFEKL/Kb complexes presented on the surface of cells. For positive control the antigen 
presenting cells (APC) were pulsed with synthetic SIINFEKL. APC were plate at 1 x 10
4
/well 
in 96-well plates. To quantify the T cell stimulation, 5 x 10
4
 B3Z cells/well were incubated 
the APC for 20 hours at 37°C in CO2 incubator. Cells were pelleted using 2000 rpm for 2min 
and the supernatant carefully aspirated. The cells were lysed in Z-buffer. Cells release the ß-
galactosidase, which reacts with the substrate, to produce red-violet light. The absorption was 
measured at 595 nm in a 96-well plate ELISA reader (Titertek Multiskan Plus, Germany), 
with 635 nm as the reference wavelength. 
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2.3.6 Western blot 
2.3.6.1 Precipitation of proteins from bacterial supernatant 
A single bacterial colony was inoculated into 50 ml of 100 µg/ml Ampicillin containing LB 
medium in a 250 ml flask and vigoursly shaken at 37°C overnight. A large number of 5 ml 
culture (x 10) was inoculated with 500 µl of the overnight culture and cultures were grown to 
an optical density at 600 nm of approximately 0.7. Cultures were pooled and bacteria were 
pelleted for 10 min at 4°C and 5000g. Pooled supernatant was filtered through a 0.22 µm-
pore-size-filter to remove residual bacterial cells. After 30 min storage at  4°C, trichloroacetic 
acid was added to the filtrate in order to obtain a final concentration of 10% and stored 
overnight at 4°C. Protein precipitates, which were collected by 1 h centrifugation at 4°C and 
15 000g, were carefully washed with 1 ml ice-cold acetone, and acetone was removed by 
evaporation at room temperature. To solubilize the precipitate, 50 µl of 2x SDS-PAGE 
loading dye and 50 µl of a saturated Tris-H20 solution were added to the samples, followed by 
incubation at 95°C for 15 min for protein denaturation. 
 
2.3.6.2 Cell lysate 
The cells were grown till 70% confluency prior to harvesting. The cells were trypsinized, 
washed 2 times in D-PBS and counted using the hemocytometer. The cells were lysed in ice-
cold lysis buffer (1% NP-40 in TBS) with 1 protease inhibitor tablet added per 50 ml lysis 
buffer. The cells were lysed at a concentration of 10
7
 cells/ml. Lysis was done for 60 min at 
4°C followed by centrifugation at 4000 rpm for 10 min to remove the nuclei and cell debris. 
The cells supernatant was further cleared by another round of centrifugation at 12 000 rpm for 
10 min at 4°C. Supernatant was mixed with 6x SDS-PAGE loading dye, denaturated by 
boiling 10 min and centrifuged 2 min at full speed.  
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2.3.6.3 SDS-Polyacrylamide (PAA) Gel Electrophoresis 
PAA gels from 10-15% were used to separate proteins according to their molecular weights. 
Before electrophoretic separation, proteins were prepared either from bacterial supernatant 
(see § 2.3.5.1) or from cell lysates (§ 2.3.5.2). To prepare SDS-PAA gels, the following 
components for the separating gel listed in the table were mixed together and poured between 
glass plates (20 x 20 cm). The resolving gel was covered with 2-propanol and let at least 20 
min to polymerize. Then, the 2-propanol was removed and the stacking gel was prepared 
according to the table, mixed and poured over the separation gel. The gel comb was laid 
avoiding air bubbles. After polymerization, gel was attached to the electrophoresis chamber 
and covered with electrophoresis buffer. The electrophoresis was carried out for 16 h at 180 
mA and 90 V. 
   
2.3.6.4 Electrotransfer of proteins from SDS-PAGE gel to membrane 
After separation by SDS-PAGE, proteins were transferred to a polyvynilidene fluoride 
(PVDF) membrane. For this, 9 pieces of GB004 Whatman filter paper were cut at the gel size. 
For the blot, the graphite plates from the transfer equipment were cleaned with dH20.  3 pieces 
of whatman paper were soaked in concentrated anode buffer, 3 pieces were soaked in anode 
buffer and the pieces were piled on the transfer plate. The membrane was moistened with 
methanol and laid on the filter pile. The protein gel was taken out from the glass plates, the 
stacking gel was cut out and the resolving gel was carefully laid on the membrane. Finally 3 
pieces of Whatman paper were soaked in the cathode buffer and laid on the gel. Air bubbles 
were eliminated with a glass pipette. After the cathode plate was put in place, and transfer was 
done for 1.5 h at 50 V and 180 mA. 
 
 
 
Resolving gel 12% 
30% Acrylamid 12 ml 
1.5 M Tris HCl (pH8.8) 7.5 ml 
20% SDS 0.6 ml 
10% APS  0.3 ml 
TEMED 0.012 ml 
Water 9.9 ml 
Stacking gel 5% 
30% Acrylamid 1.7 ml 
1.0 M Tris HCl (pH8.8) 1.25 ml 
20% SDS 0.05 ml 
10% APS  0.1 ml  
TEMED 0.01 ml 
Water 6.8 ml 
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2.3.6.5 Immunoblotting 
Following transfer, the membrane was placed with the protein side up into a container filled 
with blocking solution (5% skimmed milk, 0.1% Tween 20 in 1x PBS) and let overnight at 
4°C with shaking. Next day, the membrane was transferred in a plastic box and diluted 
primary antibody in blocking solution was added. After 1 h incubation at RT, the membrane 
was rinsed twice and then washed 3 times, 10 min each, with washing buffer (0.1% Tween 20 
in 1x PBS). The membrane was then incubated with appropriated diluted horseradish 
peroxidase (HRP) conjugated secondary antibody for 1 h at RT with shaking. Following 3 
washes as described above, chemiluminescence detection was performed using Enhanced 
Chemiluminescence Supersignal Dura West Extended (Pierce PerBio, Bonn, Germany) 
according to the manufacturer´s instructions. Blots were visualized by using a Lumi-Imager. 
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1. Selection of an optimal luciferase for BLI  
Several luciferases such as firefly luciferase (Fluc) and renilla luciferase (Rluc) are 
commercially available. Of these, firefly luciferase is the most commonly used for BLI, but it 
is not yet been thoroughly tested which luciferase is optimal for BLI. Because signal 
attenuation by tissues is lower for red light, red luciferases appear to be advantageous for BLI, 
but a comparison with other luciferase is missing. Recently, green (CBGr99, CBGr68) and 
red (CBRed) luciferases from yellow click beetle (Pyrophorus plagiophthalamus) have been 
cloned and modified for optimal expression in mammalian cells. Because of the higher 
percentage of red light emission, it has been suggested that CBRed and Fluc are the most 
appropriate luciferases for BLI (Zhao et al., 2005). However, a quantitative comparison of the 
total photons emitted at the various wavelengths of the spectra, especially in the red 
wavelengths range, has not been performed. Such measurements are required together with in 
vivo BLI studies for comparitive assessment of the various luciferases for BLI. For such 
comparisons, it is critical to generate cells expressing equimolar amounts of the different 
luciferase proteins. Coexpression of a protein with a fluorescent protein allows to refer the 
amount of protein present in a cell. Therefore, we have combined the respective luciferases 
expression to the enhanced green fluorescent protein (eGFP) expression with a “self cleaving” 
2A peptide. This allowed a quantitative comparison of three different luciferases (Fluc, 
CBGr99 and CBRed).  In the following sections, the photon yield of each luciferase in vitro 
and sensitivity of detection in vivo is compared by using stable clones having a similar eGFP 
expression, thereby the same amount of luciferase protein. 
 
 Generation of eGFP-2a-Luciferase constructs 
There are generally three ways in which two or more genes can be co-expressed. First, two 
different genes can be fused together in-frame to produce a chimeric protein, guaranteeing the 
simultaneous expression of both genes. Although some functional fusion proteins have been 
successfully expressed (Germann et al., 1989), this strategy may not work for all 
combinations of proteins as some protein fusions could result in protein misfolding or 
mistargeting. The second strategy for co-expression involves the design of bicistronic 
constructs, in which two genes separated by an internal ribosome entry site (IRES) sequence 
are expressed as a single transcriptional cassette under the control of a common promoter. 
The intervening IRES sequence functions as a ribosome-binding site for efficient cap-
independent internal initiation of translation. Such a design enables coupled transcription of 
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both genes, followed by cap-independent initiation of translation of the first gene and IRES-
directed cap-independent translation of the second gene. This approach is problematic 
because multiple proteins are often not expressed at the same level (Lee et al., 2001a). The 
third and only recently established technique is the use of “self-cleaving” 2A peptides, or 2A 
like sequences from viruses to generate multicistronic vectors. This system consists on the 
association of two proteins by the 2A peptide consensus motif (2A, Asp-Val/Ile-Gluc-X-Asn-
Pro-Gly; 2B, Pro) [Fig. 5A]. This motif is extremely rare and through a ribosomal skip 
mechanism the 2A peptide impairs normal peptide bond formation between the 2A glycine 
and the 2B proline without affecting the translation of the 2B [Fig. 5B]. 
 
Figure 5 : 2A sequences, scheme of activity 
(A) Amino acid sequence of the 2A regions of foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), 
thosea asigna virus (T2A) and porcine teschovirus-1 (P2A; used later to make the construct). Conserved 
residues are boxed. The cleavage point between the 2A and 2B peptides, and thus the N- and C- terminal 
cistrons, is indicated by the arrow. (B) The stage following the addition of the ultimate residue of 2A is shown 
(step i). Peptidyl(2A)-tRNA is translocated from the A to the P site (step ii), allowing the ingress of propyl-tRNA  
(step iii). Propyl-tRNA is unable to attack the peptidyl(2A)-tRNA
Gly 
ester linkage, and hydrolysis of the glycyl-
tRNA ester bond releases the nascent peptide (step iv and v). Deacylated tRNA is now present in the P site 
(mimicking peptide bond formation) and allows the translocation of propyl-tRNA (rather than the normal 
peptidyl-tRNA) from the A to P sites (step vi). Synthesis of the peptide C-terminal of 2A proceeds normally, 
although recommencing with proline. 
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It has been demonstrated that using 2A peptides leads to the stoichiometric coexpression of 
proteins (Holst et al., 2006; Szymczak et al., 2004). For the present study we have decided to 
link the respective luciferases to eGFP using the P2A peptides [Fig. 6] and to use eGFP as a 
reporter for the amounts of the luciferase protein expressed in a cell.   
 
 
Figure 6 : 2A constructs  
Schematic of the 2A-linked eGFP:luciferase constructs used. The CMV promoter is used to express the 2A-linked 
construct.  
 
 Cloning of the 2A constructs 
pCMV-eGFP-2A-CBGr99: An “eGFP-2A-CBGr99” cassette was produced by recombinant 
PCR and inserted under the control of the CMV promoter. Both sequences, eGFP and 
CBGr99, were PCR amplified in order to add the P2A sequence in 3´ of the eGFP and in 5´ of 
the CBGr99, respectively. The overlap in sequence, constituted by the 2A sequence, allows 
the two fragments to recombine after their mixture, denaturation and renaturation. These 
extended segments, eGFP-2A-CBGr99, served as a template for the secondary reamplification 
of the combined sequences using the outermost two of the four primers employed to produce 
the primary fragments. The recombined PCR product was digested with Hind III and Bam HI 
to allow its insertion in the pCMV-Cre plasmid digested with Hind III and BCl I. 
 
pCMV-eGFP-2A-CBRed: As CBGr99 and CBRed have 99% DNA identity, pCMV-eGFP-
2A-CBRed was constructed by exchanging a part of the CBGr99 sequence in the pCMV-
eGFP-2A-CBGr99 plasmid by the CBRed sequence from the pCBRed-basic plamid using the 
Bst XI / Xho I restriction sites. 
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pCMV-eGFP-2A-Fluc: The Fluc sequence was PCR amplified from the pGL3 plasmid using 
chimeric primers. The forward primer contained a part of the P2A cassette in 5´ and 20 
nucleotides homologous to the Fluc in 3´. The reverse primer containing 20 nucleotides 
homologous of the Fluc polyA tail. The digestion of the resulting PCR products with Bsm BI 
and Sal I followed by its ligation in pCMV-eGFP-2A-CBGr99 digested with the same 
enzyme allowed the replacement of the CBGr99 sequence. 
 
Linker Constructs: A portion of eGFP linked to the CBGR99 sequence by a (G4S)3 linker 
from pCMV-DTR-linker-eGFP-linker-CBGr99 plasmid (G.Küblbeck, DKFZ, Heidelberg) 
was first excised as a Bsr GI-Sph I fragment and inserted in place of eGFP-2A-CBGr99 
sequence in the Bsr GI-Sph I sites of the pCMV-eGFP-2A-CBGr99 plasmid to generate the 
pCMV-eGFP-linker-CBGr99 plasmid.  
The pCMV-eGFP-linker-CBRed was made by exchanging a part of the CBGr99 sequence in 
the pCMV-eGFP-linker-CBGr99 plasmid by the CBRed sequence from the pCBRed-basic 
plamid using the Bst XI/Not I restriction sites. 
The linker plus Fluc were amplified together by PCR from the pGL3 plasmid using chimeric 
primers. The forward primer contained the sequence encoding for the linker sequence in 5´ 
and 20 nucleotides homologous of the Fluc polyA tail. The resulting PCR fragment linker-
Fluc was then digested with Cfr 9I/Sal I and inserted in place of linker-CBGr99 in the pCMV-
eGFP-linker-CBGr99 plasmid, to obtain the plasmid pCMV-eGFP-linker-Fluc. 
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 2A cleavage and generation of stable clones  
For verification of correct cleavage, MO4 cells were transfected with the 2A-linked 
constructs. eGFP-2A production was detected by Western blot analysis using a GFP antibody 
[Fig. 5A]. For each 2A linked construct, migration of the eGFP-2A protein was consistent 
with the predicted molecular weight [Fig. 7A, lane 4-6] which is slightly higher than the wild 
type eGFP [Fig. 7A, lane 7] due to the presence of the “2A tail” in C-terminal. Notably, no 
uncleaved eGFP-2A-Luciferase could be found, indicating 100% cleavage efficiency. Non 
cleavable versions of the eGFP-2A-Luciferase constructs were made by exchanging the 2A 
sequences with a linker sequence ((G4S)3), and were used to indicate the position of 
uncleaved material [Fig. 7A, lane 1-3]. Because antibodies against click beetle luciferases are 
not available and antibodies against Fluc are not useful for Western blot in our hands we 
could not demonstrate the cleaved luciferases. However, from MO4 cells transfected with 
pCMV-eGFP-2A-CBGr99, we have generated several stable clones with distinct eGFP 
expression levels [Fig. 7B]. In vitro analysis of eGFP expression and luciferase activity 
reveals a high degree of correlation between eGFP mean fluorescence intensity (MFI) and 
light production by CBGr99 (r² ~ 0.9) [Fig. 7C] Together with the published stoichiometric 
coexpression in the bicistronic 2A system (Holst et al., 2006), these data demonstrate the 
usefulness of the eGFP expression for a measure of expression of the associated luciferase 
protein. 
                                                                                                                                          Results                                                
52 
 
 
Figure 7 : 2A cleavage and coexpression of eGFP and CBGr99 
(A) Western blot with an anti-GFP antibody of transiently transfected cells, lanes 1-3 non-cleavable constructs 
containing Fluc (lane 1), CBGr99 (lane 2) and CBRed (lane 3). Lanes 4-6 cleaved eGFP band of transient 
transfectants expressing 2A linked constructs containing Fluc (lane 4), CBGr99 (lane 5) and CBRed (lane 6). 
Lane 7 native eGFP, lane 8 untransfected cells.   (B) FACS histograms showing eGFP expression of stable 
transfectants expressing eGFP-2A-CBGr99 (C) Correlation of eGFP and the click beetle luciferases activities in 
stably transfected MO4 cells. Mean fluorescence intensities (MFI) are plotted against corresponding RLU for 
CBGr99 in the stable cell lines. Activity of the 2 proteins shows excellent correlation (r²~ 0.9) 
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We have selected for each luciferase a clone with similar eGFP expression [Fig. 8A]. In these 
stable clones, complete cleavage was found with comparable intensity of the eGFP bands 
[Fig. 8B], which is in agreement with the identical fluorescence intensities shown in figure 
7C. These clones were used to perform luciferase comparison in vitro and in vivo.   
 
 
 
Figure 8 : eGFP expression of the selected stable clones 
 (A) eGFP expression analysis by flow cytometry of the stable transfectants expressing eGFP-2A-CBGr99, 
eGFP-2A-CBRed, or eGFP-2A-Fluc. (B) Western blot for cleaved eGFP of the stable transfectants, lane 1: 
eGFP-2A-Fluc ; lane 2: eGFP-2A-CBGr99; lane 3: eGFP-2A-CBRed; lane 4: transient transfection with 
pEGFP-N3 plasmid. 
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 Luciferase comparison in vitro 
For comparison of light emission, the MO4 cell lines expressing equimolar amounts of the 
different luciferases were imaged. Although the luciferases utilize the same substrate, D-
luciferin, the kinetics of the enzymatic activities may differ. Therefore, imaging of the cells 
was performed every minute after luciferin addition. We could show that the kinetics and 
maximum photon yield are indeed different [Fig. 9A]. CBGr99 clearly displayed the highest 
photon yield and is characterized by an enzymatic activity that peaks at about 11 min after 
addition of D-luciferin.  For CBRed and Fluc, the maximum is reached at about 27 min and 
35 min, respectively [Fig. 7A]. The photons emitted in the red part of the spectrum (above 
600 nm) are critical for in vivo BLI as they are less absorbed by mammalian tissues.  
To estimate the light that is emitted in the red-orange part of the spectrum, collection of 
orange-red light was performed using a DsRed2-1 filter (pass band 575-600 nm). CBGr99 
activity peaks at about 10 min after addition of D-luciferin whereas for CBRed a maximum 
was after about 21 min and for Fluc after about 32 min [Fig. 9B]. CBGr99 emits more orange-
red photons than CBRed in the early phase of the enzymatic activity but after 16 min, CBRed 
displayed a strongest photon yield. Fluc clearly emits fewer orange-red photons [Fig. 9B]. 
These observations do not allow to conclude that CBGr99 emits more photons above 600 nm. 
However, they strongly suggest that despite an emission spectrum, which is mainly in the 
green wavelengths, CBGr99 is a good candidate for in vivo BLI. 
 
 
Figure 9 : Luciferase comparison in vitro. 
Stably transfected MO4 cells were plated in a black 96 well plate and imaged for 1 min (45 times) (A) without 
emission filter, (B) with a DsRed2.1 emission filter. The graph of RLU versus the time allows direct comparison 
of the different luciferases.  
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 Luciferase comparison in vivo. 
Our in vitro studies have shown that CBGr99 is potentially a good candidate for BLI. 
However, tissues have a strong influence on the detection of bioluminescence reporters in 
vivo. Therefore, I evaluated the capacity to detect light emission of the stable clones in vivo 
placed in different locations, either (1) underneath the skin (subcutaneous), (2) in the 
peritoneal cavity (intraperitoneally), or (3) in a highly vascularized organ such as the lung. 
In the subcutaneous model, 30 000 cells of each clones were injected into the same mouse. 
With this approach the luciferases are directly comparable in presence of the same amount of 
injected luciferin. In the subcutaneous model the cells are superficially located in the mouse; 
thereby light absorption due to hemoglobin is low. As observed in vitro, the signal intensity 
from the CBGr99 luciferase is much higher compared to the two other luciferases [Fig. 10].  
 
 
Figure 10 : Luciferase comparison in the subcutaneous model 
Mice were injected subcutaneously injected with 30 000 cells of each stable clone and imaged at different times 
after D-luciferin injection. A representative animal is shown. The signal intensity from 5 mice were averaged 
and plotted relative to the time after luciferin injection.  
 
 
In the intraperitoneal model, where the cells are located deep in the mouse, the presence of 
organs like the gut and kidneys will lead to higher tissue absorption than in the previous 
model. Probably because of a higher absorption of the CBGr99 signal, BLI of cells injected 
intraperitoneally (1 x 10
6 
cells) showed that the differences between the various luciferases 
are less pronounced. However, the sensitivity of detection of CBGr99 remains superior in the 
first 5 min [Fig. 11A] and then becomes similar to CBRed in the next 15 min [Fig. 11A]. The 
highest sensitivity of CBGr99 at the early time points can be explained by a higher emission 
of photons in the red part of the spectrum [Fig. 11A].  
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For comparison of BLI of a strongly vascularized organ, we have used the lung model that 
presents two main disadvantages for BLI (1) Photons must traverse through a deep, highly 
vascularized and hemoglobin rich tissue (2) Scattering of the light is also caused by the 
presence of air/alveolar boundaries and lung/muscle junctions. Because intravenously injected 
cells will be sequestrated in the capillaries of the lung tissues, mice were imaged directly after 
intravenous injection of the respective clones (0.5 x 10
6 
cells). As suggested by the previous 
observation, Fluc is less sensitive than the click beetle luciferases (CBluc) [Fig. 11B]. As 
already observed in intraperitoneal model, the bioluminescence signal emitted by the CBGr99 
luciferase is greater in the first 10 minutes and becomes similar to the CBRed in the last time 
points [Fig. 11B].  
 
Figure 11 : Luciferase comparison in the i.p. and i.v. model  
Mice were injected with stable transfectants expressing eGFP-2A-CBGr99, eGFP-2A-CBRed or eGFP-2A-Fluc, 
respectively, and imaged at different times after D-luciferin injection. Representative animals are shown. The 
signal intensities from three mice per group were averaged and plotted relative to the time after luciferin 
injection. (A) Intraperitoneal model. BLI signal of 1 x 10
6
 cells injected i.p. (B) Lung model. BLI signal of 0.5 x 
10
6
 cells injected i.v. 
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Altogether these results clearly illustrate the superiority of the CBlucs over the Fluc which is 
the most commonly used in reported BLI studies. The comparison of the CBLuc has shown 
that depending on the time point, CBGr99 has either a superior or a similar sensitivity in vivo 
than CBRed. Despite a high attenuation of its signal in vivo, the CBGr99 luciferase still 
produces a higher or a similar amount of red photons (depending on the time point). These 
properties make CBGr99 highly suitable for BLI. 
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2. BLI to follow tumor growth in mice 
 Monitoring of tumorigenesis and metastasis in vivo 
The Fluc has been used as reporter gene in both in vitro and in vivo assays. This luciferase has 
been used to tag tumor cells for the purpose of monitoring growth in vivo (Edinger et al., 
1999). Temporal measurement of tumor cell growth was quantitative and permitted spatio 
temporal evaluation of tumor growth. Moreover, Fluc and its substrate, luciferin, have been 
shown to be non-toxic to mammalian cells (Sweeney et al., 1999). We have shown that 
CBGr99 luciferase is more suitable for BLI than Fluc (see chapter C 1.4). To verify whether 
CBGr99 is also appropriate to follow tumor growth in vivo, we have further characterized, a 
stable MO4 transfectant expressing CBGr99. First, a stable clone displaying a good antigen 
presentation was selected. For this clone, the sensitivity of detection was determined in vitro 
and in vivo. Second, proliferation of this clone was assessed in vivo to ensure that CBGr99 is 
appropriate for monitoring tumor growth in vivo. 
  
 Antigen presentation 
MO4 is a melanoma cell line that stably expresses the chicken ovalbumin protein (OVA). 
OVA is a well-characterized antigen with two defined CTL epitopes: ova257-264 (Rotzschke 
et al., 1991) and ova176-183 (Lipford et al., 1993). The OVA peptide 257-264 (SIINFEKL) is 
the immunodominant peptide. In therapeutic studies in mice, SIINFEKL is often used as a 
model antigen because of abundance of tools allowing the observation of the immune 
response. MO4 cells are usually grown under antibiotic selection (G418) to make sure they 
maintain OVA expression. Using the 2A technology, we have produced several stable 
transfectants that coexpress eGFP and CBGr99 (see chapter C 1.2). To obtain a clonal 
population we have selected stable transfectants based on their eGFP expression [Fig. 7B] 
starting from a single cell. Therefore, the selection process was done in the absence of 
antibiotics to avoid an excessive stress for the cell. To have a cell line displaying a good 
SIINFEKL presentation, we have checked the ability of these clones to efficiently present the 
SIINFEKL peptide by the B3Z assay. B3Z is a lacZ-transfected SIINFEKL-specific CTL 
clone. Recognition of MHC I complexed OVA peptides leads to transcriptional activation of 
lacZ gene resulting in production of ß-galactosidase. Enzyme activity correlates with amount 
of galactosidase synthesized by transcription of the lacZ gene and hence with peptide 
presentation. As shown in figure 12, most of the clones still present the SIINFEKL peptide 
despite the absence of selection in cell culture. The clone 10 has shown a presentation of 
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SIINFEKL on MHC I which is almost as high as to the parental B16F10 cell line loaded with 
SIINFEKL and greater than the other transfectants. Therefore, we have used clone 10, 
denoted MO4/GL2A-10, for subsequent studies. 
 
 
Figure 12 : SIINFEKL presentation by stable clones 
1 x 10
4
 cells/well were co-cultured with B3Z cells for 20 h and the lacZ was performed according to the protocol 
described in Material & Methods ( § 2.3.5) 
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 Sensitivity of detection. 
To assess the relationship between bioluminescent signal intensity and cell numbers, we 
prepared a dilution series of MO4/GL2A-10 cells (range 100- 10 000 cells per well) and 
measured the luminescence for a given volume (100 µl) of cell suspension after D-luciferin 
addition [Fig. 13A]. Quantification of the luminescence signal demonstrates a linear 
relationship between cell numbers and light emission after addition of D-luciferin [Fig. 13B]. 
Hence it is important to notice that the MO4/GL2A-10 cells have a relatively good sensitivity 
of detection in vitro. As shown in Figure 10A, as few as 100 cells can be detected in vitro. We 
also estimated the sensitivity of detection in vivo by injecting a serial dilution of MO4/GL2A-
10 cells (range 5000-1250 cells) subcutaneously in mice.  BLI of these mice has indicated that 
approximatively 2500 MO4/GL2A-10 cells [fig 13C] can be detected when superficially 
located in mice, namely subcutaneously. 
 
 
 
Figure 13 : In vivo BLI of MO4/GL2A-10 cell line. 
(A) MO4/GL2A-10 were diluted from 10 000 to 100 cells, plated in black 96-well plate, and imaged  for 1 minute 
after addition of D-luciferin. (B) Correlation between cell number per well and bioluminescence (RLU). (r² = 
0.99). (C) Serial dilution of MO4/GL2A-10 cells (range 5000-1250) were subcutaneously injected in a C57Bl/6 
Tyr -/- mouse and imaged for 5 min after i.p. administration of D-luciferin. 
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To estimate the attenuation of the signal due the black fur which is a strong absorber of light,  
black and white mice were subcutaneously injected with 50 000 MO4/GL2A-10 cells and 
imaged. The white mice that we have used C57Bl/6 mice are albino due to a spontaneous 
mutation of the tyrosinase gene (C57Bl/6 Tyr-/-). As shown in figure 14, the sensitivity of 
detection in black mice is significantly reduced compared to white mice (~10 times lower). 
When black mice are shaved, the light emission signal is very similar to the signal observed in 
white mice. Therefore, subsequent experiments were performed with shaved C57Bl/6 black 
mice which are better characterized than the white C57Bl/6 Tyr-/- mice. 
 
 
Figure 14 : Black vs White mouse for BLI 
50 000 MO4/GL2A-10 cells were subcutaneously injected in the indicated mice and imaged after i.p. 
administration of D-luciferin. A representative animal is shown. The signal intensity from 3 mice were averaged 
and plotted.  
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 Monitoring of tumor growth by BLI 
 Subcutaneous tumor growth 
C57Bl/6 mice inoculated with M04 cells subcutaneously develop fast growing tumors that 
lead to death 20 to 25 days after tumor inoculation. Tumor volume is estimated after 
measurement of the tumor diameter with a caliper. To check whether MO4/GL2A-10 
melanoma cells can be used to monitor subcutaneous tumor growth in mice, we injected 0.5 x 
10
6
 cells subcutaneously. Tumor growth was then monitored by BLI [Fig. 15A] and by 
external caliper measurement [Fig. 15C]. Tumor growth was measured beginning on day 1 
and weekly thereafter. By day 1, when tumor is still not detectable by optical inspection a 
luminescence signal was detectable at the site of injection [Fig. 15A]. Evidence of tumor 
growth was already visible at day 9 by a signal increase whereas the tumor is again hardly 
visible by eye. The signal significantly increases over the next 21 days with a similar to that 
observed with the caliper method [Fig. 15B]. Linear regression analysis showed that 
luminescence correlates to the tumor volume [Fig. 15C; r² > 0.9].  No apparent signal was 
detected from sites other than the site of injection indicating that the MO4/GL2A-10 cells 
seem not to metastasize.  
 
Figure 15 : Monitoring subcutaneous tumor growth in vivo. 
MO4/GL2A-10 (0.5 x 10
6
) were injected subcutaneously into C57Bl/6 mice and tumor growth followed over 
time. (A) In vivo BLI of a representative mouse is shown. (B) Bioluminescence signal (RLU) from tumors was 
quantified and is displayed over time. (C) Tumor volume estimate after caliper measurement is displayed over 
time. (D) Correlation between tumor volume and bioluminescence signal. 
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 In vivo analysis of metastasis colonization 
One of the current models for metastasis of melanoma and other tumors is lung tumor 
formation after intravenous injection of tumor cells. In this model, MO4 tumor nodules are 
usually quantified by counting the black nodules on the outside of an excised lung. This 
methodology requires euthanasia and allows analysis at only one single time point. To 
overcome this deficiency, we have intravenously injected 0.5 x 10
6
 MO4/GL2A-10 cells in 
mice and imaged them over a period of 36 days. Immediately after injection the cells were 
detectable in the lung. At day 6, the signal is strongly decreased or absent. The absence of 
signal probably indicates an initial clearance of most of the tumor cells. At day 11, the cells 
were detectable at the anatomical site of the lung. Subsequent time points showed an increase 
of the luminescence signal indicating metastasis colonization until death approximatively 40 
days after cells inoculation [Fig. 16]. 
 
 
Figure 16 : In vivo analysis of tumor cell lung colonization.  
MO4/GL2A-10 (0.5 x 10
6
) were injected intravenously into C57Bl/6 mice. In vivo BLI of a representative mouse 
is shown. 
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 Generation of autochthonous hepatocarcinoma model for BLI 
We have previously shown that CBGr99 is suitable for monitoring transplantable tumor 
growth via BLI. Although transplantable models are frequently used for experimental tumor 
studies they do not reflect the clinical situation of cancer formation. Conditional 
autochthonous tumor model are more useful for mimicking tumor development as it occurs in 
humans. For example a conditional transgenic hepatocarcinoma model (AST: Albumin-Stop-
Tag) has been established in our laboratory (Stahl, 2004). In this model, the SV40 Tag 
oncogene (Tag) is under the control of liver-specific promoter of mouse albumin (Alb) 
(Sandgren et al., 1989; Shiota et al., 1992) and can be induced at a desired time point by Cre 
recombinase. The activation of the transgene is achieved by intravenous injection of an 
adenovirus encoding the cre gene. Hepatocarcinoma development in these mice is dependent 
on the adenovirus dose and is characterized by the formation of several nodular adenomas in 
the liver. Because an increase in alanine aminotransferase (ALT) level reflects the presence of 
lesions in the liver, the measurement of its level in the serum is, so far, the only way to detect 
the presence of tumors without sacrifying the mice. This method may indicate the presence of 
tumor, but ALT levels do not correlate with tumor size. 
To be able to monitor tumor growth, I have generated a conditional reporter mouse designed 
ASC (Albumin-Stop-CBGr99), that expresses exclusively in the liver  the CBGr99 luciferase 
preceded by a floxed STOP cassette. By breeding the ASC with the AST mice, a binary 
transgenic model (ASCT mice) was established in which the conditional expression of two 
transgenes, Tag and CBGr99, can be induced simultaneously in the same liver cells by 
injection of adenovirus encoding cre. We evaluated in this mouse model the possibility to 
monitor hepatocarcinoma formation over the course of several weeks by BLI. 
  
 Generation and characterization of ASC mice 
To generate transgenic mice expressing the CBGr99 luciferase in an inducible manner 
specifically in the liver, a Stop-CBGr99 cassette was inserted into the ATG-including exon of 
the albumin gene through homologous recombination of a bacterial artificial chromosome 
(BAC) clone containing the albumin gene. There are several advantages of using BACs as 
compared to a single promoter sequence. (1) BACs have a high stability in terms of their 
propagation in recombinant deficient E.coli host cells, (2) BACs can be modified in E.coli to 
insert transgenes at a desired position and (3) the large size of the insert in BACs of 
approximately 150-200 kb provides less integration dependency of transgene expression.  
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 Construction of the Stop-CBGr99-FlpAmp cassette 
To generate the pFstop-CBGr99-FlpAmp construct, the pCBGr99-Basic vector (Promega) 
was used as starting vector. This plasmid was digested by Hind III followed by blunting with 
Klenow polymerase. In parallel the Fstop cassette was isolated from pAST plasmid 
(G.Küblbeck, DKFZ, Heidelberg) with EcoR I and blunted with Klenow polymerase to allow 
its insertion upstream of the CBGr99 gene. The intermediate plasmid, pFstop-CBGr99, was 
opened with Sal I and subsequently blunted using Klenow polymerase. The Flp-Amp cassette 
was released from the pCMV-Cre plasmid (G.Küblbeck, DKFZ, Heidelberg) with Xho I/Nhe I 
and blunted before its ligation downstream to the CBGr99 gene. The Fstop-CBGr99-FlpAmp 
cassette was then PCR-amplified from the template plasmid using chimeric 60 nucleotides 
primers. The 3´ 20 nucleotides of each primer were homologous to the targeting cassette used 
for amplification, while the 5´ 40 nucleotides were homologous to the first exon of albumin 
where the cassette has to be targeted by recombination. The primers were designed to target 
precisely the cassette in frame with the albumin start codon.  
Zeocin and Ampicillin gene were amplified in same way by PCR to allow the replacement of 
the LoxP site present in the BAC plasmid by homologous recombination. 
 
 Modification of the albumin gene containing BAC 
To obtain a BAC containing the mouse albumin gene, the CHORI database was screened. The 
RCPI23-14C7 clone was assumed to be the best candidate because of the presence of the 
complete 5´and 3´ regulatory regions, owing to the central position of the albumin gene in the 
BAC. After transfer of the selected BAC into EL 250 bacteria, it was modified by 
homologous recombination to express the Stop-CBGr99 cassette under the control of the 
albumin promoter. BAC DNA was introduced in EL 250 bacteria that contain a defective 
prophage [Fig. 17A] that protect and recombine electroporated linearized DNA (Yu et al., 
2000). The PL operon encoding gam and the red recombination genes, exo and bet, are under 
the tight control of the temperature-sensitive λ repressor. Recombination functions can thus be 
transiently supplied by shifting the culture to 42°C for 15 min [Fig. 17B]. Gam inhibits the 
E.coli RecBCD nuclease from attacking the electroporated linear DNA, while Exo and Beta 
generate recombination activity. To insert the cassette, containing the Stop-CBGr99 sequence 
and a selection marker gene (Ampicillin) into the exon 1 harboring the translational start of 
the albumin protein, two amplified recombigenic arms of 40 base pairs were added on both 
sides of the cassette by PCR. The selectable marker can, however, interfere with the 
subsequent function of the targeted locus. Therefore the selectable marker was flanked with 
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FRT sites, so that, it can be removed from the targeted locus by Flp Recombinase. In the EL 
250 bacteria, the defective prophage contains an arabinose inducible flpe. flpe is a genetically 
engineered flp that has a higher recombination efficiency than the original flp gene. The 
selective marker can thus be removed by incubating the bacteria with L-arabinose [Fig. 17C]. 
Because of the presence of two loxP sites in the BAC plasmid, it is possible that Cre 
expression leads to the deletion of the BAC from the mouse genome. Therefore two 
homologous recombinations were performed using a cassette encoding resistance to 
Ampicillin and Zeocin to replace these two loxP sites. The modified BAC was linearized 
prior microinjection in oocystes. (For more detailed information concerning the BAC 
modification see material and methods § 2.1.15.2) 
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Figure 17 : General strategy for BAC preparation 
(A) The first step consists in the introduction of  BAC DNA into the EL250 bacteria strain which contains the λ 
gene. This is performed by electroporation using the Gene Pulser® from Biorad. (B)  A temperature-sensitive 
promoter, PL, drives expression of the red gene which is able to recombine electroporate linearDNA produce by 
PCR with short homology regions at their ends (40 bp homology region, red square). Recombination function is 
supplied by shifting the culture to 42°C during 15 min. The linear DNA contains an Ampicillin cassette, flanked 
by FRT sites (Green square), which allows selection of the positive clones after recombination. (C) The 
promoter of the araBAD operon, which can be induced by L-arabinose, controls the expression of the flpe gene. 
Expression of the flpe gene allows the removal of the selective marker in order to avoid interference with the 
subsequent function of the targeted locus. 
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 Screening of founder mice 
Following microinjection into B6D2F1 oocystes, 8 live offspring mice were tested for the 
presence of the transgene at 5 weeks of age. For this, the presence of the CBGr99 transgene 
within the mouse genome tail biopsies was analyzed by Southern blotting. For identification 
of the CBGr99 transgene a 664 bp Dig labeled probe generated by digestion of pCBRed-basic 
plasmid with Pvu II was applied [Fig. 18]. From the 8 founders obtained, 1 male harbored the 
CBGr99 transgene. 
 
 
 
Figure 18 : ASC transgenic mice carry the transgene as shown b southern blot 
 (A) Location of the 664 bp Dig labelled probe within the Alb-Stop-CBGr99 construct is shown. (B) 
Representative Southern blotting of a positive mouse. 
 
The positive founder mouse was designed ASC and mated with AST mice and presence of 
transgenes in the F1 generation was assessed by Southern blotting for CBGr99 (as shown 
previously) and by PCR for SV40 Tag [Fig. 19]. Single transgenic for CBGr99 as well as the 
double transgenic were kept for further studies. 
 
 
 
Figure 19 : ASC and ASCT transgenic mice carry the transgene as shown by PCR 
 (A) Location of Tag specific primer within the transgene used to generate the 484bp PCR product. (B) 
Recovered genomic DNA from proteinase K digested AST and ASCT mouse tail biopsies were subjected to Tag 
PCR. Depicted are a positive PCR for each transgenic line as well as a negative control (NC). 
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 Characterization of ASC and ASCT mice 
 Unrecombined mice 
Because a STOP cassette can be leaky (Willimsky and Blankenstein, 2005), ASC and ASCT 
mice were imaged before injection of Cre-recombinase encoding adenovirus. A luciferase 
signal showed that the STOP cassette is leaky in ASC mouse [Fig. 20]. Considering that a 
luminescence signal is very low when it is below 600 counts per pixel, we can conclude here 
that the signal is very low [see scale, Fig 20]. To verify that this leakiness of the STOP 
cassette is not leading to spontaneous hepatocarcinoma development or spontaneous signal 
increase, 15 ASCT mice were imaged. At the age of 12 to 14 months all mice displayed 
comparable signals as the young unrecombined mice. Their liver did not show any signs of 
hepatocarcinoma development after sacrifice (data not shown).  
 
 
Figure 20 : Leakage in ASC model. 
ASC mice were imaged immediately after intra-peritoneal injection of luciferin (180µg/g of body weight). 5 min 
exposure time, A position and medium resolution picture setting were applied. A  low signal from the liver is 
observed in unrecombined mice. 
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 Recombined mouse  
In order to induce recombination, different doses of adenovirus encoding Cre were injected 
intravenously to ASC and ASCT mice. 1 day after injection, a strong signal increase was 
observed showing efficient recombination and specific luciferase expression in the liver [Fig. 
21A]. The signal increase observed after Adeno-Cre injection is 30, 170 and 350 fold higher 
than in the unrecombined mice after injection of 1.25 x 10
8
, 2.5 x 10
8
 and 5 x 10
8
 i.f.u., 
respectively. The relationship between signal increase and viral dose is non linear with 
dramatic luminescence signal increase resulting from small increase in viral doses [Fig. 21B]; 
e.g from 30 to 170 fold signal increase when viral dose is doubled (from 1.25 x 10
8
 to 2.5 x 
10
8
 i.f.u.). This observation correlates with a previous study showing that Kupffer cells in the 
liver take up the adenovirus and thereby reduce transgene delivery to the hepatocytes (Tao et 
al., 2001). Once Kupffer cells are saturated, efficient gene delivery to hepatocytes can be 
achieved more efficiently explaining the highest induction of luciferase expression per virus 
particles with high viral dose.  
 
Figure 21 : Induction of  luciferase expression 
1 day after adenovirus injection, mice showed a strong increase in luciferase signal due to the deletion of the 
stop cassette. (A) Imaging illustrates the signal increase after injection of 2.5 x 10
8
 i.f.u. (B) The graph shows 
that signal intensity is dependent on the virus titer. 
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After induction, the mice were weekly imaged in order to see whether hepatocarcinoma 
growth induced by SV40-Tag expression in ASCT mice could be followed by BLI [Fig. 22A]. 
In parallel the presence of tumors was estimated by measurements of the ALT levels in the 
serum. For negative controls, the same measurements were performed in ASC mice. In ASC 
mice, both ALT and luciferase activity were stable over the time [Fig. 22 (B and C)] whereas  
ASCT mice showed increased level of ALT as well as increased luciferase signals [Fig. 23 (B 
and C)], thus indicating tumor development.  
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Figure 22 : BLI of hepatocarcinoma growth 
 (A) Longitudinal measurement of ASCT induce hepatoma tumor growth from individual mice 6 images of 
representative ASC and ASCT mice were after adeno-Cre injection of indicated doses of virus.(images taken 10 
min after i.p D-luciferin administration; acquisition time indicated in the figure, high resolution) the numbers of 
days annotating each individual images refers the time post-adeno-Cre injection.  (B) Graph depicting the 
longitudinal measurement of light emission from individual mice (3 mice/groups). Light emission is expressed as 
relative light units. (C) Graph depicting the longitudinal serum level of ALT. 
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For 1.25 x 10
8
, 2.5 x 10
8
 and 5 x 10
8
 i.f.u of injected virus,  most of the mice (16/17 mice) 
showed a significant signal increase that was observed 40 to 60 days after virus injection [Fig. 
23]. In all cases, signal emission was confined to the liver, demonstrating that in this model 
tumor development is indeed restricted to the liver.  
 
 
Figure 23 : Luminescence signal evolution in ASCT mice and observation ex vivo 
(A) Longitudinal measurement of ASCT induced hepatoma tumor growth from individual mice. Graph depicting 
the longitudinal measurement of light emission from individual mice after injection of the indicated dose of 
Adeno-cre. Light emission is expressed as relative light units. 
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At the final time point, mice were sacrificed and inspected for the presence of tumors. All 
mice that have shown signal increase displayed large tumor nodules that are luciferase 
positive in the liver [Fig. 24A]. Large nodules were also observed in the mouse that did not 
display luminescence signal increase within 60 days after virus injection. Only 2 nodules were 
luciferase positive [Fig. 24B] and the luminescence signal increase was visible around 80 
days after Adeno-Cre injection [Fig. 24C]. We can hypothesize that a majority of cells that 
were infected with the virus have switch on Tag expression leading to the formation of 
nodules whereas CBGr99 was kept silent. However, in some cells both transgenes were 
induced which led to the 2 luciferase positive nodules. In the case of this mouse, the 
luminescence signal does not efficiently correlate with tumor formation. We have seen here 
that the probability of having a signal reflecting hepatocarcinoma growth is high (16/17) 
therefore we can conclude that the ASCT mice serve as a suitable model for hepatocarcinoma 
monitoring by BLI.  
 
 
Figure 24 : Ex vivo observation of liver from ASCT mice  
Ex vivo visualization of CBGr99 expressing liver nodules by BLI (A) in the general situation (B) in the mouse 
13041. (C) Graph depicting the longitudinal measurement of luminescence signal in the mouse 13041 
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3. Bioluminescence imaging of tumors in live animals with bacteria 
encoding luciferase and their usage in tumor therapy 
 
Recent observations in murine models with facultative anaerobic bacteria (Pawelek et al., 
1997), as well as data generated more than 30 years ago with obligate anaerobic bacteria 
(Moese and Moese, 1964), indicate that some bacteria species can preferentially replicate and 
accumulate within tumors. Making use of BLI, tumor colonization in nude mice has been 
visualized using E.coli and three attenuated pathogens (Vibrio cholerae, Salmonella 
typhimurium, and Listeria monocytogenes) transformed with plasmid encoding the Lux 
operon (Tani et al., 2004). Starting from these observations, we have investigated whether or 
not Vibrio cholerae (V.cholerae.lux) and E.coli (Top10.lux) expressing the lux operon would 
also target tumors in immunocompetent mice which are able to mount an immune response 
against the bacteria. In addition to imaging, we have used E.coli expressing luciferase in an 
inducible fashion as delivery vectors for interleukins (GMCSF; IL-2) in order to enhance 
elimination of tumors by the immune system.  
 
 Visualization of tumors 
 Subcutaneous model 
 V.cholerae colonization 
To follow tumor targeting by V.cholerae.lux in immunocompetent mice, we injected C3H 
mice (n=5) carrying subcutaneous AG104A fibrosarcoma tumors (~ 500 mm³) with 1 x 10
8
 
cells of light emitting V.cholerae.lux. 20 minutes after injection of bacteria the luminescence 
signal was only visible at the anatomical site of the liver. 24 hours later the bacteria were still 
located in the liver but now a strong luminescence signal was visible at the tumor site 
suggesting tumor colonization by the bacteria. At day 7, the bacteria had disappeared from the 
liver, probably due to the immune response whereas the signal intensity from the tumor was 
increased indicating efficient replication of the bacteria in the tumor. From day 7 on, the 
signal started to decrease until no luminescence was visible around day 30 [Fig. 25]. In these 
studies 100% (5/5 mice) of the tumors have been targeted by the bacteria. 
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Figure 25 : Tumor colonization by V.cholerae.lux 
AG104A tumor bearing mice (n=5) were infected by intravenous injection of V.cholerae.lux. Mice were imaged 
at the indicated time point after bacteria infection. Representative animals are shown. 
 
The monitoring of tumor growth showed that V.cholerae.lux does not affect tumor 
progression [Fig. 26]. 
 
Figure 26 : Tumor growth of AG104 A tumors after V.cholerae injection. 
(A) AG104A were s.c.  injected into the shaved abdomen of mice. After developing tumors ( 500 mm
3
), mice 
were treated as indicated and volumes of the tumors were determined. Points: mean tumor volumes of groups of 
five mice in a typical experiment. Control:  PBS control. Treated: injected with 10
8
 V.cholerae cells at indicated 
time (red arrow). 
 
The plasmid encoding for the lux operon is not integrated in the V.cholerae.lux genome. 
Therefore, loss of signal after 28 days may be due to the loss of the plasmid encoding the lux 
operon in absence of antibiotic selection in vivo. Alternatively, the immune system may have 
cleared the bacteria. In order to see if loss of the plasmid would be responsible, we used E.coli 
(Top10-lux; provided by Dr. Loessner) that has the lux operon stably integrated into their 
genome. In these bacteria, the lux operon is under the control of the PBAD promoter of the 
arabinose operon [Fig. 27 A and B] (Lee et al., 1980). 
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 L-arabinose-inducible expression 
The ability to express cloned gene under a control condition is often very useful. These 
systems have been usually generated to have low basal level of expression to minimize the 
effects of exposing bacteria to toxic gene products during growth. The PBAD promoter is an 
inducible promoter which turns on the transcription machinery in presence of L-arabinose; in 
its absence, transcription occurs at very low levels (Lobell and Schleif, 1990). The PBAD 
promoter is widely used to positively control expression in bacterial culture (Guzman et al., 
1995). Together with our collaborators (Dr. Loessner, HZF, Braunschweig), we showed that 
gene expression could also be induced in vivo when L-arabinose is administrated systemically 
(Loessner et al., 2007a). Salmonella typhimurium SL7207 carrying the Fluc or the lux operon 
under the control of the PBAD promoter were engineered [Fig. 26 A and B] and injected 
intravenously into mice bearing CT 26 tumor of around 0.5 cm diameter. 3 days after 
injection of bacteria, we have determined by in vivo BLI very low luciferase activity. 
Intraperitoneal injection of L-arabinose led to a strong induction of luciferase expression that 
peaks 5 hours after injection [Fig 27 C and D]. These experiments show that the PBAD 
promoter can be efficiently induced in vivo when L-arabinose is administrated systemically.  
The lux operon is integrated in the bacterial chromosome whereas the Fluc is transiently 
express.  The lower luminescence intensity observed with the lux operon may be explained by 
the single copy of lux operon present in the carrier bacteria but also by the different photon 
yields of the two enzymatic reactions. 
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Figure 27 : In vivo BLI of L-arabinose-induced bacterial luciferase 
Representation of the plasmids encoding for the inducble expression of (A) Fluc and (B) lux operon. Tumor 
bearing mice were infected with S.typhumurium harbouring  the inducible (C) Fluc plasmid   or (D) the lux 
operon. 3 days post infection, mice were intraperitoneally injected with 120 mg L-arabinose. Images of mice 
were acquired before (0 h) or after L-arabinose administration at the indicated time points. Representative 
mouse is presented.  
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 Top10.lux tumor colonization 
E.coli bacteria (Top10.lux) that have the lux operon under the control of the PBAD promoter 
integrated in the bacterial chromosome. The use of these bacteria allowed us to investigate 
whether tumor colonization is transient. C3H mice bearing AG104A tumors (~ 500 mm³) 
were i.v  injected with Top10.lux and tumor colonization was followed by in vivo BLI of the 
mice 5 hour after L-arabinose injection.  Monitoring of the mice (n=10) showed again an 
initial increase of the luminescence which started to decrease in the tumors after about 6 days 
[Fig. 28A]. The luminescence signal peaked around day 6 and became non-visible around day 
14. The complete clearance of the Top10.lux luminescence signal suggests that the bacteria 
were eliminated by the host’s immune system. The single lux operon copy due to the 
chromosomal integration may explain the lower light intensity observed with Top10.lux in 
comparison to V.cholerae.lux where the plasmid encoding for the lux operon is transiently 
expressed [Fig. 28B]. Thereby, the earlier clearance of the luminescence signal observed with 
Top10.lux may be explained by a low luminescence signal which could not be detected or by 
a difference of colonization capacity between the 2 strains. Again, tumor colonization by 
bacteria was observed in all mice. No effect on tumor growth was observed [Fig. 27C].    
 
 
Figure 28 : In vivo BLI of AG104A colonization by Top10.lux 
(A) AG104A tumor bearing mice were infected by i.v injection of Top10.lux and imaged at the indicated time 
point. Representative animals are shown. Imaging was performed 5 hours after i.p administration of 120 mg of 
L-arabinose. (B) 10
8
 bacteria of the indicated strain were imaged to compare their light emission (C) AG104A 
tumor cells were injected s.c in mice. After development of tumors (~500 mm³), mice were treated as indicated 
and volumes of the tumors were determined. Points: mean tumor volumes of groups of five mice in typical 
experiments. Control: PBS control. Treated: injected with 10
8
 Top10.lux cells at indicated time (red arrow). 
                                                                                                                                          Results                                                
80 
To ensure that the tumor targeting by bacteria is not only restricted to the AG104A 
fibrosarcoma we have performed similar experiments in additional tumor models namely the 
RMA and B16 tumors [Fig. 29]. These experiments have shown here that bacteria are able to 
target and to transiently colonize all transplantable tumors investigated so far. In all cases 
tumor colonization by bacteria had no effect on tumor growth (data not shown).  
 
Figure 29 : In vivo BLI of tumor colonization by Top10.lux 
(A) Tumor bearing mice were infected by intravenous injection of Top10.lux. Mice were imaged at the indicated 
time point after bacteria infection. Representative animals are shown. Imaging was always performed 5 hours 
after intraperitoneal administration of 120  mg of L-arabinose. 
 
Following these observations we focused on the use of bacteria as a carrier to target 
immunostimulatory proteins, such as interleukins, to tumors. However, most bacterial systems 
for the presentation of recombinant proteins rely on the expression of proteins in the 
cytoplasm of bacterial carriers; the proteins are thus only accessible to the host immune 
system upon disintegration of the bacteria. As an alternative to cytoplasmic protein 
expression, several systems for exporting proteins from the cytoplasm of live-attenuated 
bacterial vaccines have been developed. Therefore, we have produced bacteria that efficiently 
secrete interleukins to allow their contact with the targeted cells. 
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 Bacteria secreting interleukin 
Usually recombinant proteins are expressed intracellularly in bacteria. To allow secretion of 
these proteins into the tumor environment, a secretory system needs to be used which allows 
protein secretion through the bacterial membrane. Secretion of recombinant proteins in Gram-
negative bacteria requires specific translocation of the exoprotein across the inner and outer 
membrane and depends on naturally occurring secretion systems. Gram-negative bacteria 
have evolved five basic protein secretion mechanisms, which are classified as type I to type 
IV secretion systems and autotransporters, also referred to as type V secretion systems 
(Henderson et al., 2000; Lory, 1998). The type I secretion systems combine a number of 
features that make them superior to other secretion systems for recombinant protein delivery 
(Binet et al., 1997). Among the type I secretion systems the Escherichia coli HlyA system is 
currently the only protein exporter which has been developed to a versatile and universally 
applicable secretory expression system (Gentschev et al., 1996). 
 
 The Hly secretion system.  
The plasmid-encoded HlyA secretion system initially characterized by Goebel and coworkers 
(Hess et al., 1990; Vogel et al., 1988) comprises four structural genes, organized in a single 
transcriptional unit. Besides the genes for HlyA (hlyA), the ABC translocase (HlyB), and the 
membrane fusion proteins component (HlyD), the operon encodes an acetylase (hlyC) 
required for posttranscriptional activation of HlyA [Fig. 30A]. The operon is transcribed from 
a promoter complex (Phly) upstream of the Hly C. The secretion signal (HlyAs) necessary for 
recognition of the target protein by the HlyA secretion machinery is located at the C-terminal 
end of the HlyA, comprising the last 61 amino acids [Fig. 30A]. Since the secretional signal 
does not become released during the secretion process, proteins adapted to hemolysin-
mediated transport are generally secreted as fusion proteins, carrying a C-terminal extension 
of 61 amino acids. In our study we have fused different interleukins with the HlyAs secretion 
signal for extracellular delivery [Fig. 30B].  
 
 
 
 
 
 
 
                                                                                                                                          Results                                                
82 
 
Figure 30 : Construction of GM-CSF and IL-2 fused to hlyAs. 
 (A) Representation of the plasmid encoding for secretion of hemolysin A. (B) Representation of plasmids 
encoding for the secretion of GM-CSF-HlyAs and IL-2-HlyAs fusion proteins. 
 
 Interleukins 
Since its initial discovery (Morgan et al., 1976), cytokine based immunotherapy has been 
vigorously and extensively investigated for cancer treatment. However, so far most cytokine-
based therapy trials have not fulfilled the expectations. One of main obstacles is the difficulty 
of achieving therapeutically relevant dosages in patients without generating excessive tissue 
toxicity. Deliverance of cytokines locally with a bacterial carrier has the potential of 
generating sustained high local concentration of immunostimulatory cytokine without raising 
the systemic levels of cytokines, which is responsible for most of the observable toxicity. 
Interleukin-2 (IL-2) and Garanulocyte-Macrophage Colony Stimulating Factor (GM-CSF) are 
two potential candidates for immunotherapeutic studies.  IL-2 stimulates natural killer cells, 
preactivates cytotoxic T cells, B cells and macrophages (Smith, 1988). When administrated at 
very high doses as a single agent, IL-2 was capable of inducing tumor regressions in certain 
model systems in vivo (Donohue et al., 1984; Rosenberg et al., 1985). Whereas GM-CSF has 
an effect on a number of cell types including monocytes, dendritic cells, eosinophils, and 
neutrophils (Burgess et al., 1977; Sieff et al., 1985). In preclinical and clinical studies, GM-
CSF secreted from tumor cells has been shown to be a potent stimulator of antitumor 
responses (Dranoff et al., 1993; Sampson et al., 1996; Soiffer et al., 1998; Yu et al., 1997). 
The consensus from these studies suggests that GM-CSF stimulates antigen presenting cells 
such as dendritic cells to generate potent immune responses. Hence both interleukins are 
known to be biologically active without glycosylation (DeLamarter et al., 1985; Sato et al., 
1993) which is of importance for bacterial expression as they are not able to carry out 
mammalian glycosylation and other protein modifications. 
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 GM-CSF construct 
GM-CSF cDNA was inserted in a pILH-1 plasmid encoding for the secretion apparatus of 
E.coli hemolysin. The sequence encoding mouse GM-CSF was amplified by PCR using 
pGMCSF2a plasmid (Dr.S.Weiss; Braunschweig) as template and oligonucleotide F-bfrBI-
GM-CSF as forward primer and the oligonucleotide 2.R-PacI-GM-CSF, containing a part of 
the sequence encoding for the C-terminal of HlyA, as a reverse primer. Digestion of the 
resulting PCR product with NsiI and PacI followed by its ligation in pILH-1 plasmid digested 
with the same enzyme resulted on the pIHL-GM-CSF plasmid. 
 
 IL-2 construct 
IL-2 cDNA was amplified by PCR using pBlue-IL-2 plasmid as template and oligonucleotide 
F-RI-HlyA-IL2 as forward primer and the oligonucleotide R-RI-PacI as a reverse primer. 
Digestion of the resulting PCR product with NsiI and PacI followed by its ligation in pILH-
GM-CSF plasmid digested with the same enzyme resulted on the pIHL-IL-2 plasmid. 
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 Secretion of interleukin in Top10 bacteria. 
To verify secretion of GM-CSF-HlyAs and IL2-HlyAs, culture supernatants of recombinant 
Top10.lux carrying the respective plasmid were concentrated and analyzed by Western 
blotting. In both cases, a specific monoclonal antibody detected a protein band having the 
expected molecular mass, whereas no specific signal could be found in the supernatants of the 
untransformed Top10.lux strain.  All bands displayed the expected molecular weight [Fig. 31]. 
Therefore, we have successfully produced two recombinant bacteria strains that conditionally 
express the lux operon and efficiently secrete GM-CSF (Top10.lux.GM-CSF) and IL-2 
(Top10.lux.IL-2). 
 
 
Figure 31 : Interleukin secretion by Top10.lux bacteria. 
(A) Western blot analysis of bacterial supernatant from Top10.lux.GM-CSF. Lane: 1, GM-CSF-HlyAs ( 25,7 
kDa); 2, Top10.lux supernatant; 3, recombinant GM-CSF (14,8 kDa). (B) Western blot analysis of bacterial 
supernatant from Top10.lux.IL-2. Lane: 1, Il-2-HlyAs (29,1 kDa); 2, Top10.lux supernatant; 3, recombinant Il-2 
(15,4 kDa). 
 
 Tumor studies with GM-CSF secreting E.coli 
The antitumor activity of Top10.lux.GM-CSF was determined in C3H mice bearing 500 mm³ 
(~ day 9) AG104A tumors. 10
8
 bacteria were administrated intravenously 3 times at intervals 
of 72 h and mice were evaluated by BLI for tumor colonization 24 h after each injection of 
bacteria. Although in all mice colonization with bacteria was observed, the tumor growth was 
similar to the untreated group and to the group treated with Top10.lux [Fig. 32A]. As GM-
CSF is believed to enhance the recruitment of dendritic cells to the tumor site and to 
subsequently increase antigen presentation, we have thought to use the AG104A-Tag cell line 
that expresses a strong tumor antigen namely Tag. C3H mice bearing 500 mm³ AG104-Tag 
tumors were treated with 3 intravenous administrations of bacteria as described above. Again 
tumor colonization was observed in all mice. In the Top.lux.GM-CSF group tumor growth 
was retarded at the day 4 of treatment in comparison to the Top.lux and untreated mice. Out of 
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5 mice, 2 have completely rejected the tumor, whereas the others had a slower growth [Fig. 
32B]. These results suggested that treatment with bacteria secreting GM-CSF was efficient to 
reject tumor in a therapeutic vaccination setting. However, the results obtained with the 
AG104A-Tag tumor were not reproducible. As shown, in Figure 32C, in subsequent 
experiments a decreased tumor growth was also observed in tumor bearing mice treated with 
Top.lux. (e.g. in the absence of interleukin). Therefore, the effect of GM-CSF on tumor 
growth is questionable in this model. The experiment shown in figure 32C suggested that the 
bacteria themselves might be responsible for the delay in tumor growth. 
 
Figure 32 : Treatment of developing fibrosarcoma by injection of bacteria 
 (A) AG104A and (B) and (C) AG104A-Tag cells were s.c. injected into the shaved abdomen of mice. After 
developing tumors ( 500 mm
3
), mice were treated as indicated and volumes of the tumors were determined. 
Points: mean tumor volumes of groups of five mice in a typical experiment. 
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 Spontaneous tumor model 
 Alb-Tag model 
In section § 3.1, we have shown that bacteria expressing the lux operon can efficiently 
colonize all transplantation tumors investigated so far. Next, we wished to investigate whether 
or not autochthonous tumors could also be visualized by luminescent bacteria. A murine 
model (Alb-Tag) for hepatocellular carcinoma was previously developed in our laboratory 
(Ryschich et al., 2006). Transgenic mice expressing the Tag oncogene under the control of the 
albumin promoter/enhancer develop highly vascularized liver cancers. A major advantage of 
this model over transplanted tumors is that Tag-induced tumors develop spontaneously within 
the liver. Tumor development is characterized by formation of several adenoma nodules in the 
liver. A disadvantage of this model is that tumor growth is not visible from the outside.  
We have thought to inject light-emitting bacteria in Alb-Tag mice to see whether they will 
target tumor nodules and thereby allow their visualization. 12 weeks old Alb-Tag mice were 
intravenously injected with 1 x 10
8
 V.cholerae.lux and monitored over the time. As previously 
shown in the transplantable model, all mice have a luminescence signal originating from the 
liver as early as 20 min after injection of bacteria [Fig. 33A]. At day 5, 55 % of the mice (5/9) 
displayed a signal from liver nodules. The signal increased until a maximum which was 
reached between day 6 and 9, and then gradually decreased and disappeared between day 14 
and 21.  It has already been shown in this tumor model that mice develop several nodules in 
the liver. Importantly, only few regions of the liver lighted up (3 mice with 1 signal [Fig. 
32A] and 2 mice with 2 distinct signals [Fig. 33B]). The mice that remained negative were 
rechallenged with bacteria at a late tumor stage. Although, they carried large tumors, none of 
them has shown tumor targeting [Fig. 33C]. These results show that despite the presence of 
large tumors in Albumin-Tag mice, tumor targeting by bacteria as determined by BLI is not as 
efficient as in subcutaneous transplantation tumor models. 
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Figure 33 : In vivo BLI of tumor colonization by V.cholerae.lux in the Alb-Tag model 
Tumor bearing mice were infected by intravenous injection of V.cholerae.lux. Mice were imaged at the indicated 
time point after bacteria infection. 3 representative animals are shown. 
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 RIP-Tag-5 model 
We have also investigated whether or not V.cholerae.lux could target tumors in a spontaneous 
insulinoma model, namely in RIP.Tag-5 mice, expressing the oncogene Tag under control of 
the rat insulin promotor in the beta-islets of the pancreas. Tag expression starts at the age of 
10 weeks and leads in a multistep fashion to formation of hyperplastic islets and to the 
development of solid insulinoma at about 25 weeks of age (Hanahan, 1985). 7 months old 
RIP-Tag-5 mice were intravenously injected with 1.10
8
 V.cholerae.lux. The usual 
luminescence signal originating from the liver after i.v injection of bacteria is visible 35 min 
after injection of bacteria. The mice (n=3) were monitored over a period of 3 days and none of 
the 3 injected RIP-Tag-5 mice were displaying a luminescence signal [Fig. 34]. Here, we have 
observed that V.cholerae.lux does not target tumor in the RIP-Tag-5 model.  
 
Figure 34 : In vivo BLI of tumor colonization by V.cholerae.lux in the RIP-Tag-5 model 
Tumor bearing mice were infected by intravenous injection of V.cholerae.lux. Mice were imaged at the indicated 
time point after bacteria infection. A representative animal is shown. 
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 Her2-Neu model 
Finally, we studied whether spontaneous developing mammary carcinomas are targeted by 
Top10.lux. The Her-2/neu transgenic (neu-N) mice that express the HER-2/neu oncogene 
under tissue-specific transcriptional control of the mouse mammary tumor virus (MMTV-
LTR) represent a suitable model of mammary carcinogenesis. These mice develop neu-
overexpressing spontaneous mammary carcinomas in a stochastic manner beginning at around 
4 months. To see whether bacteria would target the breast tumors in this model, 10
8
 Top10.lux 
bacteria were intravenously injected in neu-N mice with advanced tumors (5 months old). 
One day after injection of bacteria, mice were imaged 5 hours after induction of luciferase 
expression by L-arabinose. All mice tested (7/7) have shown the typical luminescence signal 
observed from the liver immediately after bacteria injection. However, only one out of the 
seven mice displayed a luminescence signal from tumors [Fig. 35]. Importantly, among the 8 
mammary tumors that are optically visible only 3 showed colonization by bacteria. 
Monitoring of bacteria colonization in this mouse showed that the luminescence signal stays 
quite stable over time in the 3 targeted tumors. The mouse had to be sacrified for ethical 
reasons which prevented us from following the survival of the bacteria in this model. The 
luminescent signal intensities are different and implicate that each tumor has a different 
ability to be colonized by bacteria. Several of the biggest tumors remained luciferase negative 
which indicates that the colonization capacity of the bacteria is not dependent on the tumor 
size. The 6 other tumor bearing mice remained negative over time, even after re-injection of 
bacteria [Fig. 35B]. Thus, colonization of mammary carcinoma in Her-2/neu mice by 
Top10.lux bacteria appears to be very inefficient. 
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Figure 35 : In vivo BLI of tumor colonization by Top10.lux in the Her-2/neu model 
Tumor bearing mice were infected by intravenous injection of Top10.lux. 5 hours after i.p. administration of L-
arabinose mice were imaged at the indicated time point after bacteria infection. (A) The single positive mouse is 
shown. (B) A representative negative mouse is shown. 
 
In conclusion, using BLI we were able to visualize tumor targeting by V.cholerae.lux and 
Top10.lux in immunocompetent mice. However, in subcutaneous transplantation tumors 
colonization with bacteria was clearly more efficient than in spontaneously developing 
tumors. These data are summarized in table 3. According to these results bacterial targeting of 
tumors in patients may not be a promising approach. 
 
Tumor Origin Bacteria 
Number of 
mice 
Positive 
(luminescence) 
Transplantation tumor models 
AG104A Fibrosarcoma V.cholerae.lux 10 10 
AG104A Fibrosarcoma Top10.lux 32 32 
AG104A.Tag Fibrosarcoma Top10.lux 43 43 
RMA Lymphoma Top10.lux 17 17 
B16 Melanoma Top10.lux 10 10 
Autochtonous tumor models 
Albumin-Tag Hepatoma V.cholerae.lux 9 5* 
RIP-Tag Insulinoma V.cholerae.lux 3 0 
Her2/neu 
Mammary 
carcinoma 
Top10.lux 7 1* 
Table 3 : Summary of bacterial targeting and tumor visualization by BLI 
* In positive autochthonous tumor mice not all tumor nodules were positive. 
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4. Generation of a conditional luciferase reporter mouse 
Since BLI represents a useful approach for tracking of a cell population in vivo, cells 
expressing luciferase have been generated by transfer of the luciferase gene using retroviral 
vector (Costa et al., 2001; Kim et al., 2004). However, the use of retroviruses is hampered by 
the large variation in its transduction efficiency, especially when the genes are to be 
introduced into primary cells. Infection with retrovirus often requires cell culture and 
activation which may alter the biological properties of the cells. An alternative approach to ex 
vivo cell labeling by retrovirus is the generation of transgenic mice that ubiquitously express 
luciferase. Luciferase positive cells can then be transferred with a minimum of ex vivo 
manipulation. To facilitate isolation of cells from the donor animal after monitoring by BLI, a 
fluorescent protein can be associated to the luciferase. Moreover, it allows multimodality 
analysis. Luciferase expression can be followed by BLI whereas flow cytometry and 
immunohistology permit eGFP expression analysis. 
Therefore, I wanted to generate a transgenic mouse line that conditionally expresses luciferase 
and eGFP in all tissues. To this we used an ubiquitous promoter, the chicken-ßActin 
promoter, to control the expression of an eGFP-2A-CBGr99 cassette. By insertion of a flox 
STOP cassette between the promoter and the reporter genes, the expression should inducible 
by Cre recombinase. The mating with Cre deleter mice (Schwenk et al., 1995) would lead to a 
mouse line, ßactin-eGFP-2A-CBGr99, that ubiquitously expresses GFP and luciferase, 
whereas, the unrecombined mouse line can be used as reporter mouse for Cre expression.    
 
 Generation and Characterization of ßactin-Fstop-eGFP-2a-CBGr99 mouse line 
 Construct 
A targeting construct was engineered for homologous recombination so that upon Cre 
expression a promoter less eGFP-2A-CBGr99 cassette is activated by an ubiquitously 
expressed promoter to indicate recombination at a single cell level. A Fstop DNA from pAST 
plasmid (G.Küblbeck, DKFZ, Heidelberg) was first excised as an EcoRV–StuI fragment and 
ligated into pCMV-eGFP-2A-CBGr99 (see § 1.2.1) cut with SmaI to make pCMV-FStop-
eGFP-2A-CBGr99. To make pßActin-Fstop-eGFP-2A-CBGr99, pCMV-FStop-eGFP-2A-
CBGr99 was cut with XbaI-HindIII. The liberated FStop-eGFP-2A-CBGr99 cassette was then 
ligated into pßactin-16-pl (Dr. C. Probst, ETH Zurich) that has been cut with the same 
restriction enzymes. Finally, pßActin-Fstop-eGFP-2A-CBGr99 was linearized with PagI/XbaI 
and resuspended into injection buffer prior to injection in oocystes. 
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 Screening of founder mice 
The 9 live offspring mice obtained after microinjection C57Bl/6 oocystes were tested for the 
presence of CBGr99 at 5 weeks of age by Southern blotting (see § 2.2.2.). The 2 positive 
founders were mated with C57B6/j mice and presence of the transgene in the F1 generation 
was also checked by Southern blot. For both transgenic lines, the transfer of the transgene to 
the next generation was observed. 
 
 Characterization of ßactin-eGFP-2A-CBGr99 mice 
The two transgenic founders were crossed each with a Cre deleter mouse that ubiquitously 
expresses Cre (Schwenk et al., 1995). BLI was performed from the resultant F1 generation. 
The results showed that both transgenic lines, denoted ßAc-G2A99/0 and ßAc-G2A99/4 mice, 
were capable of Cre-dependent luciferase expression [Fig. 36A]. We next measured the 
difference in bioluminescence from individual tissues by dissecting both transgenic lines after 
administration of D-luciferin. In the ßAc-G2A99/0 line, we observed that bioluminescence 
could be switched on in a Cre-dependent manner in all tissues but with variable signal 
intensities [Fig. 36B]. Brain, thymus, heart, lung, spleen, skin and gut show a strong signal 
whereas pancreas and lymph nodes have a lower signal and liver and kidney bioluminescence 
is very weak. Similar observations were made with the second transgenic line, ßAc-G2A99/4, 
but with much lower signals (results not shown). Therefore we have used the ßAc-G2A99/0 
line for subsequent studies. 
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Figure 36 : Characterization of the ßAc-S-G2A99. 
(A) BLI images of two transgenic lines, ßAc-G2A99, resulting from ßAc-S-G2A99/Cre deleter cross. The mouse 
in the left is ßAc-S-G2A99, thereby Cre negative, and does not luminesce, whereas the 2 mice in the right are 
Cre positive and appears to luminesce from all areas of the body (B) Images of organs from recombined and non 
recombined mice. All organs from the recombined mice luminesce. 
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In order to estimate the sensitivity of detection, splenocytes were imaged in vitro. A minimum 
of 1.25 x 10
5
 splenocytes was required for detection [Fig. 37A].  Since the luciferase signal in 
lymphocyte appears to be very weak, we asked if transferred cells could be detected in a 
mouse where tissues absorb most of the emitted photons. Indeed, after transfer of 10 x 10
6
 
splenocytes to syngeneic recipients we were not able to see any signal. As the expression of 
luciferase protein correlates with eGFP expression, splenocytes and peripheral blood cells 
(PBL) were checked for their eGFP expression. Although the ßactin promoter is supposed to 
be ubiquitously expressed, Figure 36B shows only a small percentage of the cells express 
eGFP. Probably this explains the low sensitivity of detection in vitro and in vivo. From this 
data we estimate that approximately 2000 eGFP positive splenocytes are detectable in vitro. 
FACS sorting of the small percentage of eGFP positive cells would be too tedious and require 
too many donor mice. Therefore, and unfortunately, we have to conclude that the ßAc-
G2A99/0 is not suitable as universal cell donor.  
 
 
Figure 37 : Sensitivity of dectection on BLI study in vitro. 
(A) Luciferase assay in vitro of splenocytes from 3 individual ßAc-S-G2A99/0 mice. (B) Flow cytometry analysis 
for eGFP to measure the percentage recombination in splenocytes and in PBL of ßAc-G2A99/0 mice. 
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 Generation and characterization of CAG-CBGr99-2A-mCherry mouse line 
As we failed to generate a conditional mouse line that can be used as a source of cells for 
transfer we envisaged a new transgenic line that constitutively and ubiquitously expresses a 
CBGr99-2A-mCherry cassette. This cassette contains the CBGr99 luciferase associated to a 
monomeric red fluorescent protein (mCherry) with the 2A system. The cassette is under the 
control of a composite promoter that combines the human cytomegalovirus immediate-early 
enhancer and a modified chicken ß-actin promoter (CAG). The CAG promoter is a very 
strong and ubiquitous promoter. It has been shown to produce high levels of expression both 
in vitro and in vivo (Okabe et al., 1997). 
 
 Construct 
To make pCAG-CBGr99-2A-mCherry, pCAG-CBGr99-2A-DTR-2A-mCherry (G.Küblbeck, 
DKFZ, Heidelberg) was cut with Kpn I to release the DTR gene and then self ligated to obtain 
the pCAG-CBGr99-2A-mCherry. Finally, pCAG-CBGr99-2A-mCherry was linearized with 
PagI/XhoI and resuspended into injection buffer prior to injection in oocystes. 
 
 Screening of founder mice 
The 14 live offspring mice obtained after microinjection C57Bl/6 oocystes were tested for the 
presence of CBGr99 at 5 weeks of age by Southern blotting (see § 2.2.2.). The 2 positive 
founders were mated with C57B6/n mice. Unfortunately one died during mating. Presence of 
the transgene in the F1 generation was also checked by Southern blot and transfer of the 
transgene to the next generation was observed. 
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 Characterization of CAG-CBGr99-2A-mCherry mice 
To verify luciferase expression in this transgenic line, denoted CAG-L2Ach, we have 
performed in vivo BLI. The luminescence signal is very strong and leads to the saturation of 
the CCD camera with an exposure time of 1s [Fig. 38A]. The pattern of luciferase expression 
was estimated by imaging organs after dissection. All organs displayed luciferase expression 
with differences on the signal intensity. Thymus, lung, brain, heart, kidneys, skin, pancreas 
and lymph nodes emitted a very strong luminescence signal whereas liver and spleen signal 
emission is lower but still intense [Fig. 38B].  
 
 
Figure 38 : Luciferase expression of the CAG-L2ACh transgenic mice 
 (A) BLI images of two transgenic lines, CAG-L2ACh. The mouse in the left is C57Bl/6, thereby does not 
luminesce, whereas the transgenic mouse in the right appears to luminesce from all areas of the body (B) Images 
of organs from C57Bl/6 and CAG-L2ACh mice. All organs from CAG-L2ACh mice luminesce. 
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Splenocytes were analyzed by FACS for the expression of the mCherry protein. Again, as it 
was previously described in the ßAc-G2A99 model, expression of the fluorescent reporter 
protein is not expressed in all cells. However in the CAG-L2ACh mouse model, 
approximately 60% of the splenocytes displayed mCherry expression [Fig. 39A], and 
therefore CBGr99, which is most likely sufficient to perform cell sorting of a defined cell 
population. We have stained splenocytes with a FITC labeled antibody directed against the T 
cells specific marker CD3 and showed that they all express mCherry [Fig. 39B].  
 
 
Figure 39 : mCherry expression of the CAG-L2ACh transgenic mice 
 (A) Flow cytometry analysis of total splenocytes from CAG-L2ACh mice. (B) Flow cytometry analysis of total 
splenocytes from CAG-L2ACh mice stained with CD3-FITC antibody. 
 
After cell sorting, the CD3 positive cells were serially diluted and imaged to estimate the limit 
of detection in vitro. As shown in Figure 40A, between 2500 and 5000 cells are visible in 
vitro. We were also able to visualize cells in vivo. A luminescence signal was observed in the 
lung, liver and spleen after transfer of 1 x 10
6
 CD3 positive cells in C57Bl/6 host [Fig. 40B]. 
These results indicate that most probably less than 1 x 10
6
 T cells located at the same site are 
detectable by BLI. We conclude that the CAG-L2ACh mice can serve as an universal donor 
for cell transplantation. 
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Figure 40 : Determination of BLI sensitivity of T cells from CAG-L2ACh  
(A) T cells were diluted from 50 000 to 2500 cells, plated in black 96-well plate, and imaged for 1 minute after 
the addition of D-luciferin. (B) 1 x 10
6
 T cells were intravenously injected in a C57Bl/6 mouse and imaged for 5 
min after i.p. administration of D-luciferin. 
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Molecular imaging techniques aim at the visual identification, characterization and 
quantification of biological processes in a living organism. In contrary to “classical” 
diagnostic imaging it set for the in vivo monitoring of specific molecular and cellular 
processes such as gene expression, progression or regression of cancer, drug and gene 
therapy. Many traditional and clinically used imaging techniques, such as MRI, CT, US, PET 
and SPECT have been adapted in recent years for imaging of small laboratory animal models 
(Weissleder and Mahmood, 2001).  All of these technologies differ in a variety of aspects: 
spatial and temporal resolution, depth of penetration, availability of the injectable probes and 
the detection threshold of probes for a given technology. However, the use of optical markers, 
such as bioluminescent or fluorescent markers, offer several advantages than can be used to 
refine and accelerate the study of mouse models of disease, cell migration and vector 
distribution. For example, when a reporter gene is introduced into a cell the gene is replicated 
with each cell division, therefore the signal is perpetuated over time.  Moreover, the 
instrumentation used for optical imaging allows the imaging of several mice at the same time 
(up to 5), it is easy to use because specialized imaging technicians are not required and time 
for acquisition and analysis of the pictures is relatively short. In the field of optical imaging, 
there are several approaches including fluorescence imaging and bioluminescence imaging 
(BLI). Bioluminescent reporters include genetically expressed luciferase protein such as 
bacteria, firefly, red and green click beetle luciferases. Light emission is the result of a 
chemical reaction involving luciferase, luciferin, ATP and oxygen, therefore no light emission 
is required. Firefly and red click beetle are generally preferred due to their longer wavelengths 
which are less absorbed by tissues. Fluorescence reporter does not require luciferin, but 
instead require excitation light to excite the fluorescent protein. Fluorescent reporters include 
proteins such as green fluorescent protein (GFP), red fluorescent protein (RFP) and other 
variants. Luciferase is more representative probe to rapidly changing environmental 
conditions because these proteins mature rapidly following expression and are relatively short 
lived, whereas fluorescent protein can take up to several hours to become functional after 
which they may reside in the cell for many hours (Troy et al., 2004). Another limitation of 
fluorescence imaging is the higher background signal level due to autofluorescence of tissues 
compared with bioluminescence. Therefore, we have chosen to develop tools allowing the use 
of BLI for assessment of tumor growth, bacteria distribution and cell migration studies in 
mice. We first focus on the selection of the optimal luciferase to use for in vivo BLI. 
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1. Selection of an optimal luciferase for BLI 
BLI is a widely used method for non-invasive measurement of luciferase expression in small 
research animals. The sensitivity of detection is critical and depends on several factors such as 
the photon yield of the enzymatic reaction, absorption and scattering of the light by 
mammalian tissues, and the sensitivity of the detection system. In vivo the most important 
limitation is caused by absorption and scattering of light by tissues which reduce sensitivity 
and resolution. Whereas scattering of the light is mainly dependent on the tissue composition, 
absorption depends on the light emission spectrum. Therefore, we have compared various 
commercially available luciferases to define the most appropriate one for in vivo BLI studies. 
In tissues chromophores like hemoglobin will absorb light. Hemoglobin absorbs mainly in the 
green and blue part of the light spectrum, whereas less absorption occurs at wavelengths 
longer than 600 nm. Thus, the red component of the luciferase emission spectra is the most 
useful one for BLI. Several luciferases have been cloned and optimized for expression in 
mammalian cells. Fluc is the most commonly used luciferase for BLI. Light emission by Fluc 
includes a spectral content above 600 nm within a broad-band emission spectrum (530-640 
nm) peaking at 612 nm at 37°C (Zhao et al., 2005). The click beetle luciferases, CBGr99, 
CBGr68 and CBRed, which were recently introduced also catalyze the degradation of D-
luciferin allowing their comparison with Fluc.  A comparative study of spectral imaging for 
Fluc and CBRed and CBGr68, has shown that the percentage of light above 600 nm relative 
to total light output was low for CBGr 68 (~ 15%) while the respective values were higher for 
CBRed and Fluc (80 %  and  64%, respectively) (Zhao et al., 2005). These observations 
suggested that CBRed and Fluc are better candidates for BLI than CBGr68. However, a 
quantitative comparison of the total photons yield emitted at the various wavelengths of the 
spectra especially in the red wavelengths range has not been performed. We have, therefore, 
compared CBGr99, CBRed and Fluc. CBGr68 displays the same emission spectrum as 
CBGr99 (Promega), therefore it was not included into the comparative study. 
 
For such studies it is critical that the cells used express equimolar amounts of the different 
luciferase. In order to achieve equimolar expression, CBGr99, CBRed and Fluc containing 
bicistronic plasmids were constructed in which CBGr99, CBRed and Fluc is linked to the 
eGFP sequence via a P2A sequence [Fig. 6]. The 2A peptide impairs the formation of a 
normal Gly-Pro peptide bound at the end of the 2A peptide consensus peptide without 
affecting translation of the second protein [Fig. 5] allowing the expression of the 2 proteins in 
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a stoichiometric manner (Holst et al., 2006). The transfection of MO4 cells with the 
respective constructs showed that the 2A cleavage is highly efficient (100 %) [Fig.7A]. To 
confirm that the cleavage leads to a stoichiometric co-expression of the 2 proteins, we have 
generated stable cells clones for each constructs.  In a series of transfectants expressing 
increasing amounts of eGFP we have observed a strict correlation (R ~ 0.9) with the activity 
of the respective luciferase [Fig. 7B and C]. Altogether, these results show that eGFP and the 
respective luciferases are equimolary co-expressed. Thereby, eGFP can be use to standardize 
the expression of luciferases. The selection of stable clones exhibiting the same eGFP 
expression [Fig. 8] allowed us to compare identical amounts of the luciferases. 
The comparison of light emission from the different clones demonstrated that the luciferases 
have a different kinetics regarding their enzymatic activity [Fig. 9A]. At early time points 
CBGr99 is clearly superior with regard to the total photon yield. However, the photons 
emitted in the red part of the emission spectrum (above 600 nm) are the critical photons for in 
vivo BLI as they can efficiently be transmitted through mammalian tissues. Therefore, we 
measured the red-orange component of the emission spectrum using a DsRed2-1 filter (pass 
band 575-650). These measurements indicate that in this part of the emission spectrum the 
photon yield of the enzymatic reaction catalyzed by CBGr99 is higher than that obtained with 
CBRed in the first 11 minutes and similar at later time points. Fluc clearly emits less photons 
[Fig. 9B].This observation indicates that despite an emission spectrum which is mainly in the 
green wavelengths, CBGr99 emits more photons above 600nm than Fluc or CBRed specially 
in the first minutes. Thus, CBGr99 is potentially useful for in vivo BLI. 
 
In order to determine the sensitivity of detection of the respective luciferases in vivo, the cells 
clones expressing the different luciferase were inoculated in different locations, namely 
subcutaneous, in the peritoneal cavity, or in a highly vascularized organ such as the lung. In 
the subcutaneous model, CBGr99 produces a higher photon yield over time [Fig.10], which 
correlates with the in vitro results. The absorption of green light appears to be very low in the 
skin owing to superficial location of the cells as well as the weak presence of hemoglobin in 
the skin. In the intraperitoneal and in the lung model, cells are located deeper in the animals 
where the presence of organs and blood vessels lead to a high absorption of photons below 
600 nm wavelengths. Consistent with the in vitro experiment, at early time points, detection 
of light emitted by CBGr99 is better [Fig. 11]; probably due a larger emission of red photons. 
At later time points, the sensitivity of CBGr99 and CBRed are similar; probably because 
CBRed is producing as many red photons as the CBGr99. 
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These results demonstrate that for BLI the click beetle luciferases are superior to Fluc which 
is the most frequently luciferase used for BLI. The comparison of the click beetle luciferases 
shows that CBGr99 has either a superior or a similar sensitivity in vivo as compared to 
CBRed, depending on the time point of the analysis. Despite the high attenuation of its signal 
in vivo, but owing to its high photon yield, the CBGr99 produces red photons in amounts that 
are comparable to CBRed. Together with its fast kinetic these properties characterize CBGr99 
as a luciferase that is highly suitable for in vivo BLI.  
CBGr99 is clearly the most sensitive luciferase for in vivo BLI. To validate the potential of 
CBGr99 as a reporter for tumor growth, it was applied to the measurement of growth of 
transplantation tumors by BLI. First, we have further characterized stable transfectants, 
denoted MO4/GL2A-10, expressing CBGr99 and Ovalbumin. As it was previously shown 
with Fluc (Craft et al., 2005), there is a linear correlation between cell number and the 
photons yield displayed by CBGr99 [Fig. 13B]. Notably, a low number of cells can be 
detected in vitro (100 cells) and in vivo (2500 cells subcutaneously) [Fig 13 A and C]. Even if 
the limit of detection is dependent on several factors including cell line, expression construct, 
gene copy number and luciferase concentration, these results demonstrate the high sensitivity 
that can be reached with BLI. Next, in the example of subcutaneous tumor growth of 
MO4/GL2A-10, we validated the use of CBGr99 as a reporter of tumor growth by direct 
comparisons of BLI with external caliper measurements [Fig. 15]. Again, high sensitivity of 
BLI was demonstrated in the subcutaneous tumors where tumors that were not measurable by 
calipers were quantifiable by photon emissions. BLI imaging of MO4/GL2A-10 injected 
intravenously has shown the ability to use these cells for the detection of metastasis formation 
[Fig. 16]. Altogether, we have proved here that, as it was already shown for Fluc (Jenkins et 
al., 2003), CBGr99 can also be used to assess non invasive tumor growth by BLI.  
 
2. Generation of autochthonous hepatocarcinoma model for BLI 
We have previously shown that CBGr99 can be used to follow subcutaneous tumor 
development by BLI. However, transplantation tumors in rodents do not reflect the clinical 
situation. Therefore transgenic mouse models have been developed to closely mimic the 
sporadic cancer formation as it occurs in humans. In conventional transgenic mouse models 
tumors develop spontaneously within the targeted organ, but all cells have the capacity to 
transform. Once eliminated, e.g. by therapeutic intervention, the tumor cells are likely 
replaced by new transgene expressing cells. Therefore, Cre/loxP conditional mouse models 
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have been developed. In these models, the tumor growth is induced in a time and spatial 
dependent manner. This leads to the growth of tumors from few transformed cells within their 
physiologic environment. These models have proven most useful for furthering our 
understanding of in vivo tumor etiology (Jonkers et al., 2001; Marino et al., 2000). Despite 
such improved tools for modeling cancer, the often “non-visible” nature of tumorigenesis 
makes it difficult to follow tumor growth and therapeutic success. Furthermore, as autopsy is 
often the most effective way to evaluate therapeutic treatment efficacy, longitudinal studies 
examining the dynamics of tumor responses to treatment become problematic. Consequently, 
large cohorts of mice are required to generate statistically reliable results. Therefore, 
conditional tumor models have been adapted to enable noninvasive BLI of tumor 
development. The first model reported is a mouse model of pituitary cancer. In this model, 
somatic deletion of the gene encoding for the tumor suppressor protein RB results in the rapid 
development of a tumors in mice homozygous for a conditional Rb mutation (Vooijs et al., 
1998). By crossing these mice with transgenic mouse line that conditionally expresses Fluc in 
the pituitary gland, the authors have generated a model where tumor development can by 
monitor by BLI (Vooijs et al., 2002). A similar and more general strategy was to generate a 
ubiquitously expressing conditional luciferase reporter mouse (LucRep) that can be used to 
render a wide range of Cre/loxP mouse tumor models suitable for BLI. To demonstrate that 
the LucRep mouse line could be used to image spontaneous tumor development in vivo, the 
authors have crossed the LucRep mouse with a conditional oncogenic K-ras2 transgenic 
mouse (Lyons et al., 2003). They have showed that LucRep mice could enable visualization 
of conditional Kras2-induced lung tumorigenesis by BLI.  
 
In the present thesis, we have generated the first mouse line that conditionally expresses 
CBGr99 in the liver. By breeding them with a conditional transgenic line expressing the Tag 
oncogene we have generated a bitransgenic mouse line with which we have investigated the 
ability of CBGr99 to report hepatocarcinoma growth. An inducible hepatocarcinoma model, 
named AST, has been developed in the laboratory using the Cre/LoxP system (Stahl, in 
preparation). In this mouse model expression of the oncogene Tag is initiated by intravenous 
injection of an adenovirus encoding Cre recombinase. Dose dependent liver tumor formation 
is achieved by application of different adenovirus doses. In comparison to previous 
hepatocarcinoma models such as the Albumin-Tag in which tumor development is already 
observed four weeks after birth (Ryschich et al., 2006), the AST model is closer to the clinical 
situation of sporadic cancer formation. It allows investigation of different questions such as 
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the mechanisms of tumor development in the autochthonous environment and also the 
mechanisms of tolerance induction towards tumors. Moreover, it also constitutes a good 
model for the evaluation of therapeutic strategies. A major drawback of this model is that the 
tumor nodules are not directly visible by optical inspection of the mice because the tumors 
develop in the liver. Until now, the presence of tumors is estimated by the ALT level in the 
serum which reflects liver damage but does not allow to monitor tumor progression. To 
render the tumor visible by BLI, we have generated an Albumin-floxstop-CBGr99 (ASC) 
transgenic mouse line. In ASC mice, the induction of CBGr99 expression is also dependent 
on Cre recombinase. The albumin promoter results the specific expression of CBGr99 in 
hepatocytes. Breeding of ASC mice with the AST mice yielded in a double transgenic mouse 
line (ASCT), in which expression of both transgenes can be induced simultaneously by 
Adeno-Cre injection. 
 
First we have looked for a potential leakage of the STOP cassette in unrecombined ASC mice. 
During construction of the AST mice in our laboratory, Dr. Sacher has observed that in some 
founder lines the STOP cassette is leaky, resulting in transcription of the transgene, albeit in 
very small amounts (Sacher, 2000). Willimsky et al. described also recently that a STOP 
cassette can be leaky. Briefly, these authors have generated transgenic mouse containing Tag 
in a silent form due to a STOP cassette separating a ubiquitously active promoter (chimeric ß-
actin/ß-globin promoter) from the oncogene. However, this mouse line is able to develop 
sporadic tumors in the absence of Cre recombinase (Willimsky and Blankenstein, 2005). 
Hence, unrecombined AST mice displayed tolerance to the Tag antigen. In the particular AST 
mouse line used in this thesis for the crossing with ASC mice generated here, no leakage of 
STOP cassette was observed as judged by RT-PCR or by formation of tumor nodules in old 
unrecombined mice (Stahl, 2004).  In the unrecombined ASC and ASCT mice describe here, 
a low luminescence signal from the liver was observed. Thus the STOP cassette in these mice 
appears to be leaky [Fig. 20]. BLI of old unrecombined ASCT mice (12 to 14 month old) 
show that this leakage does not increase with time and age does not lead to spontaneous tumor 
development. As this signal caused by the leaky cassette is very weak, it does not affect the 
visualization of tumor growth by BLI, because the signal emitted by tumors is at least 100 
times stronger. It is also important to notice that, so far, the ASCT model is the first reported 
mouse line expressing CBGr99. The leaky STOP cassette is expected to result in tolerance to 
immunogenic antigens epitopes from the CBGr99 whereby an immune response CBGr99 may 
be avoided.  
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We show her that in ASCT mice injection of various doses of adenovirus encoding Cre leads 
to efficient recombination that can already be observed by BLI one day after virus injection 
[Fig. 21A]. The strength of the luminescence signal is dependent on dose of adenovirus which 
is injected. However, the signal intensity does not linearly correlate with viral doses [Fig. 
21B]. The liver Kupffer have been shown to take up the adenoviral particles which reduce 
then the transgene delivery to the hepatocytes (Tao et al., 2001). Therefore, efficient transgene 
delivery to hepatocytes occurs when the liver Kupffer cells are saturated which could explain 
the highest luciferase expression per viral particles with high viral doses.  Monitoring of 
induced mice over time shows that tumor growth can be noninvasively followed over time 
[Fig. 22]. A strong signal increase is observed 40 to 60 days after adenovirus injection [Fig. 
23], at a time when hepatoma begin to grow rapidly in Cre induced mice. When in ASC 
recombination was induced with Cre, the signal intensity reached after recombination stayed 
constant over time because ASC mice lack the Tag antigen and, therefore do not develop 
tumors.  In order to obtain a good correlation between signal evolution and hepatocarcinoma 
growth, it is important that the conditional gene, e.g CBGr99 and Tag, present in one 
hepatocyte are both switched on which results in cells that carry one or more oncogenic 
lesions together with an activated luciferase reporter. This criterion can be met under two 
circumstances. First, when CBGr99 is switched on more efficiently than the Tag oncogenes 
upon recombination. Second, when conditions are created in which all the conditional alleles 
switch on efficiently in the cell. In the first situation, luciferase will also be switch on in some 
cells in which no oncogenic lesions have been induced. Because these cells do not clonally 
expand, they will not provide an appreciable contribution to the signal and thereby tumor 
growth can still be monitored efficiently. The fact that a majority of ASCT mice (16/17) 
showed a good signal increase indicating tumor growth, suggests that in most of the 
hepatocytes both transgenes were simultaneously switched on. If Tag is switched on more 
efficiently than CBGr99 upon recombination, the luminescence signal will not properly report 
tumor growth, as it may have occurred in the 1 out of 17 mice [Fig. 24], which showed tumor 
growth but no increase of increase of the luminescence signal around day 40. 
In conclusion, the ASCT model represents a physiological system for sporadic tumor 
formation in a tolerant environment, as it occurs in humans. In addition, the ASCT model has 
the advantage to allow monitoring of tumor growth by BLI. Thereby, it constitutes an 
attractive model to evaluate vaccination efficacy in mice without using a large cohort of 
animals. 
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3. Bioluminescence imaging of tumors in live animals with bacteria 
encoding luciferase and their usage in tumor therapy 
The use of mouse models to understand bacterial infections and for testing efficacy of 
antibiotics has been well established. In addition, BLI has been use to follow the fate of 
bacteria in mice (Contag et al., 1995; Hamblin et al., 2002; Hamblin et al., 2003). The first 
report of monitoring disease progression in living mice using bioluminescence was conducted 
using infection by Salmonella typhimurium (Contag et al., 1995). The virulence of three 
different strain of Salmonella typhimurium expressing the lux operon was compared by in 
vivo BLI. A subsequent study has used Vibrio cholerae, Salmonella typhimurium, Listeria 
monocytogenes and E.coli DH5α carrying the lux operon to show that survival and replication 
of bacteria in a tumor could be localized and followed in real time by BLI (Yu et al., 2004). 
These observations were made in nude mice bearing human tumors. However, nude mice lack 
a functional immune system. Therefore, in the present thesis, we have investigated the ability 
to visualize by BLI V.cholerae tumor colonization in immunocompetent mice, which have a 
functional immune system and therefore the capacity to eliminate the bacteria. 
 
To this end, C3H mice bearing subcutaneous tumors e.g. AG104A fibrosarcoma were injected 
intravenously with V.cholerae.lux. 20 minutes after injection, the bacteria were visible in the 
liver by BLI. After day 1, bacteria were found to be localized in the tumor where their growth 
could be visualized by an increase of light emission. The luminescence signal intensity 
reached a peak at about 1 week after injection and then decreases until it becomes non-visible 
around day 28 [Fig. 25]. In the experiments using nude mice bearing tumors, it has been 
estimated that one week after bacterial injection approximately 20% of the V.Cholerae.lux 
population retained the plasmid DNA in vivo (Yu et al., 2004). Even if the loss of 
luminescence signal seems to be due loss of the plasmid encoding the lux operon in the 
absence of antibiotic selection, we cannot exclude that bacterial clearance by the immune 
system occurs in immunocompetent mice. To address this issue, we have repeated the 
experiment using E.coli Top10.lux strain. This recombinant E.coli strain was generated by 
transposon-mediated integration of the luciferase operon into the bacterial chromosome in 
order to improve stability and to create a strain that remain bioluminescent in the absence of 
antibiotic selection. Moreover, in the E.coli Top10.lux strain, the luciferase expression is 
under the control of the inducible PBAD promoter (Loessner et al., 2007b). The PBAD promoter 
from the arabinose operon of E.coli can be activated by the sugar L-arabinose and is widely 
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used to positively control expression in bacterial cultures (Guzman et al., 1995). Together 
with Dr. Loessner, we were able to show that the inducible PBAD promoter driving the 
expression of either Fluc or the lux operon in Salmonella.lux can be switched on in vivo by 
intraperitoneal injection of L-arabinose [Fig. 27] (Loessner et al., 2007b). 3 days after 
infection of CT26 tumor bearing mice with Salmonella.lux, we could show that 
intraperitoneal administration of L-arabinose leads to a strong induction of luciferase 
expression peaking 5 hours after induction.  
 
To monitor the colonization of Top10.lux in C3H bearing subcutaneous tumors (AG104A), 
mice were injected intraperitoneally with L-arabinose and imaged 5 hours later. One day after 
intravenous injection of Top10.lux bacteria the luminescence signal was located in the tumor 
area and increased until day 6 followed by a decrease until being non-visible around day 14 
[Fig. 28] suggesting that tumor colonization by bacteria is a transient phenomenon. Hence, it 
is likely that the kinetics of tumor colonization is dependent on the bacterial strain. Indeed, 
V.cholerae.lux was observable until day 28 whereas Top10.lux signal was already absent at 
day 14 in the same tumor model. The colonization of tumors by Top10.lux was also visualized 
in other subcutaneous tumor models such as B16 and RMA [Fig. 29]. However, neither 
V.cholerae.lux [Fig. 26] nor Top10.lux [Fig. 28C] has affected the growth of tumor in these 
experiments. Nonetheless, all subcutaneous tumor models that we have studied, so far, were 
efficiently targeted by bacteria. Therefore, we envisaged to use bacteria as a carrier of 
therapeutic genes to the tumor sites.  
 
The ideal bacterial vector would be a vector that combines the following advantages (i) non-
toxic to the host, (ii) the replication takes place only in the tumor (iii) they are slowly 
eliminated by the host. In other studies several recombinant strains of Salmonella 
typhimurium were engineered for DNA delivery of therapeutic genes like endostatin (Lee et 
al., 2004) and TSP-1 (encoding Thrombospondin-1) (Lee et al., 2005) or genes products 
expressed by the bacteria including HSV1-TK (Soghomonyan et al., 2005), cytosine 
deaminase (Cunningham and Nemunaitis, 2001; Dresselaers et al., 2003; King et al., 2002; 
Lee et al., 2001b; Nemunaitis et al., 2003). However, a main disadvantage of Salmonella is 
that they accumulate not only in tumor tissues but also in other organs such as liver and 
spleen (Pawelek et al., 1997). Top10 has been shown to specifically target the tumor and to 
colonize tumors with the same efficiency than Salmonella (Stritzker et al., 2007) therefore it 
is an ideal vector for delivery of therapeutic genes. 
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To obtain an antitumoral effect several “therapeutic” genes may be considered, such as 
cytokines, pro-drug-converting enzymes, and agent toxic to tumor. Here, we have planned to 
elicit a specific immune response against the tumor. Therefore, we choose to express 
interleukins in bacteria for enhancement or induction of the immune responses at the tumor 
site. Interleukins are small proteins or glycoproteins that bind to cell surface receptors and 
regulate immune cell development, growth, survival, and function. As such, interleukins have 
been extensively studied as potential therapeutic agents to manipulate the immune response to 
malignantly transformed cells. Interleukin therapy thus aims at either augmenting the number 
of immune cells by stimulating growth and survival, or by activating cytotoxicity or 
interleukin production to boost immune reactivity. Among interleukins that were tested for 
immunotherapy, GM-CSF and IL-2 have shown to be promising in clinical studies (2002; 
Donohue et al., 1984; Dummer, 2001; Lafreniere and Rosenberg, 1985; Nemunaitis and 
Nemunaitis, 2003; Rosenberg et al., 1985; Tani et al., 2004). However, systemic toxicity is a 
serious issue that limits the application of interleukins in humans (White et al., 1994). A 
restriction of their expression to the tumor site may diminish their toxicity. It has been shown 
that both, GM-CSF and IL-2, are still biologically active in absence of glycosylation 
(DeLamarter et al., 1985; Sato et al., 1993). Therefore, these interleukins seems to be good 
candidates for expression in bacteria where glycosylation does not occur. 
 
To avoid retention of the “therapeutic” proteins in bacterial inclusion bodies and, in order to 
maximize their secretion into the tumor milieu, we have used the Hemolysin A secretory 
system. In gram negative bacteria, recombinant proteins are often expressed in the 
intracellular compartment because the outer membrane is non-permeable. Therefore, the GM-
CSF and IL-2 sequences were inserted into a plasmid encoding for the Hemolysin A secretory 
system [Fig. 30] which has been shown to be one of the most efficient for secretion of 
recombinant proteins (Gentschev et al., 1996). Top10.lux bacteria expressing the respective 
plasmids, pIHL-GM-CSF and pIHL-IL-2, were found here to efficiently secrete GM-CSF and 
IL-2 [Fig. 31]. The resulting Top10.lux.GM-CSF and Top10.lux.IL-2 recombinant bacteria 
strains conditionally express the lux operon and secrete GM-CSF and IL-2 through the outer 
membrane. 
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For reason of time, the Top10.lux.IL-2 bacterial strain has not been tested in the present study. 
Top10.lux bacteria secreting GM-CSF (Top10.lux.GM-CSF) were applied in a therapeutic 
vaccination setting to mice bearing subcutaneous AG104A tumors. Although tumor targeting 
by the Top10.lux.GM-CSF strain was visualized in all mice by BLI, there was no effect on 
tumor growth [Fig. 32A]. As GM-CSF is believed to enhance recruitment of dendritic cells to 
tumor site and subsequently increase antigen presentation (Timmerman and Levy, 1999), we 
have injected the Top10.lux.GM-CSF bacteria into mice bearing a tumor expressing a strong 
antigen, namely Tag (AG104A-Tag). By doing so, we thought to increase the probability for 
induction of an immune response against the tumor associated antigen. In a first experiment, a 
delay in tumor growth was visible in mice bearing AG104A-Tag tumors treated with 
Top10.lux.GM-CSF [Fig. 32B]. These data suggested that intravenous administration of 
Top10.lux.GM-CSF may affect the growth of a highly immunogenic tumor. However, in a 
second experiment the delay in tumor growth was observed in mice i.v. injected with 
Top10.lux.GM-CSF but also in animals receiving the control strain (Top10.lux) [Fig. 32C] 
suggesting that the bacteria by themselves could induce an antitumoral effect. Therefore, the 
vaccination with Top10.lux-GM-CSF has to be investigated in additional tumor models. 
 
The advantage of subcutaneous tumor models is that they allow to perform studies in a 
relative short period of time but a major disadvantage is that they do not resemble 
tumorigenesis as it is observed in humans. Therefore, we have examined the tumor 
colonization by bacteria in spontaneous tumor models that more closely mimic cancer 
development (see § A.2.2.). The first spontaneous model to be examined was the Albumin-
Tag model in which the expression of the oncogene Tag under the expression of the liver 
specific albumin promoter leads to the formation of several tumor nodules in the liver 
(Ryschich et al., 2006). When Albumin-Tag mice were injected with V.cholerae.lux, tumor 
colonization was visible by BLI only in 5 out of 9 mice. This is in contrast to the 
subcutaneous models described above where tumor colonization was observed in all mice (see 
table 3). Moreover, although Albumin-tag mice develop several tumor nodules in the liver, 
only few of them were targeted by V.cholerae.lux [Fig. 33A and B]. The fact that several 
Albumin-Tag mice with large hepatocellular carcinoma, remained negative even after several 
injection of V.cholerae.lux [Fig. 33C] indicates that the colonization of tumors in this model 
is independent on the tumor size. Therefore, the colonization of tumors may depend on the 
intrinsic properties of each tumor nodules, or depend on the accessibility of the tumor for 
bacteria. For example, a high local intrinsic pressure, as it is observed in tumors, may prevent 
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colonization. The second spontaneous model tested here is the RIP.Tag-5 insulinoma model 
in which expression of the Tag oncogene in the beta-islets of the pancreas leads to the 
development of solid insulinoma (Hanahan, 1985). None of the injected mice (3/3) displayed 
a luminescence signal 3 days after V.cholerae.lux inoculation [Fig. 34]. Thus V.cholerae 
probably does not colonize autochthonous insulinoma. Together with the observations made 
in the Albumin-Tag model, this data suggest that tumor targeting of V.cholerae.lux is less 
efficient in spontaneous tumor models. The third model investigated was the Her2/neu 
mammary tumor model in which mice develop Neu-overexpressing spontaneous mammary 
carcinomas in a stochastic manner (Guy et al., 1992).  In these mice we investigated tumor 
colonization by Top10.lux bacteria. Tumor homing by the bacteria was observed only in 1 out 
of 7 injected mice. In this particular mouse, 3 out of 8 tumors displayed a luminescence signal 
[Fig. 35] indicating that each tumor has a different sensitivity to colonization. Upon 
reinjection, the remaining 6 Her-2/neu mice bearing advanced tumors remained negative. 
Thus, colonization of tumors in the Her-2/neu mice appears to be very inefficient. 
 
From the observations made in the different spontaneous tumor models, it is questionable if 
bacterial vectors would be useful tumor vaccines against cancer. A critical issue is to 
understand the mechanisms of tumor colonization by bacteria and to improve tumor 
colonization, e.g. by manipulation of the tumor environment. 
 
4. Generation and characterization of ß-actin-fstop-eGFP-2a-CBGr99 
mouse line 
The migration of lymphocyte population through the lymphoid organs and tissue targets 
remains elusive. Some progresses have been made by applying BLI to the study of 
lymphocyte trafficking in vivo. The labeling of effector lymphocytes in vitro permits these 
cells to be imaged by BLI in animals.  For example, localization of T cells could be observed 
by BLI when T cells were transduced with a luciferase reporter gene and injected into mice 
intraperitoneally or intravenously (Costa et al., 2001; Nakajima et al., 2001). A critical issue 
in these studies is the introduction of the reporter gene into the cell of interest. Although 
multiple methods have been used, efficient transduction of reporter genes appears to be most 
effective via a viral infection method (Kootstra and Verma, 2003).  However, this method 
requires ex vivo manipulations that may alter the biological properties of the cells. Therefore, 
we thought to generate a transgenic mouse line that ubiquitously expresses eGFP and 
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CBGr99, thus serving as a universal donor for transplantation and trafficking studies. The 
presence of eGFP facilitates the isolation of the CBGr99 positive cells from the donor animal 
and can also be used as a marker in fluorescence microscopy or flow cytometry studies. As 
BLI could also be envisaged to monitor the expression of promoters, we first generated a 
reporter transgenic mouse line (ßAc-S-G2A99). In the ßAc-S-G2A99, the expression of an 
eGFP-2A-CBGr99, controlled by the ubiquitous ß-actin promoter and is inducible upon Cre 
recombination. No background expression of CBGr99 could be detected in ßAc-S-G2A99 
mice [Fig. 36A] due to the stop sequence inserted between the reporter and the coding 
sequence. When the reporter mice was crossed to Cre deleter mice (Schwenk et al., 1995) 
expressing Cre constitutively in all tissues, the resulting bitransgenic mouse line, named ßAc-
G2A99, displayed ubiquitous expression of CBGr99 [Fig. 36B] indicating an efficient 
excision of the flox STOP cassette. In comparison to the existing reporter line like ROSA26-
LacZ (Soriano, 1999) or ßactin-eGFP (Kawamoto et al., 2000), cell staining and  preparation 
of cell suspension, respectively, is not require to report promoter activity. The promoter 
activity can be estimated by the imaging of the mouse and confirmed by the imaging of the 
organs after dissection. Therefore, the ßAc-S-G2A99 mouse line is suitable reporter line for 
the fast screening of promoter activity in vivo. 
 
The ubiquitous expression of CBGr99 in the ßAc-G2A99 mouse was transmitted to the 
following generation, resulting in ubiquitously expressing lines of mice that could be useful as 
a universal donor of T cells tagged with CBGr99. However, although the signal is strong 
enough to visualize luminescent organs the sensitivity of detection of splenocytes in vitro has 
been shown to be relatively weak [Fig. 37A]. The absence of luciferase signal in recipient 
mice that have been transferred with 10x10
6
 splenocytes confirmed the low sensitivity of 
detection (data not shown). The low sensitivity of detection can be explained by the single 
copy of transgene which remains after Cre recombination but also by the low percentage of 
cells expressing eGFP and thereby CBGr99. Although the ß-actin promoter is supposed to be 
ubiquitously expressed only a small percentage of cells express eGFP (1.5 % in the spleen) 
[Fig. 37B]. Because the ßAc-G2A99 mice were not satisfying, we have envisaged the 
generation of another transgenic mouse line that could be used as a source of reporter T cells 
for transplantation. We generated a transgenic mouse line that expresses a CBGr99-2A-
mCherry cassette under the control of the Chicken ß-actin promoter and the cytomegalovirus 
enhancer (CAG). In this mouse line, named CAG-L2ACh, the mCherry protein, a monomeric 
red fluorescent protein optimized for mammalian expression (Shaner et al., 2004), is a marker 
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that can be use in fluorescent microscopy and flow cytometry. The characterization of the 
CAG-L2ACh mouse line has shown that all organs displayed a CBGr99 expression [Fig. 38] 
mCherry is expressed in around 60 % of splenocytes and, interestingly, in 100 % of the T 
cells [Fig. 39]. The measurement of the sensitivity of detection of splenocytes has indicated 
that a minimum of 2500 cells can be detected in vitro, and at about 1.10
6 
cells distributed in 
the lung, spleen and liver of recipient mice in vivo [Fig. 40]. Therefore, the CAG-L2Ach 
animals can be used as a source of T cells and other immune cells for their tracking in real 
time. Respective studies may yield new information about the physiological behavior of 
various lymphocytes populations in tumor immunology, infectious disease, autoimmunity, 
and transplantation biology. 
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In conclusion, in this thesis, I have established several tools for in vivo BLI for tumor 
immunology studies. First, the comparison of different commercially available luciferases has 
shown that the click beetle luciferase CBGr99 displayed the highest photon yield in vitro and 
exhibits a higher sensitivity in vivo than the most commonly used luciferase, namely firefly 
luciferase and another click beetle luciferase, CBRed. We conclude from our studies that 
CBGr99 is the most suitable luciferase for in vivo BLI. Moreover, CBGr99 light emission 
correlates with cell number and therefore allowed monitoring by BLI of transplantation tumor 
growth in vivo. Based on these studies, by using the Cre/loxP system, I have generated a 
conditional autochthonous hepatocarcinoma mouse model, designated ASCT, for BLI. In this 
tumor model, the Tag oncogene and CBGr99 expression are simultaneous switched on and 
allow monitoring of hepatocarcinoma growth via in vivo BLI of CBGr99 expression. The 
ASCT model will be useful for the testing of therapeutic approaches.  
Another approach for visualization of tumor is the use of bacteria as they have been shown to 
colonize and survive in tumors, probably because the tumor microenvironment constitutes an 
immune privileged site for bacteria. For respective studies that are published in the literature, 
transplantation tumors have been employed. Using bacteria expressing bacterial luciferase, 
the lux operon, we could show that E.coli Top10 and V.cholerae indeed efficiently colonize a 
number of transplantation tumors in immunocompetent mice, thereby allowing BLI 
visualization of these tumors. However, the efficiency of tumor colonization was found to be 
much less frequent in spontaneous mouse tumor model, such as the hepatoma model. Because 
spontaneous tumor model are closer to the clinical situation than transplantable tumors it is 
questionable whether bacteria vectors are indeed promising and easy approach for tumor 
targeting in patients. 
For tumor immunological studies one would like to monitor not only the growth of tumors, as 
describe above, but also to follow the fate of tumor specific T cells by non-invasive 
techniques. Therefore, a transgenic mouse was generated in which CBGr99 and mCherry are 
ubiquitously expressed, thereby allowing visualization of transferred T cells by BLI. This 
mouse will be useful for the visualization by BLI of T cell proliferation, migration and 
infiltration in tumors. 
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Abbreviation list:  
Alb  Albumin 
ALT  Alanine aminotransferase 
AMP  Adenosine monophosphate 
Amp  Ampicillin 
APC  Antigen presenting cells 
APS  Ammonium peroxodisulfat 
ASC  Albumin-floxstop-CBGr99 
AST  Albumin-floxstop-TAg 
ATP  Adenosine triphosphate 
BAC  Bacterial artificial chromosome 
BLI  Bioluminescence imaging 
bp  Base pair 
BSA  Bovine Serum Albumin 
CAG  CMV/Chicken ß-actin promoter 
CBGr99 Click beetle green 99 
CBluc  Click beetle luciferase 
CBRed Click beetle red 
CCD  Cooled camera device 
cDNA  Complementary DNA 
Chlr  Chloramphenicol 
CIAP  Calf intestine alkaline phosphatase 
cm   Centimeter 
Cre  Cause recombination 
CT  Computed tomography 
CTL  Cytotoxic T cells 
Dig  Digoxygenin 
DMEM Dulbecco´s Modified Eagle Serum 
DMSO Dimethylsulfoxid 
DNA  Deoxyribunucleic Acid 
dNTPs  Deoxyribonucleotide-5´-triphosphate 
D-PBS  Dulbecco´s modified PBS 
E.coli  Escherichia Coli 
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EDTA  Ethylene diamine tetraacetic acid 
eGFP  Enhanced Green fluorescent protein 
FACS  Fluorescence activated cell sorter 
FCS  Foetal calf serum 
Fig  Figure 
Fluc  Firefly luciferase 
g  Gram 
GM-CSF Granulocyte macrophage colony stimulating factor 
h  Hour 
HCC  Hepatocellular carcinoma 
HRP  horseradish peroxidase 
i.f.u  Inclusion forming units 
i.p.  Intraperitoneally 
i.v.  Intravenously 
IL-2  Interleukin-2 
IRES  Internal ribosome entry sequence 
Kan  Kanamycin 
Kbp  Kilo base pair 
L  Liter 
LB  Luria bertani 
M  Molar 
mA  Milli-Ampere 
MFI  Mea fluorescence intensity 
Mg  Milligram 
MHz  Mega Hertz 
min  Minute 
ml  Milliliter 
MRI  Magnetic resonance imaging 
mRNA Messenger RNA 
nm  Nanometer 
NP-40  Nonidet P40 
OD  Optical density 
OVA  Ovalbumin 
PAA  Polyacrylamide 
                                                                                                                         Abbreviation list                                                                                                                                              
130 
PBL  Peripheral blood lymphocyte 
PBS  Phosphate buffer saline 
PCR  Polymerase chain reaction 
PET  Positron emission tomography 
PPi  Pyrophosphate 
PVDF  Polyvynildene fluoride 
RIP  Rat insulin promoter 
RLU  Relative light unit 
Rluc  Renilla luciferase 
RNA  Ribonucleic Acid 
ROI  Region of interest 
Rpm  Rotation per minute 
s.c  Subcutaneously 
SDS  Sodiumdodecylsulfate 
SPECT Single photon emission computed tomography 
TAE  Tris-acetate-EDTA 
TAg  Simian virus 40 large T-antigen  
TE  Tris-EDTA 
TEMED N,N,N’,N’-Tetramethylethylendiamin 
US  Ultrasound 
UV  Ultraviolet 
V  Volt 
v/v  Volume per volume 
vol  Volume 
w/v  Weight per volume 
Zeo  Zeocin 
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